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CHAPTER ONE 
INTRODUCTION 
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General introduction 
The main subject of this thesis is the study on the immunocytochemical detection of defined 
microvascular antigens in normal human tissues and tumors and its relevance for tumor biology and 
pathology. Before presenting the results of our studies on this issue, a review of the relevant literature 
on the biology and pathology of the microvasculature is given as a general introduction. Firstly, the 
properties of the microvasculature in normal tissues, its cellular and extracellular constituents and 
methods of study are dealt with. Secondly, the process of angiogenesis and the structure and function 
of the tumor microvasculature are discussed. Finally, the questions addressed to in this thesis are 
presented and their rationale elucidated. 
General aspects of the microvasculature 
Morphology of the microvasculature 
The microcirculatory system comprises the smallest branches of the vascular tree, visible only at the 
microscopic level. It forms an integral organic unit embedded in nearly all tissues and organs. The 
architecture of the microvasculature is complex and knows many variations related to structural and 
functional differences of various tissues. Generally, it consists of an arterial side, i.e. small arteries 
and arterioles, a capillary or sinusoid network, and a venous collecting system of venules and small 
veins. Based on electronmicroscopic investigations of mesentery and muscle [19,29,116,291,292] a 
more refined classification [292] has been made (Table I). 
This basic architectural pattern can be found in most organs. However, marked differences exist, 
e.g. in capillary density, ranging from 200-4000 capillaries/square mm. In organs like liver and spleen 
sinusoids instead of capillaries are found [105,126,243], and in the kidney, the glomerulus is a 
specialized microvascular structure. In some organs, i.e. the liver and the eye, there is a dual vascular 
network [16,105]. These differences are accompanied by structural peculiarities of the cells 
constituting (he microvasculature, i.e. endothelium, pericytes and smooth muscle cells, as will be 
discussed later. 
An entity separate from the microvasculature is the lymphatic vascular system [243,292], 
composed of terminal lymphatics, which are blind ending vessels, with a diameter of 15-75 micron 
lined with endothelium with an incomplete basement membrane. They merge into collecting lymphatics 
with a diameter of up to 200 micron and a wall consisting of an internal elastic lamina, smooth muscle 
cells and connective tissue [228,243,292]. 
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Table I. Classification of microvessels based on morphological properties. 
Type of micro vessel Di ame te г Morpholoflicel properties 
Arteriole 
Terminal arteriole 
Precapillary sphincter 
Capillary 
Venous capillary 
Postcapillary venule 
Collecting venule 
Muscular venule 
Small collecting vein 
5 0 - 1 0 0 micron 
less than 5 0 micron 
4-5 micron 
θ - 1 0 micron 
8 - 3 0 micron 
3 0 - 5 0 micron 
5 0 - 1 0 0 micron 
1 0 0 - 3 0 0 micron 
elastica interna, association with nerves; several layers of 
smooth muscle cells 
no elastica interna; association with nerves, single layer of 
smooth muscle colls; myoendothehal junctions 
muscular arrangement in terminal arteriole around orifice of 
capillary; no innervation 
tubes of endothelial cells, occasional pericytes 
formed by confluence of 2-3 capillaries, thin endothelium, 
occasional pericytes 
formed by 2-4 venous capillaries; higher number of pericytes 
complete layer of pericytes end veiled cells, occasional smooth 
muscle cells 
one or two layers of smooth muscle cells 
several layers of smooth muscle cells 
Functions of the microvasculature 
The main function of the microvasulature is to transport blood to and from the tissues in order to 
ensure appropriate supply of nutrients, oxygen and other substances and adequate removal of waste 
products [135,243]. This transport function must be adapted according to variable metabolic demands 
changing with different levels of activity of the organs. This is accom- plished by local and systemic 
regulatory mechanisms interacting with the complex architecture of the microvasculature. Apart from 
this ability to cope with varying requirements of blood supply to tissues the microvascu- lature must 
have intrinsic autoregulatory mechanisms to maintain local pressure, flow and resistance within a 
range appropriate for steady-state conditions [103]. 
Also, the microvasculature serves as the main route of extravasation for immune competent cells 
which find their way guided by receptor molecules on the vascular endothelial cells [25]. 
The cellular constituents 
Endothelium 
Structure 
The (sub-)cellular characteristics of endothelium have been determined by electronmicroscopic studies 
(reviewer in 243). Endothelium consists of highly attenuated cells (0.1-0.5 micron thick) joined by 
intercellular junctions, which are lining the luminal surface of the vascular system. On their negatively 
charged luminal surface, the cellular membrane is covered by a "fuzzy coat" made up of 
glycosaminoglyeans, oligosaccharide moieties of membrane glycoproteins and glycolipids. The 
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abluminal plasma membrane is attached to the basal lamina and maintains contact with underlying 
pericytes and smooth muscle cells by means of cytoplasmic foot processes. The endothelial cellular 
membrane has a variable number of coated pits, coated vesicles and numerous plasmalemmal vesicles 
[273]. In specialized very thin areas, where luminal and abluminal cellular membranes unite, 
fenestrae, i.e. transcellular circular openings closed by a thin diaphragm, are observed. The 
plasmalemmal vesicles are connected to form transcytoplasmic channels. At the cell surface the 
openings of the channels and vesicles are covered by a thin diaphragm membrane. All these structures 
are associated with transcellular transport. The cytoskeleton of endothelium consists of different kinds 
of microfilaments containing contractile proteins, i.e. actins and myosins and the centrosome and its 
associated microtubules (297]. The cytoplasm also contains an unique organelle known as the 
Weibel-Paladebody, a rod-like granule which amongst others stores von Willebrand Factor [132,209]. 
Amongst endothelial cells from vessels of different calibre and between vascular beds in different 
organs considerable variations in morphology exist, probably related to functional requirements 
[68,243,269]. These include the size and thickness of the cells, type of intercellular junctions, the 
relative number of plasmalemmal vesicles, channels, coated pits and Weibel-Palade bodies and the 
presence or absence of different types of fenestrae. 
By these features, several types of endothelium are defined. Broadly, three classes can be recognized 
based on type of junction and fenestrae: continuous, fenestrated and discontinuous endothelium (Table 
II) [243]. Within these categories, subtypes in different segments of the vascular tree and in different 
tissues can be discerned, e.g. many pinocytotic vesicles in capillary endothelium versus only few of 
them in the endothelium of arterioles, and few fenestrae in pancreas capillaries against many in adrenal 
cortex capillary endothelium. 
Table II. Structural properties and distribution of different vascular endothelial subtypes. 
Continuous endothelium Fenestrated endothelium Discontinuous endothelium 
Properties: no fenestrae fenestrae pores 
Distribution: large vessels, artenoles, venules most visceral capillaries, sinusoids m liver, spleen end 
and capillaries m somatic tissues, pencytic venules and the bone marrow 
brain and lung glomerulus 
Functions 
The endothelium has a strategic position at the interface between the circulating blood and the tissues. 
Its main functions are therefore the passive and active transport of substances and cells across the 
vascular wall and the maintenance of an anti-thrombogenic surface. Furthermore, endothelium is 
involved in vascular tone regulation and actively synthesizes and/or secretes interleukins, clotting 
factors, complement factors and many other substances (Table III). In addition, during inflammation 
and tissue regeneration, endothelial cells can be induced to perform several specific tasks, such as 
angiogenesis [40,68,104,132]. 
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Regarding trans-endothelial transport, endothelial cells are equipped with a number of organelles and 
surface molecules involved in the exchange of water, electrolytes and other substances from and to 
the extravascular compartment. The endothelial luminal surface possesses microdomains constituted 
by a preferential distribution of anionic sites, glycosaminoglycans and other molecules involved in 
transport mechanisms [261]. The plasmalemma] vesicles and transendothelial channels are electrically 
neutral in contrast to the negatively charged fenestrae and the remaining plasma membrane, and the 
former are thought to be the main pathways of transport, together with the intercellular route 
[136,175,243]. Specific receptor-mediated transport of molecules probably also plays an important role 
[175]. The exact transport mechanisms of different substances through endothelium are, however, not 
well understood. 
Probably based on the different requirements for transport mechanisms amongst different organs, 
several functional types of endothelium are found. A well-known example is the continuous 
endothelium in the nervous system, which has a characteristic configuration constituting the 
Blood-Brain Barrier [36,47,139,243]. It consists of endothelium with a paucity of plasmalemmal 
vesicles and a special array of tight junctions. Functional features are a number of specific transport 
mechanisms for nutritients, that ensure a restriction for substances entering the nervous system 
parenchyma. A similar endothelium is found in testis and ovary. At the other extreme of the spectrum 
of transendothelial transport is the discontinuous sinusoid endothelium found in liver and spleen, 
characterized by an absence of basal lamina and presence of large fenestrae enabling free transport 
of plasma constituents [126,243] (Table II). 
Regarding transvascular migration of cells, endothelium plays a crucial role in the adhesion and 
migration of circulating lymphocytes to different parts of the lymphatic system (a process known as 
"homing" [250]) and extravasation of cells in inflammatory [25,38,138,217] or other pathologic 
conditions (such as tumor metastasis [193]). In lymphatic tissues a specialized microvessel, the High 
Endothelial Venule (HEV), is involved in this process [133]. Endothelial cells of HEV's and of 
different organs have specific receptor molecules enabling circulating cells to recognize a certain 
destination (Table III). 
Regarding the anti-thrombogenic surface, it was only until recently that the intact endothelium was 
assumed to present an inert surface with anticoagulant properties, due to its negative charge and the 
absence of tissue factor. Instead, it is now recognized that endothelial cells actually have a dynamic 
surface controlling either anticoagulant or procoagulant mechanisms [15,40,65,132,195]. 
Anti-coagulant properties are exerted by the expression of heparan sulphate (which binds anti-thrombin 
III) and thrombomodulin, part of the protein С pathway, each affecting the activity of thrombin, and 
the secretion of plasminogen activators. Under the influence of certain stimuli, procoagulant influence 
is actively achieved by secretion of an inhibitor of tissue plasminogen activator and by expression of 
tissue factor, Factor V, and receptors for several coagulation factors [4,14,40,132]. Furthermore, 
non-activated endothelial cells play a role in hemostasis by producing von Willebrand Factor which 
is deposited in the subendothelial space and which is involved in the process of platelet adhesion in 
the initial phase of hemostasis [40]. 
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Regarding endothelial activation, during inflammation (and other forms of tissue disturbance [39,40]) 
endothelium is believed to become "activated" (perturbed) by inflammatory mediators such as 
cytokines and growth factors [39,40,60,96,101]. As a result, the cells acquire a number of functions 
which are not expressed by resting endothelium. These are the specific adhesion of leukocytes, the 
display of procoagulant properties, an increased permeability, accessory cell function in antigen 
presentation, and release of enzymes (Table III) [39,40]. 
Table III. Examples of endothelìum-assodated components described in endothelium in tissues 
(in situ) or in cultured cells (in vitro) and their alleged functions. 
Component/function Molecular 
weight 
In 
vitro 
In Remarks/ specificity 
situ 
Function m Coagulation 
Membrane-associated 
1 thrombomodulin 
2 . tissue factor 
3 . Factor IX/ IXa binding sites 
Cytokme-mduced, Many 1 4 , 2 0 0 
other cells 
Synthesis or secretion 
1 von Willebrand Factor 
2 . Endothelial Derived Relaxing Factor (EDRF)-nitr ic 
oxide 
3. tissue plasminogen activator (tPA) 
220kOa Platelets + 1 3 2 
68 
Cancer cells + , all ее + 8 8 , 1 5 6 
Inflammation and immunoregulation 
Membrane associated antigens 
1 . M H C Class II (HLA-DP,DQ ,DR) 
2. lymphocyte antigen Leu 2 (MoAb Leu2) 
3 . mucosal vascular addressin ( M V A ) (MoAb 
M E C A - 3 6 7 ) 
4. high endothelial cell antigen (HECA-425) 
5. Intercellular adhesion molecule-l (ІСАМ-І) (MoAb 
RR1/1) 
Synthesis/secretion 
1 . transforming growth factor-beta (TGF-beta) 
2 interleukm 1 (IL-1) 
Cytokme-enhanced 6 8 
Only spleen sinusoid e c + 2 6 5 
58-66kDa 
+ 
+ 
+ 
+ 
+ 
+ 
Mouse high endothelial 
venules (HEV) 
human HEV 
Lymphocytes and 
fibroblasts + 
Cytokme-mduced 
19 
56 
39 
6 
9 
Endothelial activation/regeneration 
Membrane-associated 
1 . endothelial leukocyte adhesion molecule-l (ELAM-I) 1 0 0 / 1 2 0 к Da 
(МоАЬ/Н4/1в) 
2 endothelial budding antigen 7 / 4 4 (MoAb 7 / 4 4 ) 3 0 . 5 k D a 
Post-capillary 
venules,ec-speciñe 
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Component/function Molecular In In Remarks/ specificity Ref. 
weight vitro situ 
Synthesis/secretion 
1. basic-fibroblast growth factor (b-FGF) 
2. platelet derived growth factor (PDGF) 
106 
54 
Blood-tissue barners/transport functions 
1. transferrin receptor (MoAb OKT9) 
2. gamme-glutamyl tranapaptrda 
Extracellular matrix constituents 
1. collagens 1,111,IV, V 
2. fibronectm 
Brain ec and spleen 
sinusoid ec +. 
lymphocytes and cancer 
cells + 
Only brain ac +, kidney 
and choroid plexus 
epithelium + 
47 
68 
6Θ 
Miscellaneous/metabolic functions 
1. angiotensin converting enzyme (ACE) 
2. endothelin 
3. beta low density lipoprotein (LDL)-receptor 
4. alkaline phosphatase 
Kidney epithelium + 
Glomerular ec-
1 3 2 
1 3 2 
2 5 6 
2 6 5 
Antibody defined endothelial components 
1. MoAb CIV and C.VI 92kDa 
2. MoAbHEC-1 170kDa 
3. MoAb 44G4 170kDa 
4. MoAb PAL-E 
5 MoAb BMA 120 (BW200I 200kDa 
6. MoAb EN 4/EN 3 1 ЭОкОа 
7. MoAb В 721 75kDa 
8. MoAb E 431 
9. MoAb 1 FIO 
1 1 . MoAb MB1 
12. MoAb anti-CD34 115 kDa 
Monocytes + 
Haemopoietic cells + 
Haemopoietic cells + 
Basal epidermis + 
М зотЬеІіит + , 
dl omerul а г epithelium-f 
Platelet, leukocyte + 
Smooth muscle calls, 
lymphocytes + 
Macrophages + 
ec specific, sinusoid ec· 
Quail ec only, 
haemopoietic celle + 
Haemopoietic progenitor 
Ch.2 
Ch.2 
1 0 7 
Ch.2 
C h 2 
Ch.2 
2 3 3 
2 3 3 
1 0 2 
1 9 9 
2 8 4 
ec= endothelial calls 
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Pericytes 
Structure 
The pericyte, a cell type of poorly understood origin, nature and function, is situated in the adventitia 
enclosed by the basal lamina of the microvascular wall [244]. Pericytes are stretched cells (80-200 
microns of length) with elongated (primary) and circumferential (secondary) cytoplasmic processes 
enveloping terminal arterioles, capillaries and venules [243]. They are found in all microvascular beds 
with the exception of spleen and liver [244]. Regional variations as to the number of pericytes (often 
expressed as pericyte coverage of the outer endothelial boundary) exist with coverages ranging from 
10% in striated muscle to 26% in the microvasculature of the brain and lung [244,245]. 
Ultrastructurally, pericytes in normal adult tissues usually have a discoid nucleus, microtubules, 
many plasmalemmal vesicles (especially attached to the abluminal surface), and they contain bands of 
microfilaments [116,243,244]. The latter consist of several types of actins, myosins and tropomyosins 
[53,119,141,142] (Table IV). The sporadic presence of Weibel-Palade bodies in pericytes has also 
been reported [302]. The basal lamina enveloping pericytes is connected with the endothelial basal 
lamina. Pericytes form different kinds of cellular contacts with the adjacent endothelial cell. Of these 
the "peg and socket" contacts, the occluding junctions and the adhesion plaques, which contain 
fibronectin, must be mentioned [244]. 
Table IV. Some properties of pericyte-associated components. 
Component/function Molecular In In Remarks/ specificity 
weight vitro situ 
Contractile function 
1. alpha-smooth muscle actm 
(MoAbaSMa-1) 
2, bete-cytoplasmic actm 
3. gamma-cytoplasmic actm 
4. myosin isoforme 
5. tropomyosin isoforms 
6. dasmm 
7. GMP-dependent kinase 
8. endothelin-bindmg sites 
9. aldose reductase 
Unknown function 
1. butyrylehohnesterase 
2. Mo Ab anti-140 kDa 
3. Mo Ab PC4 
4. MoAb 3G5 
+ 
+ 
+ 
+ 
+ 
+ 
140 kDa 
130 kDa + 
+ 
Smooth muscle cell + ; rat,men + 
Many other cells+ 
Many other cells+ 
Rat and chicken + .man-, mesangial pericytes-, 
Smooth muscle cell + 
Smooth muscle cell + 
Smooth muscle cell + 
246,247 
247 
247 
142 
141 
269 90 
216 
163 
89 
Dog brain pericytes + smooth muscle call + , 97 
neurons + ;other organs-
Rat brain pericytes + , other organs-,arteriolar 151 
smooth muscle cell + , several epithelia + 
Vascular smooth muscle+ , pericytes in situ-/ +
 ( 216 
other cell types in vi tro+ ;CQW,man,chicken + 
ganglioside,cultured smooth muscle- 196 
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As with endothelium, different subtypes of pericytes may be found in different organs and in 
different segments of the microvasculature [70,90,141,142,227]. For example, pericytes of the brain 
have lysosomal inclusions which are strongly reactive for acid phosphatase [70]. These inclusions are 
not found in pericytes of other organs. In capillaries, pericytes contain the non-smooth muscle isoform 
of myosin, in contrast to pericytes of venules which predominantly have the smooth-muscle isoform 
[141,1421. In the sinusoids of liver and spleen, generally believed to lack pericytes, probably related 
cell types, i.e. the Ito cell and the spleen sinusoid reticular cell, respectively, are found [90,105,243]. 
Function of pericytes 
Based on biochemical and morphological observations several functions have been attributed to 
pericytes [243,244]: 
1) Contractile role: the pericyte was originally regarded as the contractile cell of the 
microvasculature. Recent ultrastructural studies in situ and biochemical studies of cultured cells 
show that pericytes, like smooth muscle cells, have all the necessary equipment to act as such, i.e. 
contractile proteins, high levels of GMP-dependent kinase, and receptors for the potent 
endothelial-derived vasoconstrictor endothelin [146,163,244,252]. In in vitro experiments it was 
shown that cultured retinal pericytes and to a lesser extent microvascular endothelial cells can 
indeed contract (in contrast to aortic endothelial cells) [146]. However, a contractile role has never 
been convincingly demonstrated in vivo. 
2) Role as resting stem cell: in one study, pericytes in rat lung were shown to be capable of 
differentiating into smooth muscle cells under the influence of hypoxia [182]. It is also recognized 
that pericytes and smooth muscle cells have many features in common and intermediate forms have 
been described in studies of microvascular ultrastructure [116,244]. These observations have led 
to the hypothesis that pericytes can act as precursors of smooth muscle cells or even of other cells 
in tissue repair and inflammation [244]. 
3) Phagocytosis: in the central nervous system, but not at other sites, pericytes were observed to have 
phagocytosed foreign material [244]. 
4) Coordinatinp role of endothelial function: based on the elaborate pericyte-endothelial contacts in 
the microvasculature it was suggested that pericytes might act as coordinators of endothelial 
functions [64,149,244]. 
5) Supportive role in capillary rigidity: in diabetic retinas depleted of pericytes, microaneurysms and 
other defects frequently develop. This has been attributed to the absence of pericytes [67,244]. 
6) Role in angiogenesis and wound healing: from early morphological studies of developing retinas 
and the diabetic retina, it was suggested that pericytes play a regulating role in angiogenesis: In 
developing retinas newly formed vessels lack pericytes; when these appear mitosis of endothelial 
cells is not observed any more [153]. In diabetes, depletion of pericytes from the retinal 
microvasculature precedes pathologic neovascularization [67]. This presumed role of pericytes will 
be further dealt with in the following chapters. 
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The extracellular matrix (ecm) 
Basal lamina 
Endothelial cells and pericytes rest on a basal lamina (BL), 40-200 nm thick, consisting of a lamina 
densa and lamina lucida. It contains collagen Type IV, laminin, heparan sulphate proteoglycan, 
nidogen, entactin and other proteins [17,158,161,172,244]. Collagen Type V, fibronectin and 
thrombospondin are also associated with the basement membrane, but their precise localization is not 
well known [17,157,204,244,249]. The basal lamina provides structural support and behaves as a 
transport barrier. Furthermore, growth factors and clotting factors are bound to it. The different BL 
components are probably also involved in modulation of differentiation, growth and migration of cells 
during tissue regeneration [106,158], as integrin receptor molecules reacting with these basement 
membrane components have been found on their surface. 
Ground substance 
Outside the microvascular basal lamina, fibrils of collagen types I and III, elastin and microfibrils are 
embedded in an amorphous ground substance consisting of proteoglycans and glycosaminoglycans, 
e.g. hyaluronic acid and chondroitin sulphate [204,244]. 
Methods in microvascular research 
In situ morphological analysis 
Histology 
Histological studies of the mierovasculature can be performed at the light and electronmicroscopic 
level [244,301]. They have provided information on the structure of microvessels in different organs 
and under different conditions. Identifying microvascular structures and their constituting cells and 
extracellular substances is often difficult by conventional histological staining methods alone, as these 
lack specificity for such different components. 
Immunohistochemistry 
The advent of vascular antigens (markers) has enabled a more precise study of the mierovasculature 
in situ [160,161]. The markers can be detected by immunohistochemical staining methods by which 
antigens in situ are demonstrated, usually by their reaction with peroxidase-labeled antibodies which 
is visualized by an enzyme staining procedure [192,232,266]. Unfortunately, most of these markers 
are not detectable in routinely processed paraffin embedded or epon embedded tissues. Therefore 
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either elaborate alternative tissue processing procedures are needed to preserve marker staining, or 
the use of frozen sections [161] (Chapter 2). 
Immunohistochemical staining for those cellular antigens that are related to a specific function of 
endothelium or pericytes may provide information on the sites and level of antigen expression in 
relation to different physiological and pathological conditions [156]. 
Injection techniques 
Techniques employing the injection of various substances visualizing the angioarchitecture of tumors 
have been used by many investigators [69,166,259,271]. Indian ink [166], fluorescent dyes and 
erythrocyte staining with benzidine [69] enable subsequent histological visualization. Also, 
microradiographical examination of tumors after injection of contrast agents has been performed [103]. 
More recently, the vascular corrosion casting technique was introduced, by which resin casts of the 
microvascular system can be examined in great detail by scanning electron microscopy [111,112]. 
Drawbacks of these techniques are that only the perfused vasculature is visualized, and also that only 
little information is obtained on the structure of the vascular wall. 
In vivo studies 
Intravital microscopy 
Studies of the microvasculature in vivo have been performed on living animals by means of intravital 
microscopical observation of the bat wing, and of granulation tissue and tumor deposits in the 
transparent chamber technique. These chambers are implanted in the rabbit ear [223], in the hamster 
cheek pouch (Sanders-Shubik chamber [222]) or in the dorsal skin of mouse [2] or rat [210]. From 
these models data on blood flow and permeability of microvessels, and on the early angiogenic 
response and angioarchitecture of tumors have been derived [134,135,136,242,281]. 
Angiogenesis models 
Angiogenesis, the process of microvascular growth, has mainly been studied in two animal models: 
1) Rabbit cornea model: An angiogenic stimulus is surgically placed in a corneal micropocket in 
rabbit eyes. Capillaries growing from the limbus towards this stimulus can be monitored grossly 
in vivo or studied by histological methods [77]. 
2) Chick embryo chorio-allantoic membrane (CAM): Living chicken eggs provide a useful model for 
the study of factors stimulating or inhibiting angiogenesis. These can be applied to the developing 
chorio-allantoic membrane of 5-10 day old fetuses where altered neovascularization can be 
monitored grossly or histologically [81,206]. 
Recently, in vivo implants of fibrin gels [148] and polymeric supports coated with collagen and 
Heparin Binding Growth Factor-1 have been introduced to study angiogenesis and granulation tissue 
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formation in vivo [24,261] Recovery of such implants allows histological and biochemical 
examinations [261] 
In vitro studies (cell culture) 
Endothelium 
Endothelial cell culture from umbilical vein was firmly established in the mid-seventies with the 
development of special culture media and the discovery of von Willebrand Factor (Factor VIII related 
antigen) as an endothelial marker [100,133) Since then, endothelial cells from many organs and 
different segments of the vasculature were successfully isolated and propagated in vitro The following 
sources are generally used and they are regarded as standardized endothelial cultures 
1) Human umbilical vein endothelium (HUVEC), source normal umbilical cords [100,133,267] 
2) Bovine aortic endothelium (BAEC), source newborn calf aortas [193] 
3) Human foreskin microvascular endothelium (MEC), source surgically removed foreskins from 
1-3 year olds [45,144] 
4) Brain capillary endothelium, source bovine cerebral cortex [155] 
Pericytes 
Pericytes have been successfully isolated and propagated in culture from brain tissues [244] As 
a specific marker discriminating between smooth muscle cells and pericytes is lacking, identification 
of pericytes in most of these studies was based on morphological grounds only [26,229,270] 
Unfortunately, succesful culture of pericytes from sources outside the nervous system sofar has not 
been reported 
The following types of pericytes are generally used 
1) bovine retinal capillary pericytes, source newborn calf eye 
2) bovine brain capillary pericytes, source calf cerebral cortex 
Co-cultures and in vitro models 
Several investigators have attempted to develop in vitro models of the microvascular wall and of 
vascular sprouting [76,155,177,187,197,198,230] Such models have great potential for the study of 
the interactions between the microvasular cells and the extracellular matrix The following seem 
especially useful 
1) three dimensional collagen eels with a monolayer of endothelial cells, which can be used as a 
model for tumor cell invasion, in this system the tumor promotor Phorbol Mynstate Acetate 
induces the endothelial cells to invade the collagen gel as capillary-like structures [158,186,187] 
2) aggegrates of endothelial cells cultured m plasma clots form vascular sprouts and channels In this 
model co-culture with tumor cells has been investigated [197] 
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3) HUVEC cultured on Matrieel. a culture substrate of basement membrane-derived proteins, and 
capillary endothelial cells from bovine adrenal cortex cultured in tumor-conditioned medium have 
been reported to form capillary-like tubes [76,158]. 
Angiogenesis 
Angiogenesis is the process of microvascular growth by means of sprouting and budding from a 
pre-existent vasculature, occurring in a number of physiological (embryogenesis, ovulation) and 
pathological (wound healing, diabetic retinopathy, tumor growth) conditions [77,94,230,281]. It should 
be distinguished from the de novo vasculogencsis as seen in the earliest embryonal development, by 
which blood vessels form by aggregation of endothelial progenitor cells [199]. 
Morphological aspects of angiogenesis 
From histological and ultrastructural studies of wound healing and the rabbit cornea angiogenesis 
model, it was deduced that angiogenesis follows a distinct stepwise pathway leading from an initial 
humoral stimulus to the eventual formation of a new capillary bed [1,8,31,32,33,228,230,279,280, 
298]. The partly overlapping steps are the following: 
1) During the initial phase of angiogenesis, the pre-existing vessels (capillaries and venules) become 
dilated, have increased permeability and their endothelial cells show signs of cell activation, i.e. 
a general increase in cytoplasmic organelles and decrease of endothelial junctions. 
2) Local basal lamina dissolution occurs by activation of proteases, subsequently endothelial 
abluminal cytoplasmic processes penetrate into the perivascular connective tissue. 
3) Migration of endothelial cells out of the vascular wall takes place towards the angiogenic stimulus. 
4) Migrating endothelial cells align in loose cords and sprouts. 
5) Lumen formation occurs in the advancing sprout by vacuole formation and curving of the 
endothelial cytoskeleton. 
6) The endothelial cells a few cells back from the tip of the sprout divide, the leading migrating cells 
do not undergo mitosis. 
7) Individual sprouts anastomose forming loops. New sprouts may derive from these loops. Onset 
of blood flow occurs. 
8) The newly formed vessels mature by deposition of a basement membrane and appearance of 
pericytes in their walls. The newly formed capillary bed is remodelled by regression, retraction 
and further sprouting [1,8,31,32,33,77,179,230,240,279,280,298]. 
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Regulation of angiogenesis 
Angiogenic factors 
Early work demonstrated that tumors acquire their vasculature by the ingrowth of blood vessels from 
the surrounding tissue [1]. The long suspected [127] existence of a humoral mediator of angiogenesis 
produced by these tumor cells was first demonstrated by studies showing induction of 
neovascularization in host tissue separated from tumor implants by Millipore filters [108] and the 
subsequent partial purification of an angiogenic factor [74]. In the past 20 years, a long list of 
components has been decribed showing angiogenic activity in vivo (in CAM or rabbit cornea) or an 
effect on endothelial migration or proliferation in vitro [77,80,86,106,230]. The angiogenic factors 
listed in Table V are mostly well-characterized and structurally different polypeptides (see also 
appendix II). 
The heparin-binding endothelial cell growth factors (HBGF): are at present considered most 
important [162]. They stimulate endothelial proliferation, migration, and the production of collagenase 
and plasminogen activator in vitro at concentrations of 1-10 ng/ml [80,106]. They also induce 
angiogenesis in vivo at equally low concentrations in chick embryo CAM and rabbit cornea [106,130]. 
In implanted sponges in rats they induce vascularized granulation tissue [260,261]. In addition to their 
angiogenic capacity, they have many other biological activities [106]. 
Interestingly, their corresponding genes lack a functional secretory signal sequence, and therefore 
the FGF's appear not to be secreted by their cells of origin [118,238,277]. Probably they leave the 
cells bound to extracellular matrix components, such as heparan sulphate proteoglycans [83,106]. 
Table V. Factors with angiogenic activity in bio-assays. 
Factor References 
1. Hepann-Binding Endothelial 80.83,106,118.130.140.147, 
Cell Growth Factors (HBGF) 177,238,260,261,277 
la. Class-1 HBGF: - acidic-Fibroblast Growth Factor (acidic-FGF) 
- Endothelial Cell Growth Factor (ECGF) 95,167,277,295 
1b. Cla9s-2 HBGF' - basic-Fibroblast Growth Factor (basic-FGF) 15,106,148,162,238,272 
2. Angiogamn 80,188 
3. Transforming Growth Factors (TGF> 80,274 
3a. TGF-alpha 
3b. TGF beta 
4. Tumor necrosis Factor-alpha (TNF-alpha) 80,86,296 
5. Vascular Permeability Factor (VPF) 35,145,165 
6. Platelet - Derived Endothelial Cell Growth Factor (PD-ECGF) 254 
7. Chemotacbc Factors 80 
8. Prostaglandins 303 
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Control of angiogenesis 
During embryogenesis and wound healing, rapid onset of an angiogenic response is followed by 
well-regulated neovascularization which stops when no further vascular outgrowth is needed 
[77,94,179,199,230] How these three phases in angiogenesis are regulated in vivo is poorly 
understood It is however well established that the above-mentioned angiogenic factors can elicit the 
initial formation of sprouts, with some of these factors probably acting directly on the endothelium 
(acidic and basic-FGF and TGF-alpha) while others might act indirectly via activation of inflammatory 
cells or mast cells (angiogenin,TGF-beta and TNF-alpha) [80] From in vitro studies using cultured 
capillary endothelial cells it was concluded that endothelial cells themselves have the capacity to form 
sprouts and capillary tubes [76,177,187,197] It is interesting that the most potent direct angiogenic 
factors (acidic-FGF and basic-FGF) can be isolated from normal resting adult tissues that have no 
apparant angiogenesis [106] In tissues these factors are therefore sequestered from the endothelium 
They might be retained within the cells of origin, or be deposited in basement membranes (basic-FGF 
bound to heparan sulphate glycosaminoglycans), as was recently demonstrated [83] Indirect 
angiogenesis factors, heparin or certain enzymes released by platelets and macrophages might act by 
mobilizing these factors from such storage sites [106] 
In addition to these factors, heparin and hepann-contaming mast cells may play a crucial role in 
angiogenesis [79] Furthermore, copper ion levels apparently influence the neovascular response to 
angiogenic stimuli in several model systems by an unknown mechanism [77] 
An important regulatory role during angiogenesis was attributed to basal lamina (BL) and other 
extracellular matrix (ECM) or ground substance components, such as laminin, fibronectin, 
proteoglycans and collagens [87,91,106,158,230] In addition, proteoglycans may have an angiogenic 
effect [289] In summary, in vitro on this subject studies show that 1) migration of cultured endothelial 
cells is enhanced by fibronectin [18,166], 2) interstitial collagens type I and HI stimulate endothelial 
proliferation [183,230] and 3) BL collagens type IV and V induce endothelial production of laminin 
and collagen type IV, endothelial differentiation and organization of the cells in tube-like structures 
[171,172] Furthermore, 4) it was shown that microvascular endothelial cells, when cultured on 
laminin, proliferate more rapidly than cells grown on collagen type IV [87] Similarly, deposition of 
laminin at the tips of advancing vascular sprouts in angiogenesis was demonstrated in vivo Collagen 
type IV was absent from the tips of sprouts but appeared during vascular maturation a few cells back 
from the tip of the sprout [87] 
Inhibition of angiogenesis 
One of the most exciting aspects of angiogenesis is the understanding of mechanisms of its arrest 
under physiological conditions, as this may lead to the development of therapeutic strategies inhibiting 
angiogenesis in pathological conditions such as tumor growth [46,75] A number of substances with 
anti-angiogemc action in bio-assays, or with anti-tumor activity in experimental animals, has been 
identified and isolated (Table VI and appendix III) 
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Table VI. Factors inhibiting angiogenesis. 
Factors derived from avascular tissues 
- cartilage 
- aorta 
- vitreous of the eye 
Protamme-sulphate 
Angiostatic steroids and heparin 
Collagen metabolism modulators 
- proline analogs 
- prolyl hydroxylase inhibitor 
- all-trans-retmoic acid 
Platelet Factor-4 (PF-4) 
140 kDa angiogenesis inhibitor 
D-penicillamme 
25Θ 
46,73,128,177,253 
129 
173 
208 
181 
Significance for biology and pathology 
Physiological conditions 
The turnover of endothelial cells in normal resting adult tissues is remarkably low, but angiogenesis 
occurs in a number of physiological conditions (Table VII). 
Table VII. Conditions associated with angiogenesis 
Physiological conditions embryonic development 
ovulation 
endometrial proliferation 
Pathological conditions wound healing 
thrombus organization 
retrolental fibroplasia 
diabetic retinopathy 
neovascular glaucoma 
atherosclerosis 
psoriasis 
chronic inflammation, e.g 
rheumatoid arthntis 
tumor growth 
tumorous endothelial 
proliferation, e.g. 
haemangiomas 
Kaposi sarcoma 
In the embryo, the earliest stage of vascular development is the vasculogenesis by the formation 
of vascular primordia from blood islands in the area vasculosa on the yolk sac [199,215]. From these 
early vessels a vascular plexus develops, which is, by means of angiogenesis (budding and branching 
of vessels), one of the sources of blood vessels during further embryogenesis. In studies using avian 
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chimeras, it was shown that in addition mesoderm throughout the embryo also retains the ability to 
differentiate into endothelium, in a fashion similar to the early vasculogenesis on the yolk sac 
[199,205,215]. Still, many tissues are invaded by sprouting primary vascular plexuses in a distinctly 
timed fashion [94,179,214]. For example, in the chicken brain, sprouts originating from the 
leptomeningeal vascular plexus invade the neural tissue at 3.5 days, when the neuroectoderm is 
proliferating and differentiating most rapidly [11,214]. 
Pathological conditions 
Wound healing : Capillary growth constitutes one of the main elements of granulation tissue 
development in wound healing [22,61,285]. Extravasated fibrin and factors released by macrophages 
and platelets probably play an important stimulating and regulatory role in this respect [7,13,190]. 
Histological studies of granulation tissue have demonstrated fine-pointed capillary sprouts and saccular 
sprouts in the most superficial layer and more mature vessels in the deeper layers [32,228,285]. 
Ultrastructural studies suggested that such vessels are surrounded by a loose meshwork of pericytes 
and their processes in these areas [61,275,285]. 
Thrombus organization : during the organization of thrombus material an intravascular fibrin network 
develops that is invaded by endothelial cells which probably originate from the adjacent vascular 
luminal surface. It was recently suggested however that monocytes, entrapped in the thrombus during 
clotting, can differentiate into myofibroblasts, endothelial, and smooth muscle cells [71,164]. 
Eve diseases : neovascularization in the retina, iris or cornea represents an important pathogenetic 
mechanism eventually leading to blindness in the course of diabetic retinopathy and other eye diseases 
[67,89,94]. Retinal hypoperfusion and resulting ischaemia may be a common pathway leading to the 
release of humoral factors provoking retinal angiogenesis and subsequent neovascularization of the 
normally avascular vitreous body. Diffusion of such factors into the aequous is believed to be the 
cause of neovascularization on the surface of the iris [94]. 
Tumor growth : continuous growth of a solid tumor is dependent on the formation of a new 
vasculature along with the tumor tissue [reviews 77,82,85,230]. This is mainly based on the following 
evidence: 
1) In tumors grown in transparant chambers, the growth rate is linear and slow before 
vascularization, but exponential and rapid after onset of neovascularization [1], 
2) Experiments in the rabbit eye demonstrated that without angiogenesis tumor deposits will not grow 
beyond a diameter of 2 millimeters, 
3) Angiogenesis inhibitors that are not cytostatic to tumor cells can inhibit tumor growth in vivo, 
4) In transgenic mice, development of neoplastic tumors in the pancreatic islets was preceded by the 
appearance of hyperplastic nodules displaying angiogenic activity [84,85]. In benign tumors of the 
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human breast, the occurrence of angiogenesis has also been regarded as a preneoplastic marker 
[77]. 
Angiogenesis in tumors is stimulated by factors produced by probably both the tumor cells and 
infiltrating inflammatory cells like mast cells and macrophages [78]. Interestingly, a new class of 
oncogenes was recently discovered encoding proteins structurally similar to the potently angiogenic 
fibroblast growth factors [ 106,180]. Furthermore, anti-angiogenic activity produced by normal hamster 
cells could be linked to a cancer suppressor gene, which is lost during neoplastic transformation of 
these cells [208]. 
Other factors than angiogenesis alone must determine the growth rate of tumors [93]. This was 
clearly demonstrated by recent studies by Ishikawa et al. They investigated the effect of transfection 
of an angiogenesis factor (PD-ECGF) into Ha-ras transformed NIH 3T3 cells on the growth of these 
tumor cells in vivo and the vascularization of the formed tumor nodules. Although the tumor cells 
transfected with PD-ECGF induced highly vascularized tumors in contrast to poorly vascularized 
tumors from non-transfected cells, both tumors had the same growth rate [131]. 
Cellular aspects of angiogenesis 
Endothelial cells 
Endothelium is the most important cell in the angiogenic response [78,91]. Elicited by external stimuli 
it performs a number of specific tasks in a distinct sequence [230]. As mentioned earlier, endothelial 
cells in vitro also have the inherent ability to organize in capillary networks [76,197] and exert these 
functions: 
Π basal lamina degradation : endothelium-derived enzymes are held responsible for degradation of 
the BL in the initial phase of angiogenesis. In support of this concept, cultured EC were shown to 
produce proteolytic enzymes, such as type IV collagenase, tissue plasminogen activator (tPA) and 
urokinase under the influence of angiogenic factors (basic-FGF) [110,143,213,300]. A sequence of 
proteolytic activations was proposed, with initial formation of plasmin by plasminogen activators, and 
subsequent activation of interstitial and type IV collagenases [213]. The latter and other specific 
proteases, by degrading collagens type 1,11 and III, might produce clefts and channels in the interstitial 
matrix allowing endothelial migration [185,213]. 
2) endothelial migration : Migratici of endothelial cells during sprout formation is independent of their 
dividing capacity. This was originally suggested by the isolation of factors with angiogenic activity 
in vivo, that did not affect proliferation of cultured endothelial cells but stimulated their directional 
migration in vitro [10,77,80]. Studies of angiogenesis in irradiated rat corneas showing that sprout 
formation occurred to a certain extent in the absence of endothelial mitosis further supported this 
theory [80,240]. 
In ultrastnictural studies of neovascularization in situ cytoplasmic processes on the abluminal side of 
endothelial cells and irregularity of their nuclei have been regarded as signs of amoeboid movements 
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of the cells The abluminal endothelial processes are 0 1 micron thick and up to 7 micron of length 
They have been mainly reported in the initial phase of sprout formation and at the tips of advancing 
sprouts [49,62,149,207] Ultrastructurally, these processes lack a basement membrane, but m 
immmunomorphological investigations at the light microscopical level they could be visualized by 
anti-laminin staining [236,237] Their function is unknown They may play a role in cell adhesion or 
collagenolysis during migration (see chapter 6) In a study of experimentally induced granulation tissue 
in fibrin gel-filled chambers, such processes were often attached to strands of the fibrin matrix, and 
these attachment sites displayed local syneresis, lending support to a function in the migration of 
endothelium through the matrix [61] 
In several EM studies of vascular sprouting, a typical cytoplasmic organelle of unknown function 
was observed in the migrating endothelial cells, the giant dense body, wich connected to mitochondria 
and multivesicular bodies [92,275] 
31 endothelial mitosis Endothelium in situ in conditions with neovascularization has a number of 
ultrastructural features previously described as endothelial 'activation' or 'regenerating endothelium', 
ι e increased number of organelles (mainly mitochondria and free ribosomes), enlargement of 
cytoplasm, paucity of plasmalemmal vesicles and irregularity of luminal and basal membranes 
[28,280] Autoradiographic labeling studies of skin wounds suggested that these features co-incide with 
endothelial proliferation [241] In experimental tumor angiogenesis and granulation tissue, endothelial 
mitosis was observed both in fully formed microvessels and in the proximal parts of vascular sprouts 
[275,280] Incubation of endothelial cells in vitro with angiogenic substances like basic-FGF induced 
their mitosis, as was determined by 3H-Thymidine uptake [86] 
Pericytes 
An important role in angiogenesis has been attributed to pericytes [42,153,203,244] Like endothelial 
cells, pericytes in immature vessels show several morphological features, described in early studies 
as pericyte "activation", ι e the cells are large, with signs of proliferation, altered orientation and 
dissociation from the endothelial cells [37,188] A recurrent dispute exists on the origin of these 
pericytes appearing in the vascular wall in the maturation phase of angiogenesis [3] The morphology 
of "activated " pericytes was regarded by some authors as evidence for these cells being derived from 
primitive mesenchymal cells [3,42,164] originating from blood-borne monocytes [42,71,164] In 
organizing thrombi, these would also give rise to fibroblasts, endothelial cells and smooth muscle cells 
[69,164] Others argue that pericytes, endothelial cells and fibroblasts all originate from pre-existing 
corresponding cells in adjacent connective tissue [32] No satisfying proof for either of these 
possibilities is yet available Still, many pericytes undergoing mitosis were observed in 
autoradiographic studies of vascular regeneration m wounds and tumors [8,241,280] suggesting an 
origin, at least partly, in pre-existing cells The presumed roles of pericytes in neovascularization are 
the following 
Π Inhibition of angiogenesis or endothelial mitosis Early descriptive studies suggested that pericytes 
are absent from newly formed sprouts and their parent vessels in the developing retina [153] These 
vessels stopped growing when pericytes appeared Similarly, in ultrastructural studies of vascular 
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development in granulation tissue, the appearance of pericytes was associated with vessel maturation 
and cessation of capillary proliferation [32,42,228]. Furthermore, degeneration and loss of pericytes 
is one of the earliest pathological changes observed in diabetic retinopathy, a condition characterized 
by uncontrolled neovascularization [92,153]. From these observations, it was suggested that pericytes 
exert a direct anti-mitotic effect on endothelial cells. Indeed, co-culture studies demonstrated decreased 
endothelial proliferation and migration [225] in the presence of pericytes or smooth muscle cells [5]. 
As the underlying mechanism activation of latent transforming growth factor-beta (produced by both 
cell types present) by direct pericyte-endothelial contact via pericyte processes [5] was suggested 
[5,6,225]. This activation appeared to be mediated by plasmin [225]. 
From the literature, a number of results argue against the above mentioned hypothesis. Although 
primarily concerned with other questions, several morphological and autoradiographic studies of 
vascular regeneration or neovascularization in wound healing and tumor growth included figures of 
endothelial cells in mitosis with closely apposed pericytes or pericyte processes [28,42,241,280]. 
Furthermore, pericytes were shown to completely surround the endothelium of capillaries in human 
and rat fetal brain, even in the earliest phases of their development [3,11]. With further vascular 
maturation in later stages of development, the number of pericytes actually decreased [11]. In human 
granulation tissue, vascular structures, including those resembling sprouts in the most superficial layer, 
were invested in a loose meshwork of pericytes and their processes [61,275,285]. These pericytes 
were intimately associated with the sprouting and proliferating endothelial cells by means of abundant 
cytoplasmic processes, caving into each others cytoplasm. Similarly, in some studies tumor vessels 
were also shown to contain many pericytes [123]. Nevertheless, autoradiographic studies show that 
in these conditions many endothelial cells are in mitosis, with endothelial labeling indices ranging from 
3-40% [51]. 
Lastly, in a study of angiogenesis in vitro using rat aorta ring expiant cultures, capillary-like structures 
containing sprouting and mitotic endothelial cells extended readily over a smooth muscle cell 
monolayer [55]. 
It is difficult to match these observations with an overruling inhibitory action of pericytes and smooth 
muscle cells on capillary growth in these circumstances. However, due to the lack of reliable markers, 
no systematic studies of the distribution of pericytes in the microvasculature of tumors and granulation 
tissue was ever performed. 
21 Support for endothelial cells : From the previously mentioned studies demonstrating newly formed 
vessels invested in a complete layer of pericytes and their basal lamina, it was suggested that these 
cells supply a scaffolding lending mechanical support to endothelium in immature vessels 
[11,244,285]. 
3) BL formation : Pericytes are thought to pay an important contribution to the production of BL 
components in immature vessels [244]. The formed components may in turn alter endothelial and 
pericyte behaviour. 
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The tumor vasculature 
The tumor stroma 
The tumor stroma contains connective tissue, inflammatory cells and vascular elements embedding and 
surrounding the tumor tissue The amount of stroma differs considerably between different types of 
tumors It is also different from that of normal tissues In general it has 1) a large interstitial space, 
2) a network of collagen fibres, 3) a hydrophihc gel formed by hyaluronate and proteoglycans, with 
a lower concentration than as found in normal tissues [136] and, 4) a high interstitial fluid pressure 
[135,136,137] These features probably cause altered values for diffusion of macromolecules and 
hydraulic conductivity in tumor stroma [reviewed in 135,136] 
The higher permeability of tumor vessels, mainly the peripheral large tumor vessels [57], results 
in extravasation of fibrinogen and other macromolecules Like in healing wounds, this leads to 
extravascular clotting resulting in the deposition of fibrin in the stroma This is the basis of the 
concept to regard tumors as non-healing wounds [58], taking the deposition of extravascular fibrin as 
a central event in the stroma generation of tumors This fibrin gel would function as a provisional 
matrix In support of this concept it was shown that both human and experimental animal tumors 
contain fibrin deposits [46,58,202], especially at the interface between tumor and host tissues and 
around individual cell formations in carcinomas It was also demonstrated that tumors produce a factor 
that increases vascular permeability (VPF.see angiogenesis factors), allowing leakage of 
macromolecules like fibrinogen By themselves, fibrin gels were shown to induce vascular sprouting 
in vitro [197] When implanted in experimental animals they attracted vascular ingrowth accompanied 
by fibroblasts and inflammatory cells leading to the formation of granulation tissue [61] In the former 
in vitro model, the formed capillary-like structures markedly enhanced spread of tumor cells in the 
fibrin clots [198] An almost identical sequence of events occurs during ordinary wound healing, 
differing from tumor stroma generation only in the nature of its initial stimulus, in the role of platelets 
and in its self-limiting course (healing) [for review 23,190] The place in this concept of the myriad 
of factors and cytokines with angiogenic capacity in bio-assays (Table V) remains to be determined 
Structure, organization and architecture of the tumor microvasculature 
As early as in 1863, the presence of a capillary network in tumors and its generation from the host 
vascular bed was demonstrated by Virchow and Thiersh, respectively [259,271] Since then, many 
authors have reported on the tumor angioarchitecture and its morphogenesis, mostly in descriptive 
histological or intravital studies of experimental animal tumors [reviewed in 134,278] The general 
conclusions from these studies are the following 
1) tumors acquire their vasculature both by incorporation of pre-existent vessels and by induction of 
neovascularization [278,282] 
2) the tumor vascular system often has a multiple arterial supply 
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3) the angioarchitecture of different tumors varies in many aspects, e.g. type of microvessels, 
vascular density, vascular volume and vascular surface area. 
4) every single tumor has its own particular microvascular organization and structure, which may 
alter with progressive tumor growth. 
5) this specific pattern is mainly dictated by the nature and (degree of) differentiation of the 
neoplastic cells. 
6) its characteristics are maintained in metastases of the tumor. 
7) with the exception of arteries, microvessels in and around tumors have altered morphological 
features when compared to normal tissue vessels, these alterations being more conspicuous in 
malignant than in benign tumors. 
Several authors have studied the relationship between the microvasculature and tumor cell 
proliferation [254]. With increasing distance from the vessels, proliferation of tumor cells decreased 
to approximately zero at distances around 80 micron [93,254], which is also the calculated critical 
oxygen diffusion distance in tumors [268]. Necrosis would then occur at distances of 90-160 microns 
[301]. From these studies, it appears that one of the causes of tumor necrosis is that tumors can 
outgrow their vasculature [93]. 
Furthermore, based on a series of early morphological studies [reviewed in 278] concerned with 
the angioarchitecture of human and experimental animal tumors [2,103,112,166,259,271], it appears 
that tumors may either have a peripheral vascularization, with new blood vessel formation occurring 
in or just outside the advancing edge of the tumor, or have a central vascularization and vascular 
proliferation expanding from the center of the tumor along with the tumor cells. Tumors of the former 
kind usually have necrotic centers, probably due to insufficient perfusion of their inner vasculature 
because of high interstitial pressure. Both peripheral and central vascularization patterns may occur 
in one tumor [57]. 
Types of tumor microvessels 
As stated earlier, tumor microvessels differ in some respects from their normal (tissue) 
counterparts. As outlined earlier, every normal tissue, depending on its architecture and function, has 
its own characteristic microvasculature. Therefore it is difficult to give abnormal features of tumor 
vessels in general terms. Furthermore, the functional significance of different vessel types in tumors, 
e.g. efferent or afferent vessels, is mostly unclear. According to Warren [278], blood flow in a tumor 
may either follow the obvious route from arterial to venous side, or may derive from venules and 
veins supplying the tumor microcirculation, thus constituting a "portal" type of vascularization. 
Another important aspect of tumor vascularization is the presumed complete absence of lymphatics 
[134,278]. 
Different types of microvessels are encountered in and around tumors [after Warren and Jain, 
134,278] (Table VIII, compare with table I). 
The walls of arteries and arterioles are remarkably resistent to the invasion of neoplastic cells, 
even when these vessels are incorporated in tumor tissue. During tumor growth, the caliber of 
supplying arteries may increase, but their anatomy remains like that in normal tissues. Differentiation 
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of newly formed vessels into arterioles was only observed in benign or highly differentiated malignant 
experimental tumors. In most tumors, therefore, newly formed arterioles and arteries are very scarce. 
Sinusoid capillaries are vessels with non-parallel walls consisting of an interrupted endothelial lining 
and occasional pericytes. They have been observed in poorly differentiated animal carcinomas [278] 
and human renal carcinomas, and resemble the sinusoids in liver and spleen. Some other abnormal 
microvascular structures in tumors: 
1) In gliomas, a characteristic feature of malignancy is the presence of glomerulus-like capillary 
collections, often described as "endothelial proliferation" or vascular glomeruli (120,226,287]. 
2) Giant capillaries are tortuous, wide-bored, vein-like vessels with a diameter of more than 50 
microns, and a wall showing ultrastructural features of capillaries or post-capillary venules, i.e. 
an endothelial lining with only little supporting fibrous tissue. Collections of these vessels, also 
named the venous capsule, have been found at the border of experimental tumors with a peripheral 
type of vascularization. 
As a manifestation of tumor angiogenesis, fragile capillary sprouts of the surrounded by red blood 
cells and fibrin deposits have mainly been observed extending from the host capillary bed during 
the initial vascular reaction to tumor implants in experimental tumor models [281]. In a given 
growing tumor, however, e.g. specimen of human tumors, it has been difficult to demonstrate 
convincingly the presence of capillary sprouts within the tumor tissue. 
Venules and veins make up a relatively large part of the tumor microvasculature, they are dilated and 
tortuous and often show saccular dilatations. From studies using injection or vascular casting 
techniques to visualize the functional vasculature, it was concluded that in some experimental animal 
melanomas, sarcomas and a carcinoma, blood channels existed without an endothelial lining [278]. 
Tumors may also contain direct shunts from the arterial to the venous side of the circulation. 
Cellular constituents of tumor vessels 
Endothelium 
Morphological and immunohistochemical aspects 
Ultrastructural studies of tumor vessels have demonstrated several cellular morphological abnormalities 
also seen in "activated" endothelium. In general, these vessels have endothelial cells with 1) 
hypertrophic, plump cytoplasm showing signs of active protein synthesis, 2) infolding of the luminal 
surface, 3) fenestrations, 4) saccular endothelial luminal membrane processes and microvilli and 5) 
an irregular, thickened, multilayered, but sometimes partly absent basal lamina [20,122,184,276,282]. 
These morphological properties are similar to those of immature vessels as observed in wound healing 
[32,224]. 
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Table Vili. Types of microvessels in tumors 
Arteries end arterioles Blood channels 
Fenestrated capillaries Giant capillaries 
Non-fenestrated capillanes СарШагу sprouts 
Sinusoid capillaries Venules and veine 
Vascular glomeruli Arteriovenous anastomoses 
In capillaries in primary and metastatic brain tumors, the presence of endothelial fenestrations, 
increased number of pinocytotic vesicles and lack of tight junctions has been demonstrated. In gliomas, 
such features were most conspicuous in the more malignant high-grade tumors [184]. These 
endothelial abnormalities, which contrast with normal brain capillaries, were considered to represent 
the absence of a Blood-Brain Barrier in these tumors [122,168,169,184]. In brain and colorectal 
tumors, endothelial cells were shown to have increased numbers of Weibel-Palade bodies, in brain 
tumors especially in their periphery [122,152,276]. 
An intriguing phenomenon observed in high grade malignant gliomas is the occurrence of 
glomerulus-1 ike vascular "proliferations" or "endothelial hyperplasia". It has been postulated that these 
vascular proliferations are the first step in sarcomatous progression leading to the development of 
gliosarcomas [109). Endothelial hyperplasia is mainly found in the cerebral cortex in the final stage 
of glioma infiltration, in areas with pleomorphic cells or near areas of necrosis [226,287]. The 
vascular glomeruli take origin from radially penetrating vessels from the meninges and their lateral 
branching [226]. By light microscopy, they appear as collections of capillaries with thick walls of 
multiple cell layers. At the subcellular level, they consist of complex, compound immature capillaries 
with many rudimentary lumina and closely packed "endothelial" cells with many Weibel-Palade bodies 
and an abundancy of other cellular organelles [122,287]. The pathogenesis of this phenomenon and 
the exact nature of the cells partaking in "endothelial" hyperplasia are poorly understood [286]. In 
immunohistochemical studies it was shown that the cells lining the lumina are stained by Ulex 
Europaeus I lectin (UEA I) and for vonWillebrand Factor (Factor VHI-related antigen (vWF)), 
suggesting an endothelial nature [224,226,248]. The cells away from the lumina, however, were 
negative for UEA I [248,286] and stained for vWF in diminishing intensity with increasing distance 
from the lumen. These multilayered perivascular cells are surrounded by basement membranes 
containing collagen type IV and laminin [13]. They sporadically express alpha-smooth muscle actin 
(a-SMa), a marker for pericytes [226], but most of these cells are negative for both vWF and a-SMa. 
Still, most authors believe that these hyperplastic cells, which do not line visible lumina, are also of 
endothelial origin [120,224,248]. 
By in situ hybridization, it was shown that cells in endothelial hyperplastic areas contain increased 
levels of messenger RNA encoding for both Platelet Derived Growth Factor (PDGF) В chain and the 
PDGF type В receptor [120]. This was unexpected, as endothelial cells , which are known to produce 
PDGF [12,54], do not express its receptor [120]. From their observations, these authors postulated 
that endothelial hyperplasia is based on an autocrine activation in endothelial cells of the PDGF 
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receptor pathway generating a mitogenic signal. Evoked by the surrounding glioma cells in an 
unknown way, this autocrine activation would lead to endothelial hyperproliferation. A similar 
mechanism was proposed for Kaposi sarcoma involving a Fibroblast Growth Factor-like oncogene 
product [48]. Unfortunately, as these authors presumed that all cells in vascular glomeruli are of 
endothelial nature, the alleged co-expression of PDGF and its receptor was derived from observations 
in serial sections of "endothelial'' hyperplasia, thus leaving the possibility that different microvascular 
cell types, if present, express these molecules. In chapter 8 of this thesis, we demonstrate that 
pericytes (expressing HMW-MAA) contribute substantially to the perivascular cells in vascular 
glomeruli in gliomas. This finding could lead to a different interpretation than as outlined above. It 
is notable that smooth muscle cells, which are closely related to pericytes, were shown to express the 
PDGF receptor in vitro [12,34,54], and are thought to be stimulated in vivo by endothelial-derived 
PDGF in a paracrine fashion [IS]. In vitro, PDGF stimulates smooth muscle cell proliferation and 
concomitantly selectively increases synthesis levels of a large chondroitin sulphate proteoglycan 
(CSPG) by at least two-fold [293]. Another cytokine, TGF-beta, stimulates smooth muscle cell 
synthesis of two different (but only partly defined) CSPG even by ten-fold, but not their proliferation 
rate [30]. A similar stimulation of pericyte proliferation (and proteoglycan expression) in vascular 
glomeruli by endothelium-derived PDGF or TGF-beta would provide an alternative explanation of the 
pathogenetic mechanism of "endothelial" hyperplasia. 
Few immunohistological studies have been concerned with endothelial cell properties in tumor vessels. 
Endothelial expression of the Epidermal Growth Factor receptor was demonstrated in capillaries in 
a small series of meningiomas, in fetal cerebral tissues, in regenerating vessels in an organizing 
cerebral haematoma and cortical infarction, and in normal adult choroid plexus [239]. The implications 
of these findings in this limited series of tissues are not clear but the authors speculate on an 
association with the angiogenic response. 
Others have demonstrated differential patterns of vWF expression in tumor vessels in colorectal 
carcinomas on the subcellular level [201]. The endothelial cells in these tumors had more vWF in the 
rER, in round granules and in the subendothelium, but less at their luminal membrane than in 
capillaries in normal tissues [201]. 
Lastly, a monoclonal antibody was described, EN7/44, recognizing a 30.5 kDa antigen of unknown 
function expressed by a subset of endothelial cells in culture, and in situ by capillaries in tumors, 
placenta, normal adult intestine and conditions with acute inflammation [114]. In tumors, endothelium 
of larger vessels was also recognized by this antibody. These authors concluded that EN7/44 staining 
marks migrating and proliferating endothelial cells in situ and, therefore, that these cells express 
distinct phenotypic characteristics, presumably at the tips of budding capillaries [114]. 
Functional aspeas 
Endothelial proliferation : Since the development of specific precursors of DNA enabling 
demonstration of proliferating cells by autoradiography (using tritiated Thymidine) or immunohistology 
(using Bromodeoxyuridine), many studies were undertaken assessing endothelial cellular kinetics in 
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the tumor vasculature [50,51,52,113,124,257]. From these studies, it appears that endothelium in 
experimental animal tumors proliferates much more rapidly than in normal resting tissues: endothelial 
labeling indices (cells in S-phase) in tumors average around 10 % in contrast to normal tissue values 
which are around 0.20%, suggesting a 40-50 fold difference in proliferation rate. This is supported 
by estimations of the turn-over time of endothelium in tumors, which is approximately 5-10 hours 
compared to 100-1000 hours in normal tissues. Similar findings have been reported for a small series 
of human tumors [51]. In a rabbit brain tumor model, employing the rabbit VX2 carcinoma, 
endothelial labeling index in the tumor center was much lower (1.7%) than in the periphery and just 
outside the tumor (26%) [21]. 
These studies, however, share two important technical drawbacks. Endothelial cells were identified 
only on the basis of their position in vessel walls near vascular lumina. This method thus necessarily 
ignores the smallest vessels or seemingly solid vascular sprouts which might have different endothelial 
proliferation characteristics. Secondly, this method does not reliably differentiate between endothelial 
cells and the also abundantly present pericytes in tumor vessels (chapter 8 of this thesis). As pericytes 
also proliferate in tumors [280], it seems more appropriate to regard the above-mentioned data as 
representing the kinetics of microvascular cells, i.e. endothelial cells and pericytes together. 
Microvascular permeability : As mentioned previously, tumor microvessels are more permeable to 
macromolecules than normal tissue vessels [121], as shown in brain tumors by the loss of the 
Blood-Brain Barrier characteristics. Quantitation of permeability has been performed by means of 
intravital fluorescent microscopy measuring concentrations of fluorescent molecules in VX2 carcinoma 
interstitium in the rabbit ear chamber [134,135,136]. These studies have shown that the microvascular 
resistance to macromolecules in tumor vessels is considerably less than that in mature granulation 
tissue and this difference increases with increasing molecular weight of the tested molecules 
(approximately eight-fold for 150 kDa dextran) [136]. 
Haemostatic properties : The endothelium of the tumor vasculature probably has altered coagulant 
properties as compared to normal resting endothelium. This was first suggested by the presence of 
microvascular occlusion caused by intravascular clotting as observed in tumors of animals treated with 
Tumor Necrosis Factor/cachectin (TNF) [27,193,194,283]. Subsequently it was shown that cultured 
endothelium acquires procoagulant properties under the influence of TNF [194]. Also certain 
tumor-cell derived factors have been isolated that induce tissue factor expression on cultured 
endothelial cells or render them more sensitive to TNF [194]. Furthermore, non-confluently cultured 
endothelium in the growing/motile state also has enhanced responsiveness to TNF compared to 
post-confluent cultures [98]. These studies suggest that, enhanced by tumor cell-derived factors or 
lymphokines, regenerating endothelium in tumors has an increased tendency to express pro-coagulant 
properties. 
Pericytes 
Little is known about function, structure and distribution of pericytes in tumor vessels. Light 
microscopical studies of tumor vessels can not distinguish properly between endothelial cells and 
pericytes and in ultrastructural studies of vascular structures the focus has usually been on features of 
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the endothelium [122,169,282]. Conversely, pericyte researchers have not been particularly concerned 
with the role of these cells in tumors [244]. The lack of markers for pericytes has prevented systematic 
investigation of the properties and distribution of pericytes in tumors. In three ultrastructural studies 
of small series of brain tumors, it was observed that the microvasculature contained an increased 
number of pericytes, which were larger than those in normal brain capillaries [123,184,287]. In a 
study of an experimental rat tumor, other authors have shown increased numbers of desmin-positive 
perivascular cells in the area of vascular development around the implants. These cells were also 
present in the vessels within the tumor tissue, but in lower numbers. They could be identified as 
pericytes by electron microscopy [282]. These studies suggest that tumor vessels have increased 
numbers of pericytes as compared to normal tissues. In human tissues, pericytes do not express 
desmin, but a study of the expression in human gliomas of alpha-smooth muscle actin (aSMa), another 
marker for pericytes, demonstrated only very few positive vessels [226]. In chapter 6 of this thesis, 
we demonstrate that this is related to the presence of large numbers of HMW-MAA-positive, 
aSMa-negative pericytes in the tumor microvasculature. As aSMa is a contractile protein, the proposed 
contractile fuction of pericytes might therefore be absent from tumor capillaries. This would be in 
concert with the absence of autoregulation of blood flow and presumed lack of contractile elements 
in tumor vascular beds [251]. 
Role of the microvasculature in tumor diagnosis and therapy 
For various reasons, the tumor microvasculature is an interesting potential target in tumor therapy or 
diagnostic imaging: 
1) Tumor growth and maintenance is dependent on angiogenesis and the microvasculature, 
respectively [85]. 
2) unlike the tumor cells themselves, the microvasculature is easily reached by circulating substances, 
especially macromolecules [57,137], 
3) in tumor areas with impaired blood flow, the functionally patent vessels will still be reached. 
4) as one single tumor capillary supplies a large number of tumor cells, selective destruction of tumor 
vessels will cause necrosis of relatively large tumor areas. 
5) as the target cells are activated, but still normal, diploid stromal cells they will therefore probably 
not become resistent to a given therapeutic approach, like tumor cells are able of by mutation in 
the neoplastic genome. 
6) in contrast to most antigens in tumor cells, many microvascular antigens may show no major 
degree of heterogeneity. Therefore, all microvascular cells in a tumor could be recognized by 
monoclonal antibodies directed against microvascular markers. 
Four therapeutic approaches have been postulated in this context: 
1) anti-angiogenesis, i.e. inhibiting neovascularization by specific components [44,75]. 
2) modulation of tumor blood flow using specific agents or hyperthermia [189,211]. 
3) anti-endothelial proliferation, i.e. developing ways of specifìcally inhibiting the proliferation of 
endothelial cells,e.g. by anti-mitotic drugs that stay within the circulation [50,51]. 
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4) anti-tumor endothelium monoclonal antibodies, i.e. identifying phenotypic differences between 
endothelium in tumors versus normal tissues [50,51,159]. 
Until now, only the first two approaches have been applied successfully in experimental animal tumors 
[85,253]. It has also been suggested that many other established cancer treatment modalities have an 
effect on tumor growth by affecting the tumor microvasculature [51]. 
Vascular markers in pathobiology 
General aspects 
The advent of the monoclonal antibody technique has enabled visualization of antigens by 
immunohistological staining methods with a high degree of specificity [ch.2 and 3]. Application of 
these techniques in order to visualize the tumor microvasculature has been the main theme of the 
studies presented in this thesis. Three approaches are possible in this respect: 
1) Identification of the presence of vascular structures, e.g. in histopathological studies of 
microvascular architecture and of vascular invasion in tumors. For this purpose, basal lamina and 
endothelial markers have been widely used with varying efficacy [161,ch.2], 
2) Identification of the cellular elements of microvessels, i.e. endothelial cell, pericytes and smooth 
muscle cells, by recognition of constitutive markers for these cell types, if these were available. 
Such markers could be useful in studies into the distribution of these cellular elements in tissues, 
the classification of poorly differentiated tumors, and the identification of cultured cells; 
3) In situ visualization of antigens with an alleged function in the microvasculature of normal tissues 
or pathological conditions,e.g. differential expression of endothelial activation antigens [138]. 
Endothelial markers 
Markers for the endothelial cell have been identified by means of monoclonal antibodies, polyclonal 
antisera and lectins. Monoclonal antibody-defined markers are dealt with in chapter 2 of this thesis. 
Lectins binding to endothelium with varying specificity are Ulex Europaeus I lectin [125] (also 
reactive with several epithelia) and Dolichos biflorus and Grifonia Simplicifolia lectins (mouse 
endothelium). Polyclonal antibodies to von Willebrand Factor and Angiotensin Converting Enzyme 
were also used as vascular markers. Lectins and polyclonal antisera are often reactive with paraffin 
embedded formalin-fixed tissue sections, making them useful in routine histopathology. It is notable, 
that none of the presently known and well-caracterized markers is either fully specific nor fully 
sensitive for endothelium. Cross-reactive cells are either of epithelial origin (e.g.UEA-I), or of 
haemopoietic lineage (e.g. vonWillebrand Factor.MoAb HEC-l,MoAb 44G4) [ch.2]. 
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These antibody or lectin-defined endothelium-associated molecules are often of unknown function. 
In addition, a large number of components with alleged functional significance in endothelial biology 
has been described in biochemical studies. Table III lists examples of such molecules, present on the 
surface or in the cytoplasm of endothelial cells or secreted by them (an almost complete list of the 
presently known components is given in appendix I of this thesis). It is striking that most of these 
components have a heterogeneous expression among different endothelia [40,68]. Furthermore, many 
are shared by other types of cells. Often these molecules have only been identified in cultured 
endothelial cells, no antibodies are available, and studies into their expression or function in vivo have 
not been performed. 
Pericyte markers 
Only a very limited number of components has been specifically linked to pericytes (Table IV). Most 
of these are shared with smooth muscle cells (SMC), especially vascular SMC. As a marker for 
pericytes in tissue sections, only alpha-smoolh muscle artin (aSMa) has been proposed [246,247], 
although specificity is limited (smooth muscle cells also positive). A MoAb 3G5 has been described 
as a specific marker for cultured human and bovine pericytes [196]. 
Basal lamina markers 
Antibodies reactive with collagen type IV and laminin have proved useful as vascular markers [161]. 
In most tissues, their distribution patterns overlap. Cross-reaction with basal laminas of other cells, 
however, often hampers precise identification of vascular structures [17,161,290]. 
Microvascular markers in the tumor stroma 
As already described in preceding paragraphs, vascular markers have been used to study the 
angioarchitecture of tumors, the invasion of vascular structures by cancer cells and the differential 
expression of specific components like vonWillebrand Factor or epidermal growth factor receptor by 
tumor endothelium in situ. Thereby, cellular functional properties of the tumor microvasculature are 
indirectly investigated. Such marker studies may provide information on the distribution of 
endothelium and pericytes in these vessels. The recognition of special properties of tumor vessels has 
an important potential clinical application, as monoclonal antibodies reacting specifically with tumor 
endothelium may be useful in diagnostic imaging or therapeutic targeting of tumors in vivo. 
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Aims of the study 
Our main interest is to find differences between the tumor microvasculature and the vessels in 
normal tissues. This may lead to a better understanding of the role of the microvasculature in tumor 
pathology but may also result in the development of therapeutic strategies aimed at the eradication 
of tumor capillaries. Monoclonal antibodies recognizing microvascular antigens may be especially 
useful in this respect. 
In the studies executed in this thesis we have specifically addressed to the following questions: 
1. Is it possible to develop monoclonal antibodies recognizing endothelial markers with a high degree 
of sensitivity and specificity? 
2. What are the properties of these and other previously described endothelial markers? 
3. What is the utility of such antibodies in diagnostic and experimental histopathology? 
4. Are there differences regarding microvascular constituents in tumors as compared to normal 
tissues? 
5. What are the distribution and phenotype of the different cellular constituents of the 
microvasculature in tumors and in granulation tissue of wound healing? 
In preliminary studies differential staining patterns between tumors and normal tissues were observed 
for the leukocyte antigen CD 34 and the high molecular weight melanoma associated antigen (HMW-
MAA). Therefore, the following questions were also addressed: 
6. What is the distribution of leukocyte antigen CD 34 in endothelium in culture and in situ in normal 
tissues and the tumor stroma? 
7. What is the distribution of the pericyte antigen HMW-MAA in cultured pericytes and in the 
microvasculature of normal tissues, the tumor stroma and granulation tissue? 
8. Is it possible to identify the different stages of sprout formation by the angiogenesis model 
proposed by Folkman [77] in human tumor lesions and in granulation tissue of wound healing? 
Approach 
Based on the foregoing, we have started our investigations on the biology of the tumor 
microvasculature. Firstly, the development and characterization of reliable vascular markers was 
needed to enable visualization of tumor microvessels and to compare our staining results with those 
in the literature (Chapters 2,4,6 and 7). Secondly, microvascular antigens were also visualized at the 
ultrastructural level which allows highly accurate documentation of their distribution (Chapters 2,4,5 
and 6). In the course of our investigations it appeared that in addition to the endothelial cell (chapters 
4 and 6), also the pericyte in tumor microvessels is a worthwile object of study (chapter 7). The 
establishment of cultures of pericytes (from human cerebral cortex) and endothelial cells from 
microvessels (human foreskin) and large vessels (human umbilical vein) allowed further study of the 
implications of the in situ observations as done in tissues (chapters 3,6 and 7). 
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Introduction 
A host of different antigens has been identified on human endothelial cells. These include 
alloantigens involved in graft rejection, antigens that can serve as endothelium differentiation 
markers, antigens involved in specific functions, such as antigen presentation, cell-cell recognition, 
hemostasis or clotting, and endothelial antigens inducible by cytokines [1,2]. 
In fact these antigens probably represent only a minority of the molecules involved in the complex 
biology of the endothelial cell. Examples of such molecules that thus far have not been defined by 
antibodies are the vasoconstrictor molecule endothelin and the vasorelaxing molecule nitric oxide. 
Other molecules, such as thrombomodulin or tissue factor, have not been used extensively in 
immunocytochemical studies for various reasons. These kinds of molecules will not be discussed 
further. 
In a true sense the term antigen is applicable to the alloantigens only, because they serve as a 
target for the humoral or cellular immune response, or both, in a graft recipient [2]. Other 
endothelial molecules are antigens in a broader sense because antibodies to them have been raised 
in another species to obtain a reagent useful for the identification of endothelial cells by 
immunocytochemistry. Most of the latter antigens probably do not play a role in graft rejection. 
Several endothelial antigens are shared antigens, i.e., they are also present on other cell types. 
In the past, some human endothelial antigens were either identified by conventional polyclonal 
antibodies or by immune competent cells in cytotoxicity assays. Examples of the first mentioned 
antigens are angiotensin converting enzyme [3] and Von Willebrand factor (Factor ПІ-related 
antigen) [4]. Monoclonal antibody technology has enabled the development of a series of specific 
antibodies that recognize previously undefined different antigens on endothelial cells. Using 
immunocytochemistry these monoclonal antibody-defined antigens can serve as vascular endothelial 
markers. A tentative classification of endothelial markers includes two overlapping categories, i.e., 
1) differentiation markers and 2) functional markers (Table I). 
Differentiation markers can be divided into constitutive (being present in all types of 
endothelial cells) and restricted (showing a distribution limited to (a) certain endothelial cell 
subtype(s), e.g., microvascular, venous, and arterial). 
In this review we focus on antigens of the human vascular endothelium, that have either 
initially been identified by monoclonal antibodies, or have been used as vascular markers in human 
oiology and pathology. Other components of the vascular wall, basal lamina, pericytes, or vascular 
smooth muscle cells, also contain more or less specific antigens, that can be used as 
immunomorphologic markers for these structures. The basal lamina contains laminin, collagen type 
Г , fibronectin, and heparan sulphate proteoglycan [5]. Pericytes and smooth muscle cells contain 
smooth muscle actin [6, and personal observations] in contrast to endothelium. Smooth muscle 
cells contain desmin in contrast to both other cell types. 
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Table I. Tentative classification of monoclonal antibody defined human endothelial antigens 
used as vascular markers 
Differentiation • Constitutive all endothelial cells 
Restricted subtype-related 
Functional related to delined biologic function 
The aim of this contribution is to make an inventory of the properties of the monoclonal 
antibody-defined endothelial antigens, and to give a critical review on their sensitivity and 
specificity in terms of their ability to serve as an immunomorphologic marker for human vascular 
endothelium. Furthermore, we discuss the immunocytochemical procedures useful for the 
identification of endothelial cells, and the application of the monoclonal antibodies in diagnostic 
pathology. Lastly, some applications in studies on the pathobiology of human vascular endothelium 
are briefly mentioned. 
Properties of monoclonal antibody-defined 
human endothelial antigens that serve as vascular markers 
A series of different antigens on human endothelium have been described that are recognized 
by monoclonal antibodies (Table II), and that serve as vascular markers using 
immunocytochemistry [3,7-12]. With the exception of angiotensin-converting enzyme and Factor 
VHI-related antigen, only limited date are known on the nature of the molecules recognized. Based 
on differences in molecular weight, binding properties, and tissue distribution, it is evident that the 
antigens involved are different entities. 
Sensitivity of most of these monoclonal antibodies for the different types of vascular 
endothelial cells is high, because capillary, venous, and arterial endothelial cells are recognized. 
Because monoclonal antibodies RPAH 21-42/43 recognizing Factor VIH-related antigen [9] and 
BW 200 [11] not only are effective on frozen but also on paraffin sections, they are broadly 
applicable in diagnostic pathology (see Application of Monoclonal Antibodies section), as are the 
conventional polyclonal anti-Factor VHI-related antigen antibodies [13]. Specificity of the 
monoclonal antibodies PAL-E [10] and BW 200 [11] for vascular endothelium is high. The other 
monoclonal antibodies listed either were not extensively tested on tissue sections, or have shown 
reactivity with non-endothelial cells. It should be mentioned here that it is not clear from the data 
provided whether most of the antibodies listed in Table II recognize lymphatic endothelium. So 
far, it has been described that Factor VIH-related antigen and the EN 3/EN 4 antigen [14] can be 
detected in lymphatic endothelium and the PAL-Ε antigen cannot [10]. Immunohistochemical 
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examination of specimen from other species thus far indicate that only BW 200 is restricted to 
human tissues [11]. 
Based on their tissue distribution the differentiation antigens (listed in Table 11) ACE, p92, gp 180-
gp 90, Factor VHI-related ag, and gp 200 can be identified as constitutive, and the PAL-Ε ag and 
EN-3 ag as restricted. In addition, ACE and Factor VHI-related ag can be considered as a 
functional marker. Obviously, differentiation markers of the constitutive type are useful in the 
identification of human endothelial cells in cell suspensions and tissue sections [3,4]. 
Differentiation markers of the restricted type may be useful for the identification of endothelial 
subtypes. Markers for particular endothelial functions are discussed in a later paragraph. 
Table II. Monoclonal antibody-defined human endothelial antigens as vascular markers 
Monoclonal 
Antibody 
Anti-ACE 3 . 1 . 1 . 
(IflM)· 
С IV and (E92) 
С VI (IgG) 
HEC-1 (IgM) 
RPAH 2 1 - 4 2 (NT) 
and 2 1 - 4 3 
PAL-Ε (lgG,a) 
B W 2 0 0 -
B M A 1 2 0 ( l e G ^ I 
E N S = 
EN 4° (IgG,) 
Antigen 
Angiotensin 
converting enzyme; 
Cell surface 
P 9 2 ; 
Cell surface 
gp 1 8 0 (non red.) 
gp 9 0 (red.); 
Cell surfece 
Von Willebrend 
factor 
(F VIII R-Ag); 
Cytoplasm 
subendothelium 
Not Known; 
Cell Surface 
gp 2 0 0 ; 
Cell surface and 
cytoplasm 
Not k n o w n ; 
Cell surface and 
cytoplasm 
Endothelial 
Cell Stained 
art + 
ven + 
cap + 
F 
art + 
ven + 
cap + 
spi sin. 
F 
art + 
ven + 
cap + 
F 
art + 
ven + 
cap + 
lymph 
F + Ρ 
art -
van + 
сер + 
lymph 
spi .sin. 
hep.sin. 
F 
art + 
ven + 
cap + 
F + Ρ 
art -
ven -
cap + 
F 
+ 
+ 
+ 
Other Cell Types 
Stained 
Renal prox tub + 
not extensively 
tested 
monocytes ± 
fibrobl. ± 
embr.stroma ± 
trophobl ± 
not extensively 
tasted 
platelets. 
megakaryocytes, 
mast cells 
basal apidarms 
mesotheliurrf, 
glomerular 
epitheliumb 
stromal cells in 
granulation tissue*, 
leucocytes*. 
platelets* 
throphoblast 
Function of 
Antigen 
Cleaving of 
angiotensin I 
Not k n o w n 
Not k n o w n 
Platelet 
adhesion to 
subendothelium 
Not known 
Not k n o w n 
Other 
Species 
Cow + 
Mouse + 
Cow + 
Swine + 
Cow + 
NT 
Dog + 
Goat + 
Rabbit + 
Cow + 
Not found 
Cat* + 
Reference 
3 
7 
8 
9 
1 0 
11 
1 2 
NT-not tested; F = frozen sections; P = paraff)n sections; art-artery; ven = vein; cap - capillary; epl.sm.s splenic sinus; 
hep.sin = hepatic sinus.; * Ig class or subclass; >l Based on personal observations. c Data on the tissue distribution were 
partJy den ved from reference 12 (EN 3), partly on own observations using EN 4. 
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Next to variations between different subtypes immunocytochemical studies on human 
endothelial antigens can reveal heterogeneity in their expression between identical types of 
endothelial cells [15]. Monoclonal antibodies recognizing such antigens may also be tools to 
separate subtypes of human endothelial cells, of which the biology and biochemistry subsequently 
can be studied. 
Immunocytochemical detection of human endothelial antigens 
Immunocytochemical procedures 
Markers for vascular structures or for endothelial cell differentiation can be demonstrated with 
different cytochemical methods at the light microscopic or electron microscopic level (Figs. 1,2). 
Table III lists the processing methods generally used and their effect on reactivity of the different 
endothelial antigens. The distribution of most endothelial antigens has been examined on frozen 
tissue sections, in which antigenicity is preserved but morphology is not optimal. In contrast, 
paraffin sections of formaldehyde-fixed tissue specimens show a much better morphology but 
unfortunately many antigens are not detectable, with the exception of gp 200 [11] and Factor VIII 
R ag [13]. The intensity of staining for Factor VIII R ag in paraffin sections, however, is variable 
and mostly pretreatment with trypsin is needed to enhance the signal. Loss of antigenicity is often 
attributed to fixation or the relatively high temperatures (± 65 0C) reached during routine 
paraffin embedding. In fact, PAL-Ε and EN-3/EN-4 could be demonstrated only in methacarn-
fixed tissues embedded in paraffin at lower temperatures [14]. 
Antigens can be demonstrated by means of immunofluorescence or immunoperoxidase techniques 
(Table III). Most endothelial antigens have a relatively low level of expression and need sensitive 
immunostaining methods for visualization. In our laboratory both two-step or three-step 
immunoperoxidase procedures using diaminobenzidine (DAB) as substrate are used. Immun-
operoxidase-stained sections with Harris hematoxylin nuclear counterstaining show good 
morphology, which cannot be appreciated using immunofluorescence preparations. A few examples 
of staining with endothelial antibodies are given in Figure 1. 
To obtain a more precise cellular and subcellular distribution, immunoelectron microscopy is 
mandatory. The method currently used in our laboratory is indicated in Table III [16]. Employing 
this procedure, we have observed different, although partly overlapping, distribution patterns of 
the antigens studied (Fig.2). 
Identification of cells in culture specimens is an important application of endothelial antibodies 
and granular staining for Factor VIII-Rag still seems the most useful marker in this respect. EN-
3/EN-4 is probably useful in isolation procedures of endothelial cells from cell suspensions as this 
membrane antigen is not sensitive to trypsin. 
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Characterization οΓ novel endothelial antigens 
A novel endothelial antigen recognized by a monoclonal antibody should be characterized 
immunocytochemically both on cultured cells and on tissue sections. This is important as the 
distribution in tissue sections does not always match that in cultured cells. Many organs have 
specialized endothelia (e.g., brain, spleen, liver, testis, lymph node) with functional and 
morphologic peculiarities, and therefore, a variety of healthy organs should be tested. Cross-
reactivity with other cell types can also be studied by a wide tissue screening. Caution must be 
taken when extrapolating results obtained from studies on cells in vitro alone or from a limited 
number of tissues. 
It is advisable to adhere to a standardized procedure for the characterization of novel antigens. 
Furthermore, it would be worthwhile to consider a standardized international nomenclature for 
endothelial antigens, as is already known for HLA antigens or lymphocyte antigens. 
Table III Effect of different cytochemical processing techniques on ¡mmunoreactivity of 
endothelial antigens. 
Technique Interpretation 
Preparation Processing Fixation Immunostaining Morphology Immunoreactivity 
Frozen tissue sections Snap Freezing in None 
isopentane; 4-6->лп 
cryostat sections 
Cytospm preparations of 
cell euspensiona or calle 
grown on cover іір 
Routine Paraffin eactions 
Vacuum paraffin 
embedding 
Rüssel Jones {14) 
Preembedding 
immuno-electron 
microscopy 
Postembeddmg 
immuno-electron 
microscopy 
Ultracryomicrotomy 
Cytocentnfuge 
Fixation 
Embedding 60 -70 e C 
2-5/лп sections 
Doparafmation 
Fixation 
Vacuum embedding 
at Б в Х 
Sectioning 
Deparaffmation 
Fixation 
50/яп víbrateme 
sections 
Immunostaining 
Epoxy resin 
embedding for EM 
Fixation 
Lowicryl resin 
embedding 
0 .1 -μτη ultrathin 
sections 
Postfixation 
Fixation 
Snep freezing 
Ultrathin 
cryos actione 
Acetone; PLP 
Buffered 
formaldehyde 
Methacarn 
Para­
formaldehyde 
2% or 4 % 
Glutaraldahyde 
2 . 5 % 
Other 
Para­
formaldehyde 
Two-or three-
step 
asa method 
with DAB as 
substrate 
Nuclear 
counter-stem: 
Herns 
Two-step 
immunoperoxid 
ase method 
with DAB as 
substrate 
Two-step 
immunostaining 
with colloidel-
gold-coated ab 
Two-step 
immunosteming 
with colloidal-
gold-coated ab 
Fair, All antigens 
better after listed in Table II ere 
fixation detectable 
Fair 
Most are not 
detectable, with ex-
eption of gp 2 0 0 and 
v W F (F Vili rag) 
PAL-Eag, EN4ag, and 
vWF are detectable 
PAL-Eag. EN3ag, 
vWF, and gp 2 0 0 t 
are detectable 
vWF; intracellular 
localisation 
PAL-Eag, intracellular 
localieation possible 
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Application of monoclonal antibodies 
recognizing human endothelial markers in diagnostic histopathology 
Applications of monoclonal antibodies recognizing human endothelial antigens in diagnostic 
histopathology include 1) assessment of vascular invasion by cancer cells and 2) identification of 
endothelial proliferations Endothelial proliferations of the skin are discussed separately from that 
of other organs For this purpose, monoclonal antibodies recognizing differentiation antigens are 
suitable (see Table II) As mentioned earlier most antigens are sensitive to formaldehyde fixation 
and/or paraffin embedding and, therefore, only detectable in frozen sections 
This finding makes the monoclonal antibodies RPAH 21-42/43 [9] and BW 200 [11] most suitable 
for application in diagnostic histopathology Other factors than fixation or processing, however, 
may influence the efficacy of the antibodies used, as is discussed later 
Assessment of vascular invasion by cancer cells 
A summary of the data from the literature on this subject is given here The studies mentioned 
were all performed on routinely fixed paraffin sections and restricted to either thyroid or breast 
cancer Harach et al [17] reported marked Factor Vili R ag staining of vascular endothelium in 
blood vessels present in follicular carcinomas of the thyroid Staining, however, was very weak in 
two of ten cases Furthermore, staining was absent m the blood vessels completely occluded by 
tumor cells Therefore, these authors conclude that immunohistochemical staining for Factor VIII-
related antigens has only limited value in the recognition of vascular invasion in follicular 
carcinoma of the thyroid Gonzales-Campora et al [18], however, report that in their series of 
follicular carcinoma of the thyroid staining with Ulex Europaeus lectin was a valuable adjunct in 
the demonstration of vascular invasion 
Figure 1 Immunoperoxidase staining of human tissues and cultured cells with antibodies 
against endothelial antigens a,b,c,d Normal human kidney showing arteries(A), 
glomerulus(G) and peritubular capillaneslPTCI a Staining with MoAb CLB-35, 
recognizing von Willebrand Factor, note granular staining pattern(arrows) in arterial 
endothelium b Staining with MoAb EN 4 of PTC, arterial(A) and glomerular(G) 
endothelium с Staining with MoAb BMA 120 of PTC(arrows), arterial 
endothelium(A) and whole glomerulus(G) d Staining with MoAb PAL-Ε, only 
PTC(arrows) are positive e,f,g Normal human cerebral cortex small vessels stained 
with MoAb CLB-35(e, note granular pattern), MoAb EN-4(f), and MoAb BMA 
120(g)(staining indicated with arrows) h,i,j Cultured human umbilical vein 
endothelial cells grown on coverslips stained with MoAb CLB-35(h, note granular 
cytoplasmic staining), MoAb EN-4(i, staining of cell membrane), and MoAb BMA 
120(cytoplasm and membrane stained) Bars 10 micron 
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Two different series of breast cancer lesions have been reported in which vascular invasion by 
tumor cells was studied Lee et al [19] conclude that immunohistochemical staining for blood 
group antigens is a more consistent and reliable method for this purpose than staining for Factor 
VIII R ag On the other hand, Saigo and Rosen [20] report a higher sensitivity for Factor Vili R 
ag staining They conclude that the use of a panel of different reagents will stain most endothelia, 
and therefore is preferable to the use of a single antibody or lectin However, the sensitivity of the 
immunohistochemical assessment of vascular invasion in their hands was comparable to 
conventional histology The size of the patient series reported is too small to allow any statement 
on a possible prognostic implication of immunohistochemically assessed vascular invasion 
In our hands Ulex Europaeus lectin is not suitable as a marker for vascular invasion, because often 
both tumor cells and endothelial cells are stained, as was also noted by Lee [21] in breast cancer 
Furthermore, no distinction can be made between lymph vessels and blood vessels using Ulex 
Europaeus lectin or anti-Factor VIII R ag antibody Moreover, the variable staining intensity with 
the latter antibody, especially in capillaries of the tumor stroma, hampers the interpretation 
Idenlifation of human cutaneous endothelial prolifcralions 
A series of immunohistochemical studies, usually on paraffin sections, of different cutaneous 
endothelial proliferations has been reported (Table IV) Agreement on the phenotype of lesionai 
endothelium exists in hamartomatous (e g , hemangioma) and reactive (e g , pyogenic granuloma) 
vascular proliferations Although most authors report that angiosarcomas are positive for vascular 
endothelial markers (be it with areas of absent staining), complete negative results also have been 
described, especially for blood group antigens [22-29] This may be due to the fact that the group 
of angiosarcomas contains both hemangiosarcomas and lymphangiosarcomas Lymphangiomas 
were also found to have a variable staining Furthermore, variable staining has been reported in 
Kaposi's sarcoma lesions In early studies the angioformative component of this tumor was found 
positive for both Factor Vlll-related antigen and Ulex Europaeus lectin, the spindle cell component 
with the vascular slits being negative [24-26] 
Figure 2 Immunoelectron microscopy of endothelial antigens in colon carcmomalDAB reaction 
product indicated with arrows) a Staining pattern of MoAb EN 4 in venule, note 
marked luminal(L) and weak abluminal(arrowheads) endothelial cell membrane 
staining, A pericyte!P) is negative b Endothelium of large vein stained with MoAb 
CLB-35 recognizing von Willebrand Factor, note staining of mtracytoplasmic 
structureslmset, arrows) and subendothelial space(arrowheads) с Staining pattern 
of MoAb BMA 120 in arteriole , note marked luminaKL.mset, arrows) and absent 
abluminal(arrowheads) endothelial(E) and smooth muscle(SM) cell staining d 
Staining pattern MoAb 1042, recognizing type IV collagen, note staining of 
basement membrane(BM), endothelial cellslE) and pericytes(P) are unstained 
Staining pattern with MoAb PAL-Ε, note staining of luminal membranelL, arrows) 
and plasmalemmal vesicleslarrowheads) Bars 1 micron 
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Recent studies, however, using more sensitive methods and other reagents also report staining in 
the spindle cell component [14,27,28,30,31]. They conclude, therefore, that Kaposi's sarcoma is 
derived from vascular endothelium. In our opinion, however, the markers used in these studies are 
not all endothelium monospecific and do not reliably discriminate vascular from lymphatic 
endothelium. Based on the absence of staining with PAL-Ε, Rüssel Jones et al [14] conclude that 
Kaposi's sarcoma orginated from lymphatic endothelium. Further studies using monoclonal 
antibodies specific for lymphatic endothelium are needed to elaborate their findings. To the best of 
our knowledge, however, so far no such antibodies have been developed. 
Because none of the monoclonal antibodies recognizing vascular endothelium has been found to 
be absolutely specific for this cell type, caution should be exercised with the interpretation of 
immunohistochemical results in the diagnosis of a poorly differentiated malignant tumor. To 
minimize the number of false-positive and false-negative results in this diagnostic procedure we 
currently use a panel of monoclonal antibodies with different specificity for different tumor types. 
By this approach, positive and negative staining results reinforce each orther, thereby increasing 
the diagnostic accuracy. 
Table IV Immunohistochemical typing of human cutaneous endothelial proliferations: staining 
results of lesionai endothelium with different markers 
Type of lesion 
Hemangioma 
Angiokeratoma 
Pyogenic granuloma 
Lymphangioma 
Hemangiopericytoma 
Angiosarcoma 
Kaposi's sarcoma 
Préexistent vessels 
Tissue preparation 
References 
F Vili Rag 
+ 
+ 
± 
+. ± and -• 
-
- and + 
slits - or + • 
end + 
2 + 
Ρ 
(alter trypsin 
treatment) 
22-24 
ULEX Eur. 
2 + 
NT 
2 + 
+ or 2 + 
+ and -
slits - or + · 
end 2 + 
2 + 
Ρ 
23,25-29 
PALE 
2 + 
NT 
2 + 
-
+ 
slits -
end -
2 + 
F 
10,14 
En-3 
NT 
NT 
NT 
NT 
NT 
slits + 
end + 
2 + 
Ρ 
(msthacern) 
14 
Bloodgroup 
Antigens Α,Β,Η 
2 + 
NT 
NT 
- or ± 
NT 
2 + or ± 
slits + 
end 2 + 
2 + 
Ρ 
27 
- = absent stamine, ± ** weak staining, + = staining; 2+ - marked staining; Ρ = paraffin sections; Ρ - frozen 
sections, NT - not tested; - and + = negative and positive areas; - or + = negative or positive lesions. 
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1
 depending on sensitivity of staining procedure (see text). 
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Identification οΓ human endothelial proliferations at other anatomic sites 
The types of lesions (mentioned in Table IV) that are not restricted to the skin show an identical 
phenotype at other anatomic sited and are, therefore, not discussed further. Based on the results of 
immunohistochemical studies on ostensibly vascular proliferations at noncutaneous sites, the 
authors concluded that epitheloid hemangioendothelioma indeed is of vascular endothelial origin 
[32]; this also holds for the endothelial variant of adenomatoid tumors [33]. Because focal staining 
for endothelial markers can be found in the spindle cell areas of anaplastic gliosarcomas, it was 
suggested that at least part of the sarcomatous components in these tumors originate from vascular 
endothelial proliferation. Cardiac myxoma cells have been shown to be weakly reactive with 
endothelial markers, but also with markers for histiocytes and smooth muscle cells [35,36]. 
This provides support for the interpretation that this tumor probably originates by differentiation of 
multipotential mesenchymal cells. No evidence of endothelial origin has been demonstrated in 
lesionai cells of angioendotheliomatosis [37], aneurysmal bone cyst [38], and hemangioblastoma 
[37,39]. Further immunohistochemical studies showed angioendotheliomatosis to represent 
angiocentric non-Hodgkin's lymfoma [40]. The origin of the other two proliferative lesions 
mentioned is not clear. Surprisingly, blastemal cells in Wilms' tumors were found to be reactive 
with PAL-E [41]. It is not certain if this is due to crossreactivity based on epitope sharing. 
Marker studies in the pathobiology of human vascular endothelium 
Visualization of the tumor vasculature 
Characterization of the tumor vasculature has not only relevance to tumor biology, but it may also 
be important for immunodiagnosis and immunotherapy of tumor lesions [42]. In the latter 
approaches, antigens on the endothelial cells of the tumor vasculature are the target structures for 
recognition by radiolabeled or drug-coupled monoclonal antibodies. This approach seems valid, as 
antigens have been described that are preferentially expressed on endothelial cells in the tumor 
stroma [43,]. To investigate the distribution of constitutive markers for endothelial cells in the 
tumor vasculature we have stained a series of 80 malignant human tumors with a panel of 
monoclonal antibodies. Our results indicate that the most discrete staining results are obtained with 
the monoclonal antibodies BW 200 and PAL-Ε. Staining for Factor VIH-related antigen is 
variable, dependent on the type of antibody used. Interpretation of the staining results with Ulex 
Europaeus lectin in several tumors is difficult, because both tumor cells and endothelial cells are 
positive. In a few tumor lesions the tumor cells also stain with EN-3/EN-4 or BW 200, indicating 
that endothelial cell markers can be expressed by certain nonvascular tumors as well. 
Differences in degree of vascularity were found by Crocker and Smith [45] between variants of 
Hodgkin's disease. Many blood vessels were immunohistochemically demonstrated in the nodular 
slerosing subtype (including the cellular variant). The other Rye subtypes, however, showed a 
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striking paucity of Factor VIH-related antigen positive blood vessels. It remains to be seen if the 
number of blood vessels in these subtypes is decreased, or if endothelial antigen expression is 
diminished. In a study using Ulex Europaeus as a marker Möller and Lennert [46] found evidence 
of a preserved primary structure of the vascular tree in the affected lymph nodes in different 
subtypes of Hodgkin's disease. 
Lastly, the distribution of markers having a preference for the tumor vaculature is discussed. It has 
been suggested that the tumor stroma highly resembles granulation tissue of wound healing. In 
granulation tissue angiogenesis takes place as in the tumor stroma. The new monoclonal antibody 
EN 7/44 developed by Hagemeier et al [43] preferentially stains budding capillary endothelium 
present in tumor stroma and acute inflammation, but also in the placenta and large intestine. The 
authors concluded that EN 7/44, therefore, recognized a subset of human endothelial cells involved 
in angiogenesis. Because the tumor vascular bed could serve as target such antibodies may be 
useful in the immunodiagnosis and immunotherapy of a variety of tumors. 
Visualization of endothelial activiation 
Endothelial activation can be defined as a state of Pertubation of the cell in which the level of a 
number of important biologic functions is elevated. This condition can be induced by cytokines, 
thrombogenic substances, and probably by other factors as well. Stern et al [47] have reported the 
intriguing finding that thrombin, by inducing the production of interleukin 1, activates the 
endothelial cell. Furthermore, TNF may activate the endothelial cell in a similar way [48]. 
It should be possible to visualize these cytokine molecules or their receptors in cell preparations 
and tissue sections using monoclonal antibodies. Furthermore, quantitation of such molecules in 
immunocytochemical preparations seems feasible. 
The monoclonal antibody H4/18 was shown to identify a state of endothelial cell activation 
induced by inflammation or immune reaction [49]. This antibody was raised by immunization with 
interleukin 1-treated human umbilical endothelial cell cultures, and is reactive with a cellular 
adhesion molecule. 
In primary and secondary brain tumors the endothelial cells express the PAL-Ε antigen, 
whereas pre-existent brain microvascular endothelial cells do not [50]. The PAL-Ε antigen, 
therefore, may have a function in the maintenance of a tissue-blood barrier, as we have observed a 
similar phenomenon in the testis and ovary. 
Further studies have to elucidate the mechanisms and functional consequences of changes in the 
antigenic phenotype of human vascular endothelium in physiologic and pathologic conditions. 
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Conclusions 
1. Monoclonal antibody-defined human endothelial antigens are useful as vascular markers in 
diagnostic histopathology and in pathobiologic research. 
2. These antigens can be divided in differentiation markers (either constitutive of restricted) and 
functional markers. 
3. None of the monoclonal antibodies described is absolutely specific for endothelial cell 
differentiation; BW 200 and PAL-Ε show the highest specificity. 
4. Immunocytochemistry at the light microscopic and electron microscopic level is a most 
valuable adjunct to the characterization of endothelial antigens, especially if a panel of 
antibodies is used. 
5. The monoclonal antibodies directed against anti-Factor VHI-related antigen and BW 200 are 
applicable on paraffin sections and are, therefore, most suitable for routine histopathologic 
diagnosis. 
6. Applications of monoclonal antibodies recognizing vascular markers in diagnostic 
histopathology are the identification of endothelial tumors and related disorders, and the 
assessment of vascular invasion by tumor cells. 
7. Applications of monoclonal antibodies recognizing vascular markers in pathobiologic research 
are the visualization of tissue-blood barriers and of endothelial cell activation. 
Summary 
A review is given on human endothelial antigens recognized by monoclonal antibodies and 
used as vascular markers. These antigens can be classified tentatively into two categories that 
partly overlap: 1) differentiation markers and 2) antigens involved in specific cellular functions. 
Monoclonal antibodies recognizing endothelial differentiation markers reacting with all types of 
human endothelium can be regarded as constitutive endothelial markers. Other differentiation 
markers have a restricted distribution that is associated with a subtype of endothelium. Although 
sensitivity of the markers is high in general, specificity for endothelium is not absolute, based on 
distribution studies in tissues or in cell lines. With the exception of PAL-Ε and EN-3/EN-4, it is 
not clear from the literature whether the antibodies also react with lymphatic endothelium. 
Immunohistochemical examination of other species indicate that only BW 200 is restricted to 
humans. Immunoelectron microscopy of microvascular cells in tissue specimens has revealed that 
the monoclonal antibodies recognizing differentiation antigens show different subcellular 
distribution patterns. PAL-Ε and BW 200 react with the luminal endothelial surface, in a local and 
diffuse pattern, respectively. Anti-Von Willebrand factor (i.e. Factor VHI-related ag) antibodies 
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react with Weibel-Palade bodies but also with subendothelial structures. Applications of 
immunohistochemistry using monoclonal antibodies in diagnostic pathology include assessment of 
vascular invasion by cancer cells, and identification of endothelial neoplasms and related disorders. 
Because anti-Factor VIH-related antigen and BW 200 are applicable on formaldehyde-fixed and 
paraplast-embedded tissue, they are most suitable for histodiagnostic application. Immunohist-
ochemistry using monoclonal antibodies recognizing endothelial antigens involved in specific 
cellular functions also may contribute to pathobiologic research on the characterization of blood-
tissue barriers, e.g., in the tumor vascular bed. 
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Introduction 
The endothelium of blood and lymph vessels plays an important role in many biologic 
processes, such as the regulation of hemostasis and vessel wall permeability. Also, in diseases of 
blood vesels, e.g., thrombosis and arteriosclerosis, the role of endothelium is substantial [19]. 
Especially after the development of reliable methods for culturing [5] and identifying [3,5] 
endothelial cells, more details about these roles have been discovered. 
To identify endothelium in histologic sections, two markers have been described, the 
coagulation factor VHI-related antigen (FVIII) [4], which can be demonstrated in nearly all 
endothelia [1, 2, 4, 10, 12], both in frozen sections and in formalin-fixed paraffin sections after 
trypsin treatment [10], and, as has been shown recently by Holthöfer et al. [3] and Miettinen et al. 
[9], a ligand recognized by the Ulex europaeus I lectin (UEA I). 
In this study we describe a new staining reagent for endothelium in frozen tissue sections, the 
monoclonal antibody PAL-E. 
Materials and methods 
Antisera and UEA I lectin 
The following chemicals and antisera were used. GAMP: Goat-anti-mouse immunoglobulin 
conjugated to horseradish peroxidase (TAGO, Inc., Burlingame, California). RAMP: Rabbit-anti-
mouse immunoglobulin conjugated to horseradish peroxidase. (DAKO Immunoglobulins Ltd., 
Copenhagen, Denmark). RA-FVIII: Rabbit-anti-human factor VIII R:Ag; diluted 1:3000 in 
phosphate-buffered saline (PBS) (Central Laboratory of the Netherlands Red Cross Blood 
Transfusion Service, Amsterdam). GAM-FITC: Goat-anti-mouse Ig, fluorescein isothiocyanate 
(FITC)-conjugated; diluted 1:50 in PBS (EY Laboratories, San Mateo, California). SWAR-TRITC: 
Swine-anti-rabbit Ig, tetramethylrhodamine isothiocyanate (TRITC)-conjugated; diluted 1:50 in 
PBS (DAKO). UEA I-FITC and UEA I-TRITC: UEA I-lectin, in calcium- and magnesium-
containing PBS as described by Holthöfer et al. [3] (ΕΥ Laboraties). 
Monoclonal antibody 
Cell suspensions of freshly obtained human lymph node metastases of melanoma were injected 
intraperitoneally into BALB/c mice. Two booster injections of melanoma cells from two other 
patients were given 3 and 5 weeks after the first injection. Three days after the third injection the 
mice were killed and spleen cells were isolated for cell fusion. Sp 2/0 myeloma cells were fused 
with the spleen cells by the procedures of Köhler and Milstein [7] and cultured in soft agar [17]. 
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Nitrocellulose filters coated with lymphocytes or melanoma cell suspensions were prepared as 
described by Sharon, Morrison, and Rabat [13]. After 10 days the agar cultures were overlaid 
with these filters for 24 hours. After removal the filters were developed with RAM-peroxidase and 
stained with diaminobenzidine and Η,Ο,. The clones that were positive on melanoma filters and 
negative on lymphocyte filters were selected and grown in suspension. Supernatants of the wells 
were screened by indirect immunoperoxidase staining on frozen sections of melanoma, 
nevocellular nevi, and normal skin. To develop monoclonal cultures the wells containing the cells 
of interest were subcloned by limiting dilution. The immunoglobulin subclass of the antibody PAL-
E was determined by an Ouchterlony immunodiffusion assay. PAL-Ε was tested against antimouse 
IgGl, IgG2a, IgG2b, IgG3, IgM, and IgA. 
Tissue samples 
Samples of normal human liver, spleen, lymph node, skin, and kidney and, in addition, samples of 
vascular lesions and a small series of malignant tumors of non-endothelial differentiation were 
removed from fresh surgical specimens and snap-frozen. The samples from the other organs were 
autopsy material snap-frozen in nitrogen within a few hours after death. Furthermore, specimen of 
various organs from rat, rabbit, dog, and goat were obtained. The tissues were stored at -70°. 
Cells 
Human umbilical cord endothelial cells (arterial or venous) were isolated and cultured as described 
by van Hinsbergh et al. [21]. For immunofluorescence studies, first, second, third, and fourth 
passage cells were seeded onto fibronectin-coated glass cover slips and cultured for 24 hours. 
Cultured human foreskin fibroblasts and endothelial cells from human aorta were treated in a 
similar way. 
Immunoperoxidase staining 
Indirect immunoperoxidase staining was done on frozen tissue sections fixed with acetone as 
described by Nakane and Pierce [11), using RAMP or GAMP as second antibody with 3-amino-9-
ethylcarbazol as substrate. All human tissues were stained with both RA-FVIII and PAL-Ε. RA-
FVUI was used in a dilution of 1:3000 in PBS. PAL-Ε staining was performed with undiluted 
culture supernatant. RA-FVm showed a tissue distribution as described by Hoyer, de los Santos, 
and Hoyer [4] and Mukai, Rosai, and Burgdorf [10]. 
Frozen sections of human skin were fixed for 10 minutes with a panel of routinely used 
fixatives: 4% buffered formaldehyde, sublimât formaldehyde, McDowell-Trump fixative (4:1 
mixture of formaldehyde and glutaraldehyde), and periodate-lysine paraformaldehyde and stained 
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with PAL-E. Paraffin sections from formaldehyde-fixed tissue were stained with PAL-Ε after 
treatment with pepsin or trypsin. 
Immunofluorescence staining 
Cultured cells were washed briefly in PBS, fixed with acetone (4*4?, 10 minutes), and washed in 
PBS (pH 7.2) Incubations with fluorescent antisera and lectin were for 30 minutes at room 
temperature, followed by brief washes in PBS. After the last wash cells were prepared for 
fluorescence microscopy in the presence of p-phenylenediamine [6]. The various incubations of the 
blocking experiments are summarized in Table I. 
Table I. Immunofluorescence staining of cultured venous endothelial cells* 
No. Preincubation Incubation Fluorescent second Fluorescence of venous endothelial cells 
Diffuse surface Granular 
1. 
2. 
3. 
4. 
6. 
β. 
7. 
β. 
9. 
10. 
PAL-E 
PAL-E 
PAL-E 
UEA І-ТШТС 
RA-FVIII 
PAL-E 
GAM-FITC 
UEA l-FITC 
UEA l-TRITC 
PAL-E 
UEA l-FITC 
UEA l-TRITC 
RA-FVIII 
PAL-E 
RA-FVIII 
PAL-E and RA-FVIII 
GAM-FITC 
SWAR-TRICT 
GAM-FITC 
SWAR-TRITC 
GAM-FITC and SWAR-TRICT 
TRITC 
FITC 
TRITC 
FITC 
+ + 
+ + + + 
+ + 
+ + 
1
 Grading: -, no fluorescence; -f, fluorescence; + -f, strong fluorescence. 
Gel electrophoresis and immunoblotting 
Homogenates of cultured venous endothelial cells and a fresh autopsy specimen of the human 
corpus cavernosum peneris were analyzed by Polyacrylamide gel electrophoresis as described by 
Maizel [8]. Binding of PAL-Ε to the substances separated by gel electrophoresis was assayed by 
the immunoblot technique described by Towbin, Staehelin, and Gordon [20]. 
Immunoelectron microscopy 
The localization of the antigenic determinant recognized by PAL-Ε was demonstrated using a 
three-step method. Cultured endothelial cells from umbilical veins were incubated in antibody 
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containing supernatant for 60 minutes at 40
c A f t e r А г е е w a s h e s w i t h p B S Л е s e c o n d s t e p 
consisted of an incubation for 60 minutes at 40C with Fc-specific goat-antimouse IgG (N. Cappel 
Laboratories Ine), diluted to a concentration of 25 /¿g/ml in PBS containing 1% bovine serum 
albumin. After washing as described before, incubation was done with protein A coupled to 
colloidal gold as described by Slot and Geuze [15]. The cells were then washed extensively with 
PBS and fixed for 10 minutes at room temperature with 1.5% glutaraldehyde in 0.1 M cacodylate 
buffer (pH 7.4). Postfixation was performed for 60 minutes at 40C with 1% 0s04 in 0.1 M 
phosphate buffer (pH 7.2). The cells were scraped from the dishes with a rubber policeman, 
pelleted in agar, and embedded in Epon 812 according to routine techniques. Ultrathin sections 
were briefly stained with saturated lead hydroxide and viewed in a Philips EM 201 microscope 
operating at 80 kv. Controls consisted of monoclonal antibodies against the intestinal brush border 
enzyme sucrase-isomaltase or against class I major histocompatibility complex antigens. 
Results 
Monoclonal antibody 
From one fusion 20 antibody-producing clones were detected reacting with the melanoma filters 
only. After culturing these clones in microliter wells the supernatants of the wells were further 
tested on cryostat sections of normal human skin, nevocellular nevi, and malignant melanoma. One 
well produced an antibody that bound specifically to endothelium. This well was subcloned to 
develop the monoclonal antibody PAL-E. By Ouchterlony analysis it was found that PAL-E was an 
IgG2A. 
Table II. Staining pattern of PAL-E in normal tissues* 
Endothelium of Staining 
± or-
+ +# 
(periportal only) 
Arteries : 
Arterioles 
Capillaries 
Sinusoids : 
Veins : 
Lymphatic ducts 
Sinus histiocytes 
Large elastic 
Medium-sized and small 
Liver 
Spleen 
Venules 
Medium-sized and small 
Large 
* Grading: -, no staining; +, staining; + +, marked staining; ± , weak staining. 
0 Glomerular capillaries of the kidney were negative. 
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Immunoperoxidase on tissue sections 
Frozen sections incubated with PAL-Ε, followed by RAMP or GAMP, showed a marked and 
discrete staining of endothelial cells in a diffuse pattern (Figs. 1 to 4). Staining was strong in 
endothelium of medium-sized veins, venules, and capillaries of all organs tested and weak or 
absent in medium-sized arteries and arterioles (Table II and Fig. 3B). The endothelial lining of 
large veins and arteries did not stain. 
The staining of sinusoidal lining cell was variable. The sinusoidal lining cells of the liver were 
markedly positive in the periportal area. This staining faded to negative toward the central vein. It 
could not be excluded that Kupffer cells in the periportal area were also positive. In the spleen the 
sinusoidal lining cells showed very extensive staining. (Fig. 4). 
FIG. 1. DitfcrentstaininRpatternofRA-FVIIK/DandPAL-EiS) f,
c
 2 Granularpatternof endothelial staining with KA FVIII (Л) 
in human adrenal gland (frozen sections) Counterstained with hema-
 a n
d a diffuse pattern with PAL E (Й) in epitheloid venules of a human 
toxylin. X300. lymph node (frozen sections) Counterstained with hematoxylin: Ж480 
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FIG. 3. Different staining pattern of КАТ ІІІ(Д) and PAL E (ß) 
in capsule and marginal sinus of ahuman lymph node Note the absence 
of staining of an arteriole (отжО (frozen sections) Counterstained 
with hematoxylin. хЗОО 
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FIG- 5. Staining pattern of endothelial cells with PALE in a he­
mangiopericytoma (Д ) and breast carcinoma (B). Note that the tumor 
cells are negative (frozen sections) Counterstained with hematoxylin: 
Figure ЬА. X380; В. ХІ50 
ν-, 
x* 
FIG. 7. Immunolabeling of endothelial cells by antibody PALE. Note the gold particles on the exterior of endothelial vesicles (arrowheads 
and inset) X78.000; Inset ХІ75.000 
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The endothelium of lymph vessels adjacent to lymph nodes was negative; in the lymph nodes 
the sinus histiocytes were also negative for PAL-E. (Figs. 2B and 3B). 
In bone marrow the megakaryocytes, previously found to be positive for FVIII, were negative 
with PAL-E. 
The vascular proliferations showed staining as described in Table HI. In tumors of non­
endothelial differentiation the tumor cells did not stain, but the capillaries in the tumorstroma 
showed a marked staining with PAL-E (Table ΠΙ; Fig. S). 
Table III. Staining pattern of monoclonal antibody PAL-E in tumors and tumor-like conditions* 
Vaeoformative tumors No. of Steirang results 
and tumor-like conditions tissues studied lesionai endothelium stromal endothelium 
Cavernous haemangiome 
Capillary hemangioma 
Pyogenic granuloma 
Hamangiopencytoma 
Angiosarcoma 
Other tumors 
Carcinoma 
Sarcoma 
Melanoma 
Lymphoma 
2 
1 
2 
1 
1 
4 
4 
4 
4 
+ + + + 
+ + 
{locally) + + 
' Grading* + +, marked staining, +, staining, not marked; -, no staining 
Frozen sections of skin showed no staining after fixation with McDowell-Trump fixative, 
whereas the other fixatives had only a weak influence on staining with PAL-E. Paraffin sections, 
even after treatment with trypsin or pepsin, showed no staining with PAL-E. In the non-human 
tissues a similar staining pattern was seen as in human tissues, with the exception of rat tissues. 
UEA I showed no binding to endothelium in non-human tissues (Table IV). 
Table IV. Staining pattern of PAL-E, UEA I, and RA-FVIII in non-human tissues* 
Staining reagent and tested structures 
Animal species Tested 
Dog Goat Rabbit 
Arterioles 
Capillanes/venules + + + 
Other cells 
All vessels 
Epithelial structures + ND 
All vessels ND ND 
' Grading: -, no staining; + , staining; + +, marked sunning, ND, not done. 
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Immunofluorescence studies on cultured endothelial cells 
PAL-Ε gave a diffuse peripheral surface fluorescence on first, second, third, and fourth passage 
cultured venous endothelial cells. A strong perinuclear granular staining was also seen (Fig. 6, 
Table I, no. 1). Blocking experiments indicated that the reaction of cultured venous endothelial 
cells with PAL-Ε was not influenced by prior incubation of the cells with UEA I or by 
preincubation with RA-FVIII (Table I, no. 4 and 8) or vice versa (Table I, no. 2, 3, and 9). 
Cultured arterial endothelial cells gave a very weak diffuse surface fluorescence with PAL-Ε. Both 
venous and arterial cells were positive for FVIII (granular fluorescence) (Table I, no. 7) and UEA 
I-reactive material (strong diffuse fluorescence and perinuclear granular fluorescence) (Table I, no. 
S and 6). No fluorescence was seen in cultured fibroblasts or in endothelial cells from human aorta 
incubated with PAL-E. 
ImmunobloUing 
PAL-Ε did not react in the immunoblots with any of the substances separated by gel 
electrophoresis. 
Immunoelectron microscopy 
Colloidal gold particles were present on those parts where the endothelium-specific vesicles 
contacted the luminal plasma membrane (Fig. 7). Other parts of the membrane as well as coated 
pits did not show any labeling. The antibody against sucrase-isomaltase gave no labeling, whereas 
the anti-class I major histocompatibility complex antibody gave a diffuse labeling over the entire 
plasma membrane, indicating that the localization described for the staining with PAL-Ε is highly 
specific. 
Discussion 
In this study we describe a monoclonal antibody specific for endothelium that was detected 
accidentally during a search for anti-melanoma monoclonal antibodies. 
The specificity of this antibody was established by examining a large number of human tissue 
sections and that of some animal species by immunohistochemical staining. We compared the 
monoclonal antibody with known staining reagents for endothelial cells, i.e., RA-FVIII and UEA 
I, and we found differences in both cellular staining pattern and tissue distribution, indicating that 
different determinants are recognized by the various reagents. 
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This was confirmed by the results of experiments on cultured endothelial cells, showing that 
the binding of PAL-Ε was not reduced by preincubation of the cells with RA-VFIII or UEA I 
(Table I). The cellular staining with PAL-Ε was both diffuse and granular, in contrast to the 
exclusively granular staining with RA-FVIII [4,10]. PAL-Ε showed no staining of 
megakaryocytes, platelets, or epithelia in contrast to RA-FVIII, which has been reported to stain 
megakaryocytes and platelets [4], and to UEA I, which stains some epithelial structures [3]. PAL-
E also did not react with monocytes and, therefore, does not recognize a determinant common to 
monocytes and endothelium [16]. PAL-Ε staining of human tissue sections showed this antibody to 
be more restricted in staining endothelium than UEA I and RA-FVIII. Our antibody appears to be 
highly sensitive for staining endothelium of capillaries, venules, and medium-sized and small 
veins, but medium-sized and small arteries and arterioles were stained only weakly. In some 
tissues we also observed staining with RA-FVIII in areas adjacent to vessels, whereas our 
antibody showed a delicate pattern restricted to the endothelial lining of those vessels only. It was 
remarkable that PAL-Ε showed very weak or no staining of cultured cells from human aorta and 
umbilical artery and of the endothelium of arteries and arterioles in tissue sections. The biological 
basis of this difference between arterial and venous endothelium is not clear. Indeed, regional 
variations in endothelial morphology have been described [18], e.g., the number of endothelial 
vesicles, Weibel-Palade bodies, and intercellular junctions. None of these features could be linked 
to the distribution of PAL-Ε along the vascular tree. The results of the immunoelectron 
microscopic studies indicate a relation of the antigenic determinant with structures known as the 
endothelial vesicles [22]. It was suggested [14] that the endothelial cell membrane consists of 
differentiated microdomains. The specific binding of PAL-Ε with the endothelial vesicles supports 
these results. 
Our findings indicate that PAL-Ε is a very useful new staining reagent for some types of 
endothelium in frozen sections of normal human tissues and recognizes an antigen with interesting 
features. A limited series of endothelial proliferations studied also showed staining. The 
monoclonal antibody PAL-Ε may, therefore, also be useful in the diagnosis of tumors or related 
proliferations of endothelial differentiation and in studying the vascularization of tumors. 
Summary 
A monoclonal antibody, PAL-Ε, is described that is specific for endothelial cells. The 
monoclonal antibody, an IgG2a, markedly stains endothelium of capillaries, medium-sized and 
small veins, and venules in frozen sections of human and some animal tissues tested. It reacts not 
at all or only weakly with endothelium of large, medium-sized and small arteries, arterioles, and 
large veins and does not stain the endothelial lining of lymphatic vessels and sinus histiocytes. The 
cellular staining pattern and tissue staining were different from those obtained with antifactor VIII 
81 
RAG antiserum and Ulex europaeus I lectin. Blocking experiments indicated that these three 
reagents recognize different endothelial binding sites. Therefore, PAL-Ε is a new staining reagent 
for endothelium in frozen sections. Based on immunoelectronmicroscopic observations, the 
antigenic determinant recognized by PAL-Ε is associated with endothelial vesicles. 
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Introduction 
The microvasculature is an important component of the tumor stroma. It mediates transport of 
nutrients to the tumor cells and, therefore, is a crucial element in cancer growth [1,2,3]. Based on 
the dependence of tumor growth on neovascularization [1,2,4], it was suggested that (both) the 
process of angiogenesis and the vasculature itself are potential targets for tumor therapy [4,5,6]. In 
support of this hypothesis, it was found that the microvasculature in tumors differs from that of 
vessels in normal tissues, both in structure and function [1,3,7-18]. As to structure, it consists of 
dilated and irregular vessels which lack the strict organization of the vasculature of normal organs 
[7,15,18]. Functionally, the tumor vessels have an increased permeability for macromolecules 
[11,19] and a high proliferation rate of the endothelial cells [5,20,21]. In tumors, ischemic 
necrosis often occurs, probably due to insufficient angiogenesis [2,3] or deficient blood supply 
[11]. Functional abnormalities of the tumor vasculature may be accompanied by phenotypic 
changes as detected by antibodies. Such phenotypic abnormalities may result in an aberrant 
expression of surface molecules on endothelium or pericytes, and they may be a target to visualize 
and eliminate the tumor vasculature [5]. 
Studies of vascular function in tumors are hampered by the lack of an in vitro model of the 
complex microenvironment present in the tumor stroma. Investigations of the tumor 
microvasculature therefore must rely on animal models or on histological examination of (human) 
tumor material [11,13,22]. The functional (i.e. perfused) vasculature in a tumor can be visualized 
by vascular resin casting [7,13] or histologically after intravenous administration of dyes [13,15]. 
These methods, however, fail to detect functionally impaired or unperfused vessels [13], nor do 
they provide information on the different cellular or extracellular constituents of the vessels. Such 
techniques are furthermore limited to experimental animal tumor models. Markers for the 
structural microvasculature in tumors, however, can be investigated in both animal and human 
tumor material and they can selectively identify the endothelium, pericytes and their basal lamina 
[16,17,23]. Based on the foregoing, we have investigated the distribution of a number of recently 
described markers of these microvascular components in tumor tissues. All staining patterns were 
confirmed by electron microscopy, which is an essential technique for the discrimination of such 
closely apposed components. In addition, granulation tissue of wound healing was studied for a 
comparison. In these lesions, 3 zones with increasing maturation and decreasing intensity of 
neovascularization can be demarcated. Our findings allowed an evaluation of the value of the 
different antigens as histological markers for the microvasculature in human tumors. 
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Materials and methods 
Antibodies 
1. Mab CLB-35Rag (kindly provided by Dr.J. van Mourik, Central Laboratory of the Red Cross 
Blood Transfusion Service, Amsterdam, The Netherlands) and a polyclonal antiserum 
(Dakopatts, Copenhagen, Denmark) to Von-Willebrand-Factor (vWF=Factor VHI-related 
antigen), a molecule involved in platelet adherence and present in endothelial cells [24-26], the 
subendothelium, megakaryocytes, platelets and plasma, 
2. MAbs PAL-Ε, EN4 (Sanbio, Uden, The Netherlands) and BMA 120 (formerly designated 
BW200, Boehringer Mannheim.FRG), all recognizing endothelial determinants of unknown 
molecular weight or function, 
3. MAb anti-alpha-smooth muscle actin (anti-aSMa-1) (Biomakor, Rehovot, Israel) to a marker 
for smooth muscle cells and pericytes [27], 
4. MAb 225.28S to the high molecular weight-melanoma associated antigen (HMW-MAA), 
another marker for pericytes [16] (kindly provided by Dr.S.Ferrone, Department of Microbio­
logy and Immunology, New York Medical College, Valhalla, New York), 
5. MAb 4E10 to laminin (kindly provided by Dr.U.Wewer, The University Institute of 
Pathological Anatomy, Copenhagen) and 
6. MAb 1042 to collagen Type IV, (kindly provided by Dr.F.T.Bosman, Department of 
Pathology, University Hospital Maastricht, Maastricht, The Netherlands). They were described 
in detail elsewhere [22,26,28-31]. 
The lectin Ulex Europaeus I (UEA-I) (Ε-Y laboratories), that binds alpha-fucose residues on 
endothelial cells [32], was also used. Horseradish-peroxidase (HRP) conjugated goat anti-mouse 
IgG antibodies (HRP-GAM) and HRP-conjugated rabbit anti-mouse IgG antibodies (HRP-RAM) 
were purchased from TAGO Inc. (Burlingame, CA, USA), and from Dakopatts (Copenhagen, 
Denmark), respectively. 
Tissue samples 
Human tissue samples were obtained from fresh surgical specimens (Table I), granulation tissue 
from patients with decubitus lesions. All tissues were snap-frozen and stored at -70^. 
Immunoperoxidase staining 
Air-dried 4 micron frozen tissue sections were fixed with acetone for 10 minutes and stained by a 
standard indirect immunoperoxidase procedure [16,33,34] using antisera at appropriate dilutions in 
PBS containing 1% BSA. UEA-I conjugated to HRP was used in a direct immunoperoxidase 
procedure [34]. З-3-Di-Amino-Benzidine (DAB) containing 1.0 mM imidazole and 0.01% H202 
was used as substrate. Sections were counterstained with hematoxylin. When indicated, a double-
So 
staining procedure by immunoperoxidase and immunofluorescence was performed according to 
Lechago et al [35], using combinations of the Mabs 22S.28S and anti-aSMa-1. The staining 
intensity was graded as follows: no staining (-), weak staining (+/-), moderate staining (+) and 
marked staining (+ +) . 
Table I. Tissues used in this study. 
Origin or type Number of cases 
Granulation tissue Decubitus lesions 
Tumors Carcinomas 
Lymphomas 
Sarcomas 
Blastoma 
skin 
lung 
mamma 
colon 
ovary 
stomach 
lymph node 
malignant fibrous 
histiocytoma 
ewing Sarcoma 
neuroblastoma 
4 
6 
8 
8 
6 
4 
6 
2 
1 
1 
Immunoelectronmicroscopy 
A pre-embedding immunoperoxidase technique was used to demonstrate the precise cellular 
localization and the subcellular distribution of the staining with the MAbs [16,17,23]. Tissue 
specimen with a maximum size of 4x6x2 mm were fixed for 4 hours at room temperature in 
freshly prepared 4% paraformaldehyde in Sorensen's phosphate buffer pH 7.4, and washed 
overnight in Tris-buffered saline pH 7.4 (TBS). Fifty micron vibratome sections were cut, washed 
in TBS and incubated overnight at 4°C with the Mab's at appropriate dilutions in TBS containing 
0.5% BSA and 5.0 mM. saponin. For the incubations and washing steps a rotary shaker was used. 
After four 30 minutes washings with TBS, the sections were incubated with a mixture of 
HRP-RAM and HRP-GAM at appropriate dilution in TBS containing 20% normal human serum 
for 90 minutes at room temperature. The control sections were incubated with second antibodies 
alone. After extensive washings in TBS, the sections were preincubated in 0.75 mg/ml DAB in 
TBS pH 5.7 containing 1.0 mM imidazole for 10 min. The sections were then developed for 10 
min. in the same solution containing in addition 0.01% Yl202; the reaction was terminated by 
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rinsing with H2O Subsequently, the sections were post-fixed in 1% osmium tetroxide in Palade 
buffer for 30 mm , dehydrated, embedded in Epon 812, and processed routinely One-micron 
sections were cut for light microscopy and stained with toluidin blue Ultrathin sections were cut 
and not contrasted They were examined and photographed on a Philips 300 electron microscope 
(Eindhoven, The Netherlands) at 40 kV 
Value of vascular markers in ¡mmunohistochemistry 
The evaluation of the value of the different vascular markers in visualizing the tumor 
microvasculature in frozen sections was based on the specificity and sensitivity of the 
immunostaming The specificity was defined as the degree to which one microvascular cell type or 
structure, was recognized exclusively The sensitivity of the endothelial markers was defined as the 
proportion of microvascular structures that were recognized by a particular marker Due to its high 
specificity and sensitivity for endothelium, MAb PAL-Ε was used as golden standard in a 
semi-quantitative evaluation of sensitivity The sensitivity was scored as high (more than 90% of 
microvascular structures stained), moderate (50-90% stained) or low (less than 50% stained) 
Results 
(sub-)Cellular distribution of the vascular antigens in tumor stroma 
Staining results in tumors are summarized m Table II A short description of the reaction patterns 
is given for endothelial, pericyte and basal lamina antigens separately 
Figure 1 Immunoperoxidase staining with anti von Willebrand Factor MAb CLB35 Rag 
(1 A,left panel) and with anti endothelium MAb PAL E (IB right panel) of serial frozen 
sections of a carcinoma of the breast MAb CLB35 Rag only stains a large vessel in 
the tumor stroma In contrast, MAb PAL E stains all microvessels, including 
capillaries (arrows) 1x450) 
Figure 2 Immunoperoxidase staining with Ulex Europaeus I lectin of frozen section of a 
carcinoma of the lung UEA-I stains both the vascular structures (arrow) and tumor 
acini (asterisks) (x450) 
Figure 3. Immunoperoxidase staining with anti-endothehum MAb EN-4 of frozen section of a 
carcinoma of the breast MAb EN-4 stains the vascular structures (arrows) and 
inflammatory cells in the tumor stroma (arrowheads) (x450) 
Figure 4 Immunoperoxidase staining with anti-endothelium MAb BMA 120 of frozen section 
of an adenocarcinoma of the lung MAb BMA 120 stains both the vascular 
structures (arrows) and the luminal side of tumor acini (asterisks) 1x450) 
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Endothelial antigens 
von-Waiebrand Factor (Mab CLB-Rag 35 and PcAb) 
Light microscopy: In the larger vessels of tumor stroma, marked cytoplasmic staining in 
endothelial cells was observed (monoclonal antibody CLB-Rag35), (Fig. 1A). The arterial walls 
also showed a weak diffuse subendothelial staining. In contrast, the staining of small vessel 
endothelium localized in tumor nests was variable and often focal (Fig. 1A and B). Many tumors, 
especially carcinomas, often did not show any staining of the capillary endothelium. In malignant 
Table II. Staining patterns of the vascular markers in frozen sections of tumors. 
Antibodies recognizing microvasculer constituents 
Endothelium Pericytes 
Microveseels 
Connective Tissue 
Inflemmetory 
Infiltrate 
Tumor 
Capillary EC3 
Large Vessel 
EC 
Pericytes 
BL 
Fibroblasts 
Myofibroblasts 
Interstitium 
Lymphocytes 
Histiocytes 
Tumor cells 
BL 
Mab2 
vWF 
+ /-
+ + 
-
-
-
Pcab 
vWF 
+ + 
+ + 
-
+ /-
+ + 
-
. 
lectin 
UEA-I 
+ + 
+ + 
+ + 
. 
Mab 
EN-4 
+ + 
+ + 
+ 
+ 
-
Mab 
BMA 
120 
+ 
+ 
+ 
Mab МоАЬ МАЬ MAbs 
PAL-E aSMo 225.28 1042/4E10 
+ +/-
1
 : BL = basal lamina; 2 : Monoclonal (Mab) and polyclonal (PcAb) antibodies: see Materials and Methods; э : EC = 
endothelial cells 
Figure 5. Electronmicroscopy of immunoperoxidase staining with anti-endothelium MAb BMA 
120 of a colon carcinoma. MAb BMA 120 stains endothelial cells (E) on their luminal 
side (arrowhead). E = endothelium; L = lumen; (bar = 0.32 μπ\). 
Figure 6. Double-staining with MAb anti-aSMa-1 (6A, left panel; immunofluorescence) and 
anti-HMW-MAA MAb 225.288 (6B, right panel; immunoperoxidase) of frozen 
section of a seminoma. MAb 225.28S stains the pericytes in the wall of the 
microvessels (arrows) (6B). Note that not all these vessels are stained with MAb 
anti-aSMa-1 (6A). (x450). 
Figure 7. Electronmicroscopy of immunoperoxidase staining with MAb anti-aSMa-1 of a colon 
carcinoma lesion. MAb ami-aSMa-1 stains the cytoplasm of pericytes (arrowhead). 
E = endothelium; L = lumen; (bar = 1.25 ¿im). 
Figure 8. Electronmicroscopy of immunoperoxidase staining with anti-collagen type IV MAb 
1042 of a colon carcinoma lesion. MAb 1042 stains basal lamina adjacent to the 
endothelial cell and pericyte. Ρ = pericyte; E = endothelium; L = lumen; 
(bar = 0.68Am). 
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lymphomas and in lymphocytic infiltrates associated with carcinomas, however, a marked and 
uniform staining of the microvessels was found (not shown). Non-endothelial cells did not stain. 
The polyclonal anti-von-Willebrand antiserum showed staining of more microvascular structures 
than the MAb, with a diffuse staining of the complete vascular wall, whereas, in addition, the 
perivascular stroma was often diffusely positive. This stromal staining was not observed in 
adjacent normal lung and colon tissues (not shown). 
Electron microscopy: In the cytoplasm of endothelial cells lining arterioles and venules, a marked 
staining of organelles, compatible with Weibel-Palade bodies, was found with MAb CLB-Rag35 
(not shown). The reaction product was also present in the subendothelial space. The luminal 
endothelial membrane did not stain. 
Я blood group (Vlex Europaeus I lectin) 
Light microscopy: UEA-I markedly stained the endothelium of the tumor vessels. The tumor cells 
were also positive in the majority of the different types of carcinomas (Fig.2) and in a 
neuroblastoma. 
Endothelial antigen recognized by Mab EN-4 
Lipht microscopy: In the tumor bed a marked endothelial staining could be observed. The tumor 
cells of two cases of carcinoma and one lymphoma were also positive. Marked staining of 
mononuclear infiltrate cells compatible with histiocytes was seen in all carcinomas (Fig.3). The 
alveolar macrophages stained, but lymphocytes were negative. 
Electron microscopy: A marked staining of the luminal endothelial membrane and a weak staining 
of the abluminal membrane was found in all vascular structures (not shown). 
Endothelial antigen recognized by Mab BMA 120 
Light microscopy: The endothelial cells in all tumors tested stained in a discrete pattern. In half of 
the carcinoma lesions, a focal tumor cell staining was noted, often at the luminal side of the 
adenocarcinoma cells (Fig.4). Neuroblastoma cells and non-tumorous mesothelial cells also 
stained, whereas other cell types were negative. 
Electron microscopy: Endothelial cells were diffusely positive at their luminal surface (Fig.5), the 
abluminal side was negative. 
Endothelial antigen recognized by Mab PAL-E 
Light microscopy: A discrete endothelial staining was found with a preference for the cell contour; 
this pattern was seen in all tumors (Fig IB). 
Electron microscopy: Plasmalemmal vesicles at the luminal and locally at the abluminal endothelial 
surface were markedly positive. The luminal membrane proper stained locally and weakly (not 
shown). 
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Figure 9. Immunoperoxidase staining with anti-collagen type IV MAb 1042 of a frozen section of 
granulation tissue of a decubitus lesion of the skin. MAb 1042 stains vascular structures 
throughout the three maturation zones 11,11 and III), including microvessels in the most superficial 
one (arrows). (x35). Figure 10. Immunoperoxidase staining with anti-pericyte MAb anti-aSMa-1 
of a frozen section of zone I of granulation tissue of a decubitus lesion of the skin. MAb 
anti-aSMa-1 stains pericytes in only one vessel (arrows). Note the absence of staining in most 
microvessels (asterisks). (x350). Figure 11 . Immunoperoxidase staining with anti-collagen type 
IV MAb 1042 of a frozen section of zone I of granulation tissue of a decubitus lesion of the skin. 
MAb 1042 stains all microvascular structures with pericytes (arrows). (x350). 
Figure 12. Immunoperoxidase staining with anti-HMW-MAA MAb 225.28S of a frozen section 
of zone I of granulation tissue of a decubitus lesion of the skin. MAb 225.28S stains pericytes In 
all microvascular structures (arrows). (x350). 
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Pericyte antigens 
Alpha-smooth muscle actin (MAb ami-aSMa-l) 
Light microscopy: Staining of the pericytes in the tumor microvasculature was variable: locally, 
vascular structures were positive but in many tumors large areas were observed without any 
pericyte staining. The presence of unstained pericytes in these areas was established by double-
staining with anti-HMW-MAA MAb 225.28S (Fig.6A and B). In addition to staining of pericytes, 
the myofibroblasts in the stroma of carcinomas and smooth muscle cells in artery walls and colon 
carcinomas also stained with MoAb anti-aSMa-1. 
Electron microscopy: The reaction product was observed in the cytoplasm of pericytes and their 
processes in capillaries in the tumor stroma (Fig. 7). 
High molecular weight-melanoma associated antigen (HMW-MAA;MAb 225.28S) 
Light microscopy: The pericytes in the tumor microvessels were mostly markedly but locally 
variably stained (Fig. 6A and B). 
Electron microscopy: The reaction product was observed at the cell membrane of pericytes and 
their processes in the capillaries of the tumor stroma (not shown). 
Basal lamina antigens 
Collagen Type IV (Mab 1042) 
Light microscopy: The basal lamina of the vascular, epithelial and fat cells stained markedly, as 
did that of most tumor cells in the carcinomas. Also the intercellular substance and myofibroblasts 
in the stroma of the carcinomas and sarcomas stained. In the lymphomas, the interdigitating cells 
were positive (not shown). The marked stromal staining often hampered a proper identification of 
the microvascular structures (data not shown). 
Electron microscopy: Staining was observed at the basal lamina of the endothelial cells and 
surrounding pericytes (Fig. 8). 
Laminin ßlAb 4E10) 
Light microscopy: The basal laminas stained in a pattern similar to that with the anti-collagen type 
IV MAb 1042, but the staining of the tumor stroma was less marked (not shown). 
Staining distribution of the vascular antigens in granulation tissue 
On the basis of histological criteria, three zones in the granulation tissue with a different degree of 
maturation were recognized (Fig.9, Table III). In all three zones the microvasculature 
demonstrated staining for both endothelial and basal lamina markers. In contrast, the pericyte 
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markers showed a zonal distribution of staining (Table III): in the superficial, "immature" zone, 
MAb anti-aSMa-1 only sporadically stained the pericytes, whereas most vessels were positive for 
HMW-MAA. In the "mature" zone, however, the expression of HMW-MAA in microvessels was 
focal in contrast to an extensive staining for aSMa-1 (Fig. 10,11 and 12) 
Table III Distribution of microvascular components in the maturation zones of granulation 
tissue. 
Maturation zones of granulation tissue 
(Zone I) 
Superficial 
(Zone II) 
Intermediate 
(Zone III) 
Deep 
Hietdogy vessels 
inters titium 
infiltrate 
Immunostaimng endothelium 
pericytes 
basât lamina 
' - / + = occasionally positive; + 
MAb PAL-E 
anti-aSMa-1 
anti-HMW-MAA 
anti-collagen 
- positive; 
IV 
+ + 
capillaries 
fibrinous coating 
edema 
neutrophils 
+ +' 
-/ + 
+ + 
+ + 
= markedly positive 
cepillarles 
venules 
slight edema 
slight fibrosis 
mononuclear cells 
+ + 
+ 
+ + 
+ + 
capillaries 
venules 
arterioles 
no edema 
marked fibrosis 
few cells 
+ + 
+ + 
/ + 
+ + 
Value of the reagents against markers for vascular elements in the tumor stroma 
A comparison of the value of the antibodies against vascular markers is presented in Table IV. 
With the exception of von-Willebrand Factor, all endothelial markers were found to have a high 
sensitivity for the tumor endothelium. The specificity, however, was often limited. A cross-
reactivity with non-endothelial cells, observed in a number of tumors with UEA-I and Mab EN4, 
obscured the vascular staining and thereby limited the marker efficacy. In the lymphomas, the 
sinusoid endothelium showed a varying staining with the tested reagents (not shown). The 
sensitivity of alpha-smooth muscle actin for pericytes was low in the stroma of tumors in contrast 
to that of HMW-MAA. 
Architectural patterns of tumor vasculature 
On the basis of their discrete staining, the MAbs PAL-Ε and BMA 120 demonstrated the 
morphological outlay of the tumor microvasculature best. The number of vascular structures and 
the distribution of vessels of different size in different tumors varied widely. Individual tumors, 
however, tended to demonstrate the same microvascular architecture throughout. These 
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microvascular patterns were apparently associated with the stromal architecture, depending on the 
direction and degree of differentiation of the tumors. 
Table IV Comparison of vascular markers in visualizing the tumor vasculature in tissue sections. 
Specificity 
Sensitivi ty 
Frozen' Parafin2 
Cross-reactions Remarks 
Endothelium vWF 
UEA-I 
EN4-age 
Pericyte 
Basal lamina 
BMA 1 2 0 - 6 9 
PAL-E-ae 
aSMa-1 
H M W - M A A 
Collagen IV 
T l 4 
h 
h 
h 
h 
I 
m 
h 
h 
m 
h 
n.a.7 
h 
n.a. 
1 
n.a. 
h 
h 
M a b : none Pcab: 
Stroma 
Tumor cells 
Infiltrate cells, 
tumor cells 
Tumor cells, 
serosa 
None 
Myofibroblasts, 
smooth muscle 
Smooth muscle 
BLe of tumor, 
myofibroblasts 
BL of tumor, 
stroma 
PcAb most sensitive, but 
stromal reaction 
obscures vascular 
staining 
Reaction with tumor 
cells obscures vascular 
staining 
Cross-reaction makes 
vascular staining less 
discrete 
Useful as a marker; 
staining discrete 
Useful as marker 
Venable staining 
Less variable staining 
Reaction with 
perivascular stroma 
obscures vascular 
staimngs 
Reaction with 
perivascular stroma 
obscures vascular 
staining 
1
 = frozen sections; ' = paraffin sections; 3 = high; * = moderate; 6 = low; β = antigen; T — not applicable; fl= basal lamina. 
Discussion 
The microvasculature consists of endothelial cells and pericytes [9,16-18,36] surrounded by 
basal lamina. Therefore, antibodies to components of any of these constituents may theoretically be 
used to visualize both the degree of vascularization and the structural abnormalities of vessels in a 
tumor, and to study vascular invasion by tumor cells [23,29,37]. We now report on the 
distribution of microvascular antigens in tumors and present an evaluation of their use as markers 
for the tumor microvasculature. Furthermore, we have compared the microvasculature of tumor 
stroma with microvessels in different maturation stages of granulation tissue of wound healing. 
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Regarding the anti-endothelial antibodies in respect of their use to recognize vascular markers, 
the Mabs PAL-Ε and BMA 120 had the highest value. Mab BMA 120 and UEA I react with 
paraffin sections [23,28,32,37], and thus seem to be the best choice for formalin-fixed human 
tissues. As a marker for tumor vessels, von-Willebrand Factor does not seem suitable in view of 
its low sensitivity. Of some of the other tested reagents the specificity was limited: UEA-I lectin 
and the Mabs EN4 and BMA 120 reacted occasionally with tumor cells of non-endothelial origin. 
Moreover, the Mab BMA 120 reacted with mesothelium and Mab EN4 stained infiltrating 
mononuclear cells and alveolar macrophages. Staining for these markers has been used as evidence 
for an endothelial origin of tumor cells in histogenetic studies of neoplasmata [23]. Our data 
suggest that the results of such studies must be interpreted with caution. The typical granular 
staining for von-Willebrand Factor with MoAb CLB-35Rag was not observed in non-endothelial 
cells and might still provide the most reliable means of identifying the endothelial origin of tumor 
cells in a histogenetic study. It emerges from our work, however, that a fully specific and sensitive 
histological marker for the structural microvasculature in tumors, or endothelium in general, is not 
yet available. 
In order to confirm the cellular localization and to assess the subcellular distribution of the 
antigens a pre-embedding immunoperoxidase staining of víbrateme sections was used. On the basis 
of the specific cytoplasmic staining with the MAb CLB-35Rag against von-Willebrand Factor and 
MAb anti-aSMa-1 against pericytes, and of the basal lamina with the anti-collagen type IV Mab 
1042, this technique appears reliable in determining the differential staining of the different 
microvascular components. Our results further demonstrate that most of the endothelial membrane 
determinants studied are expressed predominantly at the luminal surface. 
The degree of staining observed in the tumor stroma with the MAbs PAL-Ε, EN4 and BMA 120 
was similar to results obtained in normal adult tissues [23,31]. However, the anti-vWF monoclonal 
antibody demonstrated decreased or even absent staining in the capillaries of the carcinomas and 
the other tumors, indicating that in the tumor stroma a marked quantitative heterogeneity in the 
degree of vWF expression among the microvascular endothelial cells exists. In two previous 
studies subsets of tumor vessels in paraffin sections of follicular carcinoma of thyroid and of 
gliomas were also found not to stain [29,38]. In normal tissues however, vWF (Mab CLB-35Rag) 
stains the capillary endothelium [26], but this staining is weaker than that of large vessel 
endothelium (own unpublished observations). The biological implication of these differences is 
unclear. The granular staining of endothelial cells probably is due to the presence of Weibel-Palade 
bodies which have been identified as the storage vesicles for von-Willebrand Factor [24]. The 
lesser staining for vWF in the tumor microvessels might therefore either reflect a decrease in the 
number of these organelles, or indicate that vWF is discharged by the cells instead of being stored 
in WP-bodies [24,39], as suggested by ultrastructural observations of increased numbers of WP 
bodies in tumor microvessels [39]. 
Apart from the decreased expression of vWF in the tumor capillary endothelium, the pericytes 
in the tumor stroma were found to have decreased or absent expression of alpha-smooth muscle 
actin (aSMa) compared to normal adult tissues, which may indicate an altered contractile function 
97 
of the pericytes in the tumor microvasculature The pericytes in the tumor stroma, however, 
markedly expressed the proteoglycan HMW-MAA [16] 
Double-staining of the tumor microvessels by antibodies to HMW-MAA and aSMa identified a 
heterogeneous expression of these antigens in the pericytes, which may reflect the existence of 
subtypes of vessels 
The tumor stroma is similar to granulation tissue of wound healing, as indicated by the 
presence of fibrin, inflammatory cells and immature connective tissue and microvessels [40-46] 
Therefore, we compared the microvasculature of the tumor stroma with that of various maturation 
zones in granulation tissue (Table III) In every zone, including the most superficial "immature" 
one, all microvessels expressed the endothelial and basement membrane antigens Even the most 
superficial microvessels contained pericytes However, depending on the zone, the pericyte 
markers displayed different patterns of staining (Table HI) Likewise, microvessels in the tumor 
stroma contained pericytes with heterogeneous expression, but no evident zonal microarchitecture 
could be established From the results obtained in our studies with granulation tissues can be 
inferred, however, that pericytes lacking aSMa positivity, but expressing the HMW-MAA antigen, 
accompany a proliferative microvascular system, and may be regarded, therefore, as a sign of 
active angiogenesis 
Our findings prompted us to reconsider the current model of stepwise angiogenesis as proposed 
by other authors [2,22,47] If we interprete this model well, vascular sprouts consist of immature 
vessels, with an incomplete basement membrane [22,47], and migrating endothelial cells at their 
tips, but without pericytes [48,49] The composition of the basement membrane in these sprouts, 
especially the content of collagen type IV and lammin, is thought to be an important factor in the 
regulation of endothelial migration and proliferation [47,50,51] Furthermore, the absence of 
pericytes is believed to stimulate endothelial mitosis [49] In our study, however, we did not find 
any cross-sections of microvessels without pericytes in the superficial layer (zone I) of granulation 
tissue, where vascular sprouting should be most abundant [15], nor did we observe vessels without 
collagen type IV or lammin m their basal laminas In the tumor stroma, we could not determine 
the exact sites of the vascular sprouting and endothelial mitosis Still, it is assumed that both 
phenomena occur frequently throughout the tumor microvasculature [2,4,20,21] As was the case 
in granulation tissue, we were unable to demonstrate in tumor stroma the immature phenotype (as 
predicted by the angiogenesis model), in which pericytes are lacking Therefore, taken together 
with ultra-structural observations by other authors of vascular sprouting in close relation with 
pericytes m granulation tissue [46,52], our results suggest an early recruitment of pericytes during 
angiogenesis Further research is needed to elucidate these apparent contradictory results between 
the angiogenesis models and those of immunohistochemical and ultrastructural studies of human 
lesions 
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Summary 
The structure and function of the tumor microvasculature is of great interest for cancer 
biology, diagnosis and therapy. The distribution of endothelial cells, pericytes and basal lamina in 
tumors is not well documented. In this study, we investigated the distribution of markers for these 
different components in a series of malignant human tumors and in human granulation tissue, both 
situations with extensive angiogenesis. Our results show a striking heterogeneity in the expression 
of markers for pericytes and endothelial cells between different tumors, but also within a single 
tumor lesion. To be able to distinguish between these two adjacent cell types decisively, all marker 
studies were carried out both on the light and the electron microscopical level and compared with 
parallel staining results in granulation tissue. In the granulation tissue, well-defined zones with 
increasing levels of maturation can be delineated. It was found that antibodies recognizing von 
Willebrand Factor often failed to stain the tumor capillaries. Of the pericyte markers, alpha-smooth 
muscle actin was only locally expressed by pericytes in the tumor vasculature, whereas the high 
molecular weight melanoma-associated antigen, a chondroitin sulphate proteoglycan, stained the 
microvasculature broadly. Staining of the basal lamina components collagen type IV and laminin 
was, within the tumor, not restricted to the microvasculature. From our findings we conclude that: 
1) for the visualization of the tumor vasculature, anti- bodies recognizing endothelial markers, 
especially MAbs PAL-Ε and BMA 120, are preferable to those recognizing pericytes or basal 
lamina, 2) within the microvasculature of tumors and granulation tissue, a heterogeneity of 
expression of endothelial and pericyte markers is observed, 3) during the formation of granulation 
tissue, all three microvascular components can be demonstrated already in the histologically 
earliest stage, suggesting not only an involvement of endothelial cells but also of pericytes and 
basal lamina in the initial steps of angiogenesis in wound healing. 
References 
1. Algire GH, Chalkley HW, Legallais FY, Park HD: Vascular reactions of normal and malignant tissues 
in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer 
Inst 6:46-73.1945. 
2. Folkman J: Tumor angiogenesis. Adv Cancer Res 43:175-203,1985. 
3. Reinhold HS, van den Berg-Blok A: Factors influencing the neovascularization of experimental tumours. 
Biorheology 21:493-501,1984. 
4. Folkman F, Cotran R: Relation of vascular proliferation to tumor growth. Int Rev Exp Pathol 
16:207-248,1976. 
5. Denekamp J: Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 
45:136-139,1982. 
6. Schor AM, Schor SL: Tumour angiogenesis. Br J Pathol 141:385-413,1983. 
7. Grunt TW, Lametschwandtner A, Karrer K, Staindl O: The angioarchitecture of the Lewis lung 
carcinoma in laboratory mice. Scanning Electron Microsc II: 557-573,1986. 
99 
8. Hagemeier HH, Vollmer ES, Goerdt S, Schulze-Osthoff K, Sorg O A monoclonal antibody reacting 
with endothelial cells of budding vessels in tumors and inflammatory tissues, and non-reactive with 
normal adult tissues. Int J Cancer 38-481-488,1986. 
9 Ho KL: Ultrastructure of cerebellar capillary hemangioblastoma IV. Pencytes and their relationship to 
endothelial cells Acta Neuropathol 67:254-264,1985. 
10 Hobson B, Denekamp J: Endothelial proliferation in tumours and normal tissues: continuous labeling 
studies. Br J Cancer 49.405^13,1984. 
11 Jam RK: Determinants of tumor blood flow: A review. Cancer Res 48:2641-2658,1985. 
12. McLone DG: Ultrastructure of the vasculature of central nervous system tumors of childhood. Child's 
Bram 6:242-254,1980. 
13. Murray JC, Rhandawa V, Denekamp J: The effects of melphalan and misomdazole on the vasculature of 
a munne sarcoma. Br J Cancer 55.233-238,1987. 
14. Nawroth P, Handley D, Matsueda G, de Waal R, Gerlach H, Blohm D, Stem DM: Tumor necrosis 
factor/cachectin-mduced intravascular fibnn formation in meth A fibrosarcomas. J Exp Med 168:637-
647,1988. 
15. Rofstad EK: Growth and vascular structure of human melanoma xenografts. Cell Tiss Kin 
17:91-101,1984. 
16. Schlingemann RO, Rietveld FJR, De Waal RMW, Ferrone S, Ruiter DJ: Expression of the high 
molecular weight melanoma-associated antigen by pencytes during angiogenesis in tumors and in healmg 
wounds. Am J Pathol 1990 (in press) 
17. Schlingemann RO, Rietveld FJR, de Waal RMW, Bradley NJ, Skene AI, Davies AJS, Greaves, MF, 
Denekamp J, Ruiter DJ: Leukocyte antigen CD 34 is expressed by a subset of cultured endothelial cells 
and on endothelial ablununal microprocesses m the tumor stroma. Laboratory Investigation 1990 (in 
press). 
18. Warren BA: The vascular morphology of tumors. In: HI Peterson e.d.). Tumor blood circulation, edited 
by H.-I. Peterson (Boca Raton, FL: CRC Press, Ine ), pp. 1-»7,1979. 
19. Heuser LS, Miller FN. Differential macromolecular leakage from the vasculature of tumors. Cancer 
57 461-464,1986. 
20 Cavallo Τ, Sade R, Folkman J, Cotran RS Ultrastructural autoradiographic studies of the early 
vasoproliferative response in tumor angiogenesis. Am J Pathol 70· 345-362,1973. 
21. Tannock IF: Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts ш a 
transplanted mouse mammary tumor.Cancer Res 30.2470-2476,1970 
22. Ausprunk DH, Folkman J: Migration and proliferation of endothelial cells in preformed and newly 
formed blood vessels during tumor angiogenesis. Microva.sc Res 14:53-65,1977. 
23. Ruiter DJ, Schlingemann RO, Rietveld FJR, de Waal RWM: Monoclonal antibody defined human 
endothelial antigens as vascular markers. J Invest Denmat 93-25S-32S,1989. 
24. Reinders JH, de Groot F, van den Berg A, Vervoom R, Sixma J, van Mounk J: The Weibel-Palade 
body is the storage vesicle for von Willebrand factor in endothelial cells. Proc 4th Int Symp on biol of 
the vascular endothelial cell, 1986 
25. Stel HV, Sakanassen KS, Schölte BJ, Veerman ECI, van de Kwast ThH, de Groot PhG, Sixma JJ, van 
Mounk JA: Characterization of 25 monoclonal antibodies to Factor VHI-von Willebrand Factor: 
Relationship between nstocetm-induced patelet aggegration and platelet adherence to subendothelium. 
Blood 67-222-227,1984. 
26. VandeKwast TH, Stel HV, Cnsten E, Bertina RM and Veerman ECI: Localization of factor 
VHI-procoagulant antigen: an immunohistochemical survey of the human body using monoclonal 
antibodies. Blood 67.222-227,1986. 
27. Skalli O, Ropraz P, Trzeciac A, Benzonana G, Gillesen D, Gabbiani G: A monoclonal antibody against 
alpha-smooth muscle aclin: A new probe for smooth muscle differentiation. J Cell Biol, 103: 2787-2796, 
28. Alles JU, Bosslet К: Immunohistochemical and immunochemical characterization of a new endothelial 
cell-specific antigen. J Histochem Cytochem, 34:209-214,1986. 
29. Harach HR, Jasani B, Williams ED: Factor VIII as a marker of endothelial cells in follicular carcinoma 
of the thyroid. J Clin Pathol 36:1050-1054,1983. 
30. Laune GW, Leblond CP and Martin GR: Localization of type IV collagen, laminin, heparan sulphate 
proteoglycan, and fibronectin to the basal lamina of basement membrane. J Cell Biol 95:340-344,1986. 
31. Schlingemann RO, Dingjan GM, Blok J, Emeis JJ, Warnaar SO, Ruiter DJ: Monoclonal antibody 
PAL-Ε specific for endothelium. Lab Invest 1:71-76,1985. 
100 
32. Holthofer H, Virtanen I, Kanniemi Al, Hormia M, Lmder E, Miettinen A: Ulex europaeus I lectin as a 
marker for vascular endothelium m human tissues Lab Invest 47:60-66,1982. 
33. Nakane PK, Pierce GB' Enzyme-labeled antibodies: preparation and application for the localization of 
antigens. J Histochem Cytochem 14:929-1002,1966. 
34. Scopsi L, Larsson LI: Increased sensitivity in peroxidase immunocytochemistry. Histochemistry 
84:221-230,1986. 
35. Lechago J, Sun NCJ, Weinstein WM' Simultaneous visualization of two antigens in the same tissue 
section by combining immunoperoxidase with immunofluorescence techniques. J Histochem Cytochem 
27:1221-1225,1979. 
36. Sims DE: The pencyte-a review. Tiss Cell 18:153-174,1986. 
37. Lee AK' Basement membrane and endothelial antigens: Their role in evaluation of tumor invasion and 
metastasis. In: Adv. Immunohistochem. ed RA De Lellis. Raven Press, New York, pp 363-393,1988. 
38. Sawada T, Nakamura M, Sakurai I: An immunohistochemical study of neovasculature m human brain 
tumors. Acta Pathol Jpn 38(6):713,1988. 
39. Kumar P, Kumar S, Marsden HB, Lynch PG, Eamshaw E: Weibel-Palade bodies m endothelial cells as 
a marker for angiogenesis ш bram tumors. Cancer Res 40:2010-2019,1980. 
40 Clark RAF, Dellapelle P, Manseau E, Lanigan JM, Dvorak HF, Colvin RB: Blood vessel fibronectin 
mcreases in conjunction with endothelial cell proliferation and capillary ingrowth during wound healing. 
J Invest Dermatol, 79-269-276,1982. 
41. Cliff WJ: Observations on healing tissue: A combined light and electron microscopic investigation. 
Trans Roy Soc London Ser В 246: 305-325,1963. 
42. Crocker DJ, Murad TM, Geer JC: Role of the pencyte in wound healing. An ultrastructural study. Exp 
Mol Pathol 13:51-65,1970. 
43. Dvorak HF: Tumors: wounds that do not heal. New Engl J Med, 315: 1650-1659,1986. 
44. Schoeñ Gl: Studies on inflammation. III. Growing capillanes:their structure and permeability. Virchows 
Arch 337:97-141,1963. 
45. Seemayer TA, Lagace R, Schurch W, Tremblay G: Myofibroblasts m the stroma of invasive and 
metastatic carcinoma. Am J Pathol 3:525-532,1979. 
46. Weber K, Braun-Falco 0: Ultrastructure of blood vessels in human granulation tissue. Arch Derm 
Forsch 248:29-44,1974. 
47. Form DM, Pratt BM, Madn JA. Endothelial cell proliferation during angiogenesis: in vitro modulation 
by basement membranecomponents. Lab Invest 55.521-530,1986. 
48. Kuwabara T, Cogan DG: Retinal vascular patterns IV. Mural cells of the retinal capillaries. Arch 
Ophtalm 69:492-502,1963. 
49. Orlidge A, D'Amore PA: Inhibition of capillary endothelial cell growth by pericytes and smooth muscle 
cells. J Cell Biol 105:1455-1462,1987. 
50. Furcht LT: Critical factors controlling angiogenesis: cell products, cell matrix, and growth factors. Lab 
Invest 55:505-509,1986. 
51. Gospadorowicz D, Savion N, Giguere L: The control of proliferation and differentiation of endothelial 
cells. Palhobiology of the endothelial cell,edited by EA Jaffe, (New York, Academic Press), pp. 19-
39,1982. 
52. Wakui S: Two- and three-dimensional ultrastructural observation of two cell angiogenesis in human 
granulation tissue. Virchows Arch В Cell Pathol 56:127-139,1988. 
101 
102 
CHAPTER FIVE 
DIFFERENTIAL EXPRESSION OF ENDOTHELIUM-
SPECIFIC ANTIGEN PAL-Ε IN VASCULATURE OF BRAIN 
TUMORS AND PREEXISTENT BRAIN CAPILLARIES 
R.O. Schlingemann, H.Th.A.M. Bots, S.G. van Duinen, and D.J. Ruiter. 
Published in: Annals of the New York Academy of Sciences. 
Vol 465:111-114,1986. 
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In the brain, blood vessels are lined by uniquely differentiated endothelium forming a barrier 
of selective permeability to a wide range of solutes, the blood-brain barrier (BBB) [1]. Tight 
junctions, a scarcity of plasmalemmal vesicles, and the absence of fenestrations in brain 
endothelium are cellular properties associated with this barrier function, [2] but the brain 
endothelium also differs from endothelium outside the brain with respect to several molecular 
properties related to transcellular transport like the presence of the transferrin receptor [3] and the 
enzyme glutamyl transpeptidase [4]. In certain anatomic sites, like the choroid plexus and the 
pituitary gland, and some pathological conditions, including brain tumors, the BBB seems to be 
lacking or defective, and the endothelium of these sites resembles endothelium outside the central 
nervous system. 
We investigated the expression of the antigen recognized by the monoclonal antibody PAL-E 
on endothelium in the CNS. This antibody recognizes an endothelium-specific molecule of 
undefined molecular weight and function, which is associated with endothelial vesicles [5]. 
Immunoperoxidase staining of frozen sections of normal (human, sheep, cow, rabbit) and 
neoplastic brain tissues (Table I) with this antibody and of serial sections with the lectin Ulex 
Europaeus I as a vascular marker [6] revealed that PAL-Ε is absent from endothelium in sites with 
a patent BBB (Table I, fig. 1). In contrast, anatomic sites with fenestrated or permeable 
endothelium showed marked staining (Table 1, fig. 1). A striking observation was the strong 
staining of endothelium in the stroma of primary and metastatic brain neoplasms (Fig. 2). This 
finding parallels the defective BBB observed in brain tumors using permeability tracers and 
ultrastructural studies on the vasculature in brain tumors, showing endothelium with fenestrations 
containing many endothelial vesicles [7,8], like endothelium outside the CNS. The absence of the 
antigen in brain endothelium is another feature distinguishing this specialized endothelium from its 
counterpart in other tissues. 
Though its function is unknown, our results may suggest a correlation of the PAL-Ε antigen 
with trans-endothelial transport. Its presence exclusively in the endothelial cell, the previously 
shown association with endothelial vesicles and the remarkable absence from brain endothelium in 
areas with BBB favor such a hypothesis. The marked staining of permeable endothelium in the 
brain and the absence of staining in endothelium with few endothelial vesicles (brain, lung) [9] 
may be based on a topologie relation with these structures [9]. 
Still it is noteworthy that arterial endothelium does not stain with PAL-Ε, though it contains 
numerous vesicles. This suggests that this determinant is restricted to a subpopulation of 
endothelial vesicles. It has been proposed that specific receptors exist in endothelial vesicles 
regulating transendothelial transport [9], such as a receptor for albumin demonstrated in mice [10]. 
It is noteworthy that the tissue distribution of this albumin receptor in mice shows a striking 
similarity with the distribution of PAL-Ε in other mammals. 
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Table I. Staining of brain endothelium by PAL-E 
Tissues Tested 
Normal tissues 
Tumore 
Cerebral cortex 
Cerebellum 
Midbrain 
Medulla 
Spinal cord 
Eye Chono capillans 
Retina 
Meningee 
Dura mater 
Arachnoidal granulations 
Choroid plexus lateral ventncle 
fourth ventncle 
Pituitary gland 
Primary brain tumors 
Oligodendroglioma 
Astrocytoma 
Meningioma 
Schwannoma 
Ependymoma 
Neurofibroma 
Craniopharyngioma 
Lymphoma 
Métastasée 
Adenocarcinoma of kidney 
of ovary 
of colon 
of lung 
of unknown sites 
Planocellular carcinoma 
Melanoma 
of lung 
Number Staining results 
-
+ + 
-
+ + 
-
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Figure 1. Frozen section of normal rabit brain stained with PAL-E in an indirect 
immunoperoxidase staining procedure using 3-3-di-amino-benzidine as a substrate 
and hematoxylin counterstaining. Note marked staining of capillaries in choroid 
plexus |CP) and absent staining in parenchymal capillaries (arrows and inset) (x160; 
inset x280). 
Figure 2. Frozen sections of metastatic adenocarcinoma stained with PAL-E. Nuclei were 
counterstained with neutral red. Note marked staining of vascular endothelium in the 
tumor stroma (SI; Τ = tumor (x400). 
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As mentioned earlier, PAL-Ε markedly stains the endothelium of the vasculature in brain 
tumors; adjacent normal or even edematous brain tissues are negative. This difference may be 
useful for immunoscintigraphy of brain tumors, as an endothelial antigen is highly accessible to a 
circulating antibody. Further studies are needed to investigate the in vivo binding properties of 
PAL-Ε and its efficacy for this approach. 
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Introduction 
The human haemopoetic progenitor cell antigen CD34 is known to be synthesized and expressed 
by certain cells of hemopoietic lineage [4,5,17,36,41]. Furthermore, antt-CD34 monoclonal antibodies 
have been reported to stain blood vessels in tissue sections [4,41]. It has however remained unclear 
whether this vascular staining was due to cross-reacting epitopes or to production and expression of 
the CD34 molecule proper by endothelial cells. 
In order to elucidate this phenomenon we have investigated the (sub)cellular distribution of this 
antigen in cultured human endothelial cells and in the vasculature of normal human tissues and tumors. 
The investigations reveal staining in tissues for CD34 on the luminal endothelial membrane and of 
abluminal endothelial microprocesses associated with vascular sprouting during angiogenesis. 
Angiogenesis is characterized by a series of events, i.e. migration of endothelial cells, followed 
by sprout formation, endothelial proliferation, fusion of sprouts and eventually maturation of the newly 
formed vessel by formation of basement membrane and the appearance of pericytes 
[2,6,7,13-16,18,33]. In embryogenesis and wound healing this process is well-regulated and ceases 
when tissue repair or organ development is completed [16]. In contrast, angiogenesis in the tumor 
stroma seems to be continuously induced by the growing tumor [11,13,28,40]. 
In early morphological studies on wound healing and embryogenesis it was observed that 
endothelial cells during the initial migration step of angiogenesis project abluminal extensions to the 
surrounding interstitium [7,33]. We now demonstrate by CD34 staining the presence of equivalent 
processes in the human tumor vasculature which we would like to call endothelial abluminal 
microprocesses (EAM). In addition we report on the preferential expression of CD34 on a small subset 
of cultured human endothelial cells in vitro. 
Experimental design 
1) The distribution of the CD34 antigen in the microvasculature of tumors was compared with that 
in granulation tissue of wound healing, normal human fetal tissues and normal human adult tissues 
by immunohistochemistry using anti-CD34 monoclonal antibodies ICH3 and QBEND-10 on frozen 
tissue and thick vibratome sections. 
2) The subcellular distribution of CD34 was studied by an immunohistochemical analysis on the 
electronmicroscopic (EM) level. 
3) In order to find evidence for production of the CD34 molecule by endothelial cells, 
immunocytochemistry on the lightmicroscopic (LM) and EM level was performed on cultured 
human umbilical vein endothelium. 
4) The influence on CD34 expression of agents known to affect endothelium during angiogenesis, 
e.g. tumor necrosis factor, the phorbol ester PMA and co-culture with tumor cells on cultured 
endothelium was assessed. 
Ill 
Results and discussion 
The CD34 antigen is expressed by a subset of cultured endothelial cells 
Our results provide the following evidence that CD34 is synthesized by endothelium 
1) Anti-CD34 MoAbs ICH3 and QBEND-10 markedly stain a subset (5-20%) of cells in monolayers 
and suspensions of human umbilical vein endothelial cells (HUVEC), (Figure 1,2). In monolayers, 
the CD34-staining cells seem to lay on top of the endothelial monolayer and they show 
bidirectional extensions Staining was performed with cells at serial passage number 5 to avoid 
contamination with non-endothehal cells Double-labeling with a polyclonal antibody directed 
against von Willebrand Factor confirmed the endothelial nature of the CD34 stained cells (data not 
shown) Staining with irrelevant antibodies (e g anti-CD3 MoAb WT32, anti-HLA Class II MoAb 
Q2/70 and MoAb RC38) was negative in all cells Cultured human brain pericytes, smooth muscle 
cells and melanoma cells failed to stain with anti-CD34 MoAbs 
Figure 1 Immunoperoxidase staining with anti-CD 34 MoAb QBEND-10 of fifth passage human 
umbilical vein endothelial cells cultured on plastic covershp MoAb QBEND-10 stains a 
subset of cells apparently situated on top of the endothelial monolayer Note staining 
of bidirectional endothelial extensions (arrows) 1x450. with haematoxylin counterstai-
nmg). 
Figure 2 Electronmicroscopical immunoperoxidase staining with anti-CD 34 MoAb QBEND-10 
of a cell suspension of fifth passage human umbilical vein endothelial cells MoAb 
QBEND-10 markedly stains the surface (arrows) of one cell (El), whereas other 
endothelial cells (E2-5) are not stained N = nucleus (x3600, no counterstaming) 
Figure 3 Immunoperoxidase staining with anti-CD 34 MoAb ICH3 of thick víbrateme section of 
surgically removed normal kidney MoAb ICH3 stains capillaries, (C) but no sprouts or 
endothelial ablummal microprocesses are seen (x450, no counterstaming) 
Figure 4 Immunoperoxidase staining with anti-CD 34 MoAb QBEND-10 of frozen section of 
surgically removed colon carcinoma lesion MoAb QBEND-10 stains all vascular 
structures (arrows) (xl 80, with haematoxylin counterstaming) 
Figure 5 Immunoperoxidase staining with anti-CD 34 MoAb ICH3 of thick víbrateme section of 
surgically removed neuro-blastoma lesion MoAb ICH3 stains capillaries (C) and 
numerous endothelial ablummal micro-processes (arrowheads) I =interstitium (x450, 
no counterstaming) 
Figure 6 Immunoperoxidase staining with anti-CD 34 MoAb ICH3 of thick víbrateme section of 
surgically removed colon carcinoma lesion. MoAb ICH3 stains endothelial lining of large 
vessel (asterisks indicate lumen) and two blind-ending vascular sprouts (S) with 
endothelial ablummal microprocesses (arrowheads). I = mterstitium (x450, no 
counterstaming) 
Figure 7 Immunoperoxidase staining with anti-CD 34 MoAb QBEND-10 of thick víbrateme 
section of surgically removed normal fetal tissue of 10 weeks gestation MoAb ICH3 
stains capillaries(L = lumen) in paravertebral plexus Several endothelial ablummal 
microprocesses are seen (arrows) I = mterstitium. 1x1600, no counterstaming) 
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2) The anti-CD34 MoAbs used in this study recognize distinct epitopes on the CD34 molecule (41) 
Still, we observed identical staining patterns of the two MoAbs both in cultured endothelial cells 
and in tissues 
Other authors have shown that anti-CD34 MoAbs MylO, 12 8 and BI 3C5 (recognizing different 
epitopes on the CD34 antigen) react with blood vessels in tissue sections [4,41] as do all (of 6) 
recently identified CD34 antibodies (Fina et al,in preparation) Moreover, CD34 cDNA was recently 
cloned and corresponding mRNA could be demonstrated by northern blotting in our endothelial cells 
(Fina et al, manuscript in preparation) All these data strongly suggest that endothelial cells synthesize 
a molecule similar to the haemopoetic progenitor CD34 antigen Incubation of the endothelial cultures 
with Tumor Necrosis Factor or cultured colon carcinoma cells, stimuli capable of influencing the 
angiogenic process in vivo [23], or addition to the culture medium of the phorbol ester PMA, an agent 
modulating cellular differentiation, did not affect the percentage of CD34-staining endothelial cells 
(data not shown) 
Normal tissues: polarized expression of cd34 on endothelium 
Light microscopy 
Overall staining of the vasculature was observed in both frozen and thick víbrateme sections of normal 
tissues stained with anti-CD34 MoAbs ICH3 and QBEND-10 (shown in Figure 3) By light 
microscopy, no clear distinction between luminal and ablummal endothelial staining could be made 
A detailed tissue distribution of anti-CD34 MoAb QBEND-10 or a series of anti-CD34 monoclonal 
antibodies will be presented in separate papers (Bradley et al , Fina et al, manuscripts in preparation) 
Figure 8 Electronmicroscopical immunoperoxidase staining with anti-CD34 MoAb QBEND-10 of 
surgically removed colon carcinoma lesion Electronphotomicrograph of one ultrathin 
section (8A,top panel) and 3D reconstruction of ten serial ultrathin sections of the same 
vascular sprout (8B, bottom panel) MoAb QBEND-10 stains luminal endothelial 
membrane and ablummal microprocesses IEAM,arrowheads) EAM are often associated 
with electronlucent areas (figure ΘΑ, asterisks) Branching EAM in figure 8B is indicated 
by arrow Note that a pericyte in close relation with advancing sprout is not stained 
Ρ = pericyte, E = endothelium, L = lumen (x2000, no counterstaimng) 
Figure 9 Electronmicroscopical immunoperoxidase staining with anti-CD34 MoAb QBEND-10 of 
surgically removed colon carcinoma lesion MoAb QBEND-10 stains luminal endothelial 
membrane and endothelial ablummal microprocesses (small arrowheads) The remaining 
ablummal endothelial membrane is only weakly stained (large arrowhead) 
E = endothelium, L = lumen (x3200, no counterstaimng) 
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Electronmicroscopy: 
At the subcellular level, a marked, evenly distributed staining of the luminal endothelial membrane 
was observed in blood vessels of normal tissues. In contrast, the abluminal membrane of the 
endothelial cells was only weakly stained, indicating a polar expression of CD34 in endothelium in 
vivo. 
Tumor and fetal vasculature: expression of cd34 on endothelial abluminal microprocesses (earn) 
Light microscopy 
In frozen and thick vibratome sections of tumor tissues, anti-CD34 Mo Abs ICH3 and QBEND-10 
markedly stained vascular structures, as is shown for MoAb ICH3 in Figures 4,5 and 6. No reaction 
with tumor cells was seen. However, in addition to the overall vascular staining which was also 
observed in normal tissues, in the vibratome sections striking CD34-staining of vascular abluminal 
microprocesses (Figures 5 and 6) was observed. These structures were seen extending up to 20 
microns into the surrounding tissue both from apparantly blind-ending vascular sprouts (Figure 6) as 
from other sites along fully formed vessels (Figure 5). Often several microprocesses were connected 
with one site. In adjacent vibratome sections from the same lesions stained with MoAbs PAL-Ε or 
EN-4, no abluminal microprocesbes were observed. Similar microprocesses could be detected in 
vibratome sections of fetal tissues of 10 weeks gestation, being locally present in the microvasculature 
of the paravertebral and the cutaneous plexus (Figure 7). Neither in fetal tissues of 18 weeks gestation 
evident EAM could be found nor in granulation tissue of wound healing. 
Electronmicroscopy 
A marked staining with anti-CD34 MoAbs ICH3 and QBEND-10 of both the luminal endothelial 
membrane and of EAM was observed in tumor tissues (Figures 8 and 9). The extensions were 
continuous with the endothelial cell membrane (Figure 8 and 9) and occasionally branched. They 
mostly extended into electronlucent areas of the interstitium (Figure 8 and 9) and lacked basement 
membrane as shown in control sections stained for collagen type IV. 
Comments 
Endothelial abluminal microprocesses have been observed by other authors in studies of wound-healing 
and embryogenesis. They were first described by Klosovskii [19] and Schoefl [33]. Klosovskii showed 
by lightmicroscopy that capillary sprouts have the aspect of polyps with tendril-like processes at their 
tips. Schoefl demonstrated long cytoplasmic extensions devoid of basement membrane at the tips of 
vascular sprouts in an EM study of cornea wounds. According to one of his figures these extensions 
had a diameter of approximately 0.1 micron and a length up to 7 microns [33]. Later, again in studies 
of wound- healing and developing tissues, similar processes have been reported 
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[1,3,7,10,12,20,27,29,39]. Several authors have associated EAM with amoeboid movements and 
migration of endothelial cells in angiogenesis [6,7,33,39]. 
We localized many EAM in tumor vessels without the presence of blind-ending vascular sprouts 
(Figure S). In some tumors most endothelial cells extended EAM into the interstitium. This 
distribution pattern contrasts with our observation of sparsely distributed EAM in thick vibratome 
sections of fetal tissues of 10 weeks gestation and with observations by other authors of EAM solely 
at the tips of vascular sprouts in embryogenesis [20] and wound-healing [33]. It is also interesting that 
the prevalence of vascular sprouts and EAM in the various tumors studied varied widely. In one 
poorly differentiated adenocarcinoma of the colon and two neuroblastomas, EAM were numerous and 
could be observed on most vessels (Figure 5). In other moderately and highly differentiated 
adenocarcinomas, sprouts and EAM were confined to just a few areas. These patterns did not differ 
in central as compared to peripheral parts of the tumors studied and are therefore a consistent property 
of a particular tumor. As the degree of angiogenesis may vary among the various tumors 
[13,21,29,40], it may be interesting to study the frequency of EAM in relation to this process. Since 
the distribution of EAM in human tissues can be studied by light microscopical examination of 
vibratome sections stained with anti-CD34 MoAbs, this method provides a new way of studying 
angiogenesis in situ. It is conceivable that for this approach lectins could also be useful [42]. 
We found that vascular structures and sprouts with endothelial abluminal processes in tumor 
stroma were often associated with pericytes (Figure 10). However, neither pericytes nor fibroblasts 
stained with anti-CD34 MoAbs (Figure 10). The close association of pericytes with sprouting 
endothelial cells is unexpected, as this does not fit in the classical model of angiogenesis [13,16, 25], 
by which pericytes are absent from the tips of sprouts and present only in the stage of final vascular 
differentiation [8,25,35]. The structure and function of CD34 are unknown. Its expression in both 
human hemopoietic progenitor cells and endothelium is interesting in the light of the proposed early 
embryonic common origin of these cells [26]. Previously, an antigen (MB1) was described in the 
quail, that is also shared by endothelial and hemopoietic cells [26]. In conclusion, our results suggest 
that the CD34 antigen is a marker for EAM present during angiogenesis. Especially, demonstration 
of EAM and their distribution in thick vibratome sections by staining with anti-CD34 monoclonal 
antibodies could provide a key method for studying angiogenesis in situ. 
Methods 
Tissue Samples 
Samples from normal and pathological human tissues were obtained from fresh surgical specimens and 
autopsies obtained within 6 hours after death. The normal tissues and pathological tissues are listed 
in Table I. All tissues were snap-frozen and stored at -70 C. 
117 
For preparation of thick vibratome sections and immunoelectronmicroscopy, samples from eight 
colon carcinomas, two neuroblastomas, a mixed tumor of the parotid gland, a full-term placenta 
obtained at caesarean section, two cases of granulation tissue of wound-healing, normal fetal tissues 
of 10 and 18 weeks gestation (including striated muscle, vertebral column, limb, liver), normal adult 
kidney, bladder and prostate, were used within 30 minutes of surgical removal. 
Table I. Tissues and cultured cells used in this study 
Normal Tiseuee Pathological Tissues Cultured Cells 
ktdnev 
etnated muscle 
thyroid 
bladder 
prostate 
lung 
placenta 
fetal tissues 
tumors 
neuroblastoma (n = 2) 
lung care 
colon care (η = β) 
mixed tumor of 
parotid gland 
granulation tissue (n = 4) 
foreskin rTHcrovascular EC' 
umbilical vain EC 
fibroblasts 
smooth muscla calls 
brain pericytes 
EC = endothelial cells 
Cultured Cells 
The microvascular endothelial cells were isolated from human foreskin as decribed by Davison et al. 
[9] and cultured in Dulbecco's minimal essential medium supplemented with 20% normal human 
serum. HUVEC was isolated from umbilical cords and cultured as described by van Hinsbergh et al. 
[37]. For experiments, fifth passage cells were used. Human brain pericytes were cultured from 
cerebral cortex obtained from autopsy patients in a modification of the method described by Vinters 
et al [38], (described in more detail in reference 32). Briefly, microcapillaries were isolated from 
cerebral cortex by mechanical disruption (Dounce tissue grinder) followed by differential 
centrifugation and adherence to plastic surfaces. For this latter purpose, untreated petri dishes were 
used instead of a column filled with beads. The capillary fragments were subsequently digested with 
collagenase (0.1%,10-20 min at 37 C) and seeded in culture flasks. Endothelial cell outgrowth was 
followed by outgrowth of pericytes, which could be freed of contaminating elements by limiting 
dilution. These cells were characterized as pericytes on the basis of their morphology and positive 
staining with MoAb 3G5 (a specific marker for pericytes, kindly provided by Dr.C.Nayak) [24]. 
Cultured human smooth muscle cells, the human colon carcinoma cell line Colo 320 and the melanoma 
cell line M14 were kept at standard culture conditions. For studies of modulation of CD34 expression 
on HUVEC, third or fourth passage cells were seeded on plastic microscope coversiips coated with 
fibronectin (kindly provided by Dr.J.van Mourik, Central Laboratory of the Red Cross Blood 
Transfusion Service, Amsterdam, The Netherlands). After 24 hrs, the cells were incubated for another 
24 hrs with either 5 and 20 ng/ml Phorbol Myristate Acetate (Sigma), 5,20 and 100 nM Recombinant 
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Tumor Necrosis Factor or were co-cultured with 10* Colo 320 colon carcinoma cells. The effect of 
the different incubations was evaluated by determining the percentage of cells staining with anti-CD34 
MoAb QBEND-10. 
Immunohistochemistry 
Airdried 4-micron frozen tissue sections, culture coverslips and cytospins of cultured cells were fixed 
with cold acetone for 10 minutes and stained by a sensitive indirect immunoperoxidase procedure 
[22,34], using antibodies at appropriate dilutions in PBS containing 1 % BSA. З-3-Di-amino-benzidine 
(DAB), 0.07S % in TBS pH 6.0 containing 0.001 M imidazole and 0.01% H202 was used as 
substrate [32]. In control sections incubation with first antibody was omitted or replaced by an 
irrelevant monoclonal antibody (anti-CD3 MoAb WT32 anti-HLA Class II Moab Q2/70 or MoAb RC 
38 recognizing renal cell carcinoma). Sections were counter-stained with hematoxylin for visualization 
of the nuclei. 
Immunoelectronmicroscopy of tissue samples 
Small tissue specimen were fixed at room temperature for 4 hours in freshly prepared 4% 
paraformaldehyde in Sorensen phosphate buffer pH 7.4 and washed overnight in Tris-buffered saline 
pH 7.4 (TBS). Fifty-micron vibratome sections were cut, washed in TBS and incubated at 4 С 
overnight with MoAb ICH3 or MoAb QBEND-10 at appropriate dilutions in TBS containing 0.5% 
BSA and 0.005% saponin. Incubations and washing steps were performed using a rotary shaker. After 
four 30-minute washings with TBS the sections were incubated with a mixture of HRP-conjugated 
rabbit anti-mouse IgG and HRP-conjugated goat anti-mouse IgG for 2 hours at room temperature. 
Control sections were incubated with second antibodies alone. Serial sections were stained with 
MoAbs PAL-Ε and EN4, and with MoAb 1042, to enable exact localization of the basement 
membrane. After extensive washings in TBS, the sections were preincubated for 10 min in 0.75 mg/ml 
DAB in TBS pH 5.7 containing 0.001 M Imidazole. Sections were then developed for 10 min in the 
same solution containing in addition 0.01 % H202and the reaction was terminated by rinsing with TBS. 
Subsequently, the sections were post-fixed for 40 min in 1 % osmium tetroxide in Palade buffet, then 
dehydrated, embedded in Epon 812 and processed routinely. One-micron sections were cut for light 
microscopy. Ultrathin sections were cut and without further staining examined and photographed on 
a Philips 300 electron microscope at 40 kV. 
Immunoelectronmicroscopy of cells 
Cell suspensions of HUVEC were prepared by treating fifth-passage endothelial monolayers with 
EDTA 0.01% for 30 min at 37° С Subsequently the cells were fixed for 10 min with 2 % 
paraformaldehyde in Sorensen phosphate buffer pH 7.4 and washed in TBS. After staining of the 
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suspended cells with MoAb QBEND-10 or irrelevant antibodies and DAB as described in a preceding 
paragraph, the cells were spun down and further processed for electronmicroscopy as a pellet in a 
fashion similar to that of the stained vibratome sections. 
Monoclonal antibodies and conventional antisera 
The monoclonal antibodies (MoAb) ICH3 and QBEND-10 to distinct determinants of the CD34 
molecule, the MoAbs PAL-Ε and EN4 to endothelial differentiation markers, MoAb 1042, recognizing 
Collagen Type IV, (kindly provided by Dr.F.T. Bosman, Department of Pathology, State University 
Maastricht, The Netherlands), anti-CD3 MoAb WT32, MoAb 3G5, MoAb Q2/70 and MoAb RC 38 
were developed and characterized as described elsewhere [24,30,31]. A polyclonal antibody 
recognizing von Willebrand Factor (Factor VIH-related antigen), horseradish-peroxidase (HRP) 
conjugated goat anti-mouse IgG antibodies and HRP-conjugated rabbit anti-mouse IgG antibodies were 
purchased from TAGO Ine, Burlingame, CA and from Dakopatts, Denmark. 
Summary 
It has been reported that the human haemopoietic progenitor cell antigen CD34 is also expressed by 
vascular structures. To investigate its precise vascular localization we have studied the cellular and 
subcellular distribution of CD34 in normal tissues and pathological tissues with neovascularization. 
In normal resting tissues, anti-CD34 antibodies ICH3 and QBEND-10 predominantly stain the luminal 
endothelial membrane, whereas the abluminal membrane is negative or weakly positive. In contrast, 
a striking staining of endothelial abluminal microprocesses (EAM) was found in the tumor stroma. 
These structures, measuring up to 20 microns in length, could be observed in thick vibratome sections 
both at the tips of vascular sprouts and, also frequently, on fully-formed microvessels. The number 
of vascular sprouts and EAM varied widely between different tumors. CD34-stained EAM were 
sparsely present in fetal tissue of 10 weeks gestation, but they could not be demonstrated in 
granulation tissue of wound healing. By immunoelectronmicroscopy the EAM were continuous with 
the cytoplasm of endothelial cells showing an immature phenotype as seen in regeneration. In cultured 
human umbilical vein endothelium, CD34 was preferentially found on a small subset of cells with the 
morphological appearance of migrating cells These findings suggest that CD34 is an endothelial 
marker for angiogenesis. 
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Introduction 
The high molecular weight-melanoma associated antigen (HMW-MAA), a chondroitin sulphate 
proteoglycan, also designated the melanoma proteoglycan (Mel- CSPG or MP) [1,2,3], was 
described previously as a marker for melanoma cells [4,5]. Functional studies in cultured 
melanoma cells suggested a role of HMW-MAA in cell-substratum and cell-cell interactions [3,6] 
associated with metastasis and autonomous growth of neoplastic cells. In the course of 
immunohistochemical analysis of tumor lesions with anti-HMW-MAA monoclonal antibodies we 
observed staining of microvascular structures in the tumor stroma. Therefore in the present 
investigation we addressed ourselves to the following questions: 
1) what vascular cell type is stained by anti HMW-MAA monoclonal antibodies, 
2) what is the nature of the antigen recognized, and 
3) which mechanism(s) underlie(s) the higher staining of vessels in tumor stroma than in normal 
tissues? 
Materials and methods 
Tissue samples 
Samples from normal and pathological human tissues (Table I) were obtained from fresh 
surgical specimen and from patients who were autopsied within 6 hours after death. Granulation 
tissue was obtained from burn wounds and decubitus lesions and inflamed synovia from patients 
with chronic rheumatoid arthritis (Table I). Liver, spleen, skin, gut, lung and eye from a 20 week 
old human fetus and normal adult (gut, cerebral cortex and tonsil) and neoplastic tissues from rat, 
rabbit, cat and cow were also included. All tissues were snap-frozen and stored at -700C. 
Cultured cells 
Microvascular endothelial cells were isolated from human foreskin as decribed by Davison et 
al. [7] and cultured in Dulbecco's minimal essential medium supplemented with 20% normal 
human serum. Human umbilical vein endothelium was isolated from umbilical cords and cultured 
as described by van Hinsbergh et al. [8]. Human brain pericytes were isolated from cerebral cortex 
obtained from autopsy patients and were cultured following Vinter's method [9]. Briefly, capillary 
fragments were isolated via adherence to plastic surfaces, treated with collagenase (Boehringer 
Mannheim, FRG) (lmg/ml for IS min. at 37C) and seeded into fibronectin-coated culture dishes. 
125 
After 5-10 days, outgrowth of pericytes was observed, and pure cultures of these cells were 
obtained by selective cloning. Cultured human fibroblasts, U937 haemopoietic cells, smooth 
muscle cells and the melanoma cell line M14 were cultured in medium RPMI 1640 supplemented 
with 10% FCS. 
Table I. List of organs and lesions used for immunohistochemistry 
Normal Organe 
pancreas 
esophagus 
jejunum 
colon 
spleen 
lymph node 
tonsil 
thymus 
k i d n e y · 
lung 
liver 
cerebral corten 
cerebellum 
skin 
skeletal muscla 
thyroid' 
ovary 
testis 
placenta' 
Number of samples 
4 
1 
1 
4 
4 
4 
2 
4 
4 
1 
4 
S 
2 
β 
2 
2 
1 
1 
4 
Benign and Malignant lesione 
endothelial tumors 
haemangioma 
pyogenic granuloma 
angiosarcoma 
other tumors 
colon carcinoma' 
breast carcinoma 
lung carcinoma 
sarcoma" 
melanoma 
meningioma 
glioma 
haemangiopencytoma 
rabbit VX2-carcinoma 
feline carcinoma 
wound healing 
decubitus lesion 
burn wounds 
synovitis 
Number of samples 
lesions included in immunoeloctronmicroscopical study 
Monoclonal antibodies and conventional antisera 
The monoclonal antibodies (MoAb) AMF-6 (provided by Dr.C. Figdor), 225.28S, 763.74 and 
TP41.2 to distinct and spatially distant determinants of HMW-MAA, the MoAb PAL-Ε and EN4 
(Sanbio BV, Uden, The Netherlands) to endothelial markers, the MoAb CLB-35 to von Willebrand 
Factor (provided by Dr.J. van Mourik), the MoAb RD301 to desmin (Organon Teknika, Boxtel, 
The Netherlands), the MoAb anti-alpha-sml to alpha-smooth mus-cle actin (Biomakor, Rehovot, 
Israel), a marker for smooth muscle cells and pericytes, the MoAb 3G5 (provided by Dr.C.Nayak) 
to a marker for pericytes in culture and the anti-Collagen Type IV MoAb 1042 (provided by 
Dr.F.T.Bosman) were developed and characterized as described elsewhere [10,11,12,13, 14,15]. 
Horseradish-peroxidase (HRP) conjugated goat anti-mouse IgG antibodies, HRP-conjugated rabbit 
anti-mouse IgG anti-bodies and 10 nm gold conjugated goat anti-mouse IgG antibodies were 
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purchased from TAGO Ine, Burlingame, CA, from Dakopatts, Copenhagen, Denmark, and from 
Janssen Pharmaceutics, Beerse, Belgium, respectively. 
Immunoperoxidase staining 
Staining was performed as previously described [13]. Briefly, cultured cells at different passages 
were seeded on plastic microscope covers!ips coated with fibronectin and cultured for 24 hrs. 
Air-dried 4 micron frozen tissue sections, culture covers!ips and cytospins of cultured cells were 
fìxed with acetone for 10 minutes and sequentially incubated at room tem-perature with appropriate 
dilutions of monoclonal antibodies for 120 min. and HRP conjugated anti mouse Ig xenoantibodies 
for 60 min. [16,17]). 0.075% З-3-Di-Amino-Beiizidine (DAB) in tris buffered saline (TBS) pH 6.0 
containing 0.001 M imidazole and 0.01% H202 was used as a substrate [17]. Sections were 
counterstained with hematoxylin. Staining was graded as -, when no staining was detectable, +/-, 
when the staining intensity was weak, +, when it was moderate and + + , when it was marked. 
When indicated, staining was quantitated by counting the percentage of stained capillary cross-sect­
ions, using MoAb PAL-Ε stained capillaries in consecutive sections as a reference. Specificity of 
staining was monitored by incubating tissue substrates with HRP-conjugated anti mouse Ig 
xenoantibodies. In some tumors, a double staining procedure by immunoperoxidase and 
immunofluorescence in consecutive steps was performed according to Lechago et al [18], using the 
MoAb anti-alpha-sml and the anti-Collagen Type IV MoAb 1042. 
Indirect immunoprecipitation and sodium dodecylsulphate polyacrilamide gel electrophoresis 
(sds-page) 
Melanoma cells and pericytes were grown to 50% confluency in a 150 cm culture flask (5x10* 
cells/flask). After a 30 min. incubation in precursorfree medium, containing 10% dialyzed fetal 
bovine serum (FBS), cells were labeled in 25 ml of the same medium, supplemented with 100 
microCi of 14C-Ieucine or 1000 microCi of 35S-sulphate (Amersham International, Amersham 
UK). Following a 16 hour incubation at 370C, cells were harvested by scraping, washed three 
times with HBSS, solubilized with NP40, precleared with Protein A-sepharose (Pharmacia, 
Uppsala, Sweden) coated with rabbit anti mouse Ig xenoantibodies and mixed with monoclonal 
antibodies bound to anti mouse Ig xenoantibody coated Protein A-sepharose. At the end of a 2 
hour incubation at room temperature immunocomplexes were washed ex-tensively and analyzed by 
SDS-PAGE (7,5%) utilizing the buffer system described by Laemmli [19]. Gels were fluoro-
graphed as described by Bonner and Lasky [20]. 
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Immunoelectronm'icroscopy; Рге-embedding immunoperoxidase technique in tissues. 
Tissue specimen (Table I) with a maximum size of 4x6x2 mm were fixed for 4 hours at room 
temperature in freshly prepared 4% paraformaldehyde in Sorensen phosphate buffer pH 7.4 and 
washed overnight in TBS pH 7.4. Fifty micron vibratome sections were cut, washed in TBS and 
incubated overnight at 4°C with MoAb 225.28S or MoAb 763.74 at appropriate dilutions in TBS 
containing 0.5% BSA and 0.005%. saponin. Incubations and washing steps were performed using 
a rotary shaker. After four 30 minute washings with TBS sections were incubated for 3 hours at 
room temperature with a mixture of HRP-conjugated rabbit anti-mouse IgG antibodies and 
HRP-conjugated goat anti-mouse IgG antibodies diluted in TBS containing 20% normal human 
serum and 0.005% saponin. Control sections were incubated with anti mouse Ig xenoantibodies 
alone. To define the exact localization of basement membranes serial sections were stained with 
the anti-Collagen Type IV MoAb 1042. After extensive washings in TBS sections were 
preincubated for 10 min in TBS pH 5.7 supplemented with DAB 0.75 mg/ml and 0.001 M imida­
zole. Sections were then developed for 10 min in the same solution supplemented with 0.01% 
H202; the reaction was terminated with TBS. Subsequently, sections were post-fixed for 40 min in 
1% osmium tetroxide in Palade buffer, then dehydrated, embedded in Epon 812 and processed 
routinely. One micron sections were cut for light microscopy. Ultrathin sections were cut and not 
contrasted further. They were examined and micrographed on a Philips 300 electron microscope at 
40 kV. 
Pre-embedding immunogold staining of cultured cells. 
Immunogold staining was performed according to Garrigues et al [3]. Briefly, human brain 
pericytes and human umbilical vein endothelial cells were cultured for 48 hours on 5x12 mm Meli-
nex coverslips [20]. Coverslips were fixed for 2 hours at 370C in 0.65% gluteraldehyde and 2% 
paraformaldehyde in PBS, pH 7.7. After a 30 min. incubation with 20% human serum in TBS to 
reduce background staining coverslips were incubated for 4 hours at room temperature with MoAb 
763.74 or MoAb EN4. After washing with PBS, coverslips were incubated for 2 hours with 
colloidal 10 nm gold-conjugated goat anti-mouse IgG antibodies. After further washing, 
postfixation was performed for 40 min. with 1% buffered osmiumtetroxide in Palade buffer and 
coverslips were embedded in Epon 812. Ultrathin sections were cut in two planes, perpendicular 
and paralleli to the Melinex surface. Sections were contrasted further with lead citrate and uranyl 
acetate. To quantitate differential labeling of the membrane of cellular processes versus underlying 
cell surface, micrographs of three complete immuno-gold stained cells were used. Gold particles 
were counted and the mean number of particles per micrometer of membrane was determined for 
the two categories of cell surface. 
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Results 
Distribution of HMW-MAA in malignant lesions, in benign lesions and in normal tissues 
The distribution of HMW-MAA in the microvasculature of pathological conditions and normal 
tissues was studied using immunohistochemistry on frozen sections and three different anti-HMW-
MAA MoAbs. 
In the tumor stroma anti-HMW-MAA MoAbs 225.28S, 763.74 or TP41.2 stained capillaries with 
strong intensity (Table II), corresponding with the vascular staining of anti-endothelial MoAb 
PAL-Ε in consecutive sections (Figure 1). All anti-HMW-MAA MoAbs reacted with equal 
intensity and similar distribution. The strongest positivity was found in colon and brain tumors in 
areas with apparent capillary proliferation as characterized by glomerulus-like structures (Figure 
2). Occasionally endothelial cells unstained for HMW-MAA were seen at the luminal side of the 
DAB reaction product (Figure 2). This observation suggested that the antigen was expressed by 
non-endothelial microvascular cells. Of the tumors tested, staining of tumor cells was found in 
melanoma and haemangiopericytoma. In addition, myoepithelial cells in breast carcinoma were 
occasionally stained. Vascular structures in two spontaneously developed feline breast carcinomas 
and the rabbit VX2 carcinoma were also stained by anti-HMW-MAA MoAb 225.28S but not by 
the other anti-HMW-MAA MoAbs. Similar results were obtained when 50 micron vibratome 
sections were stained for HMW-MAA (Figure 3). 
Table II. Staining with anti-HMW-MAA monoclonal antibodies* of frozen sections of lesions 
associated with neovascularization 
Artenee, arterioles 
Capillanee 
smooth muscle cells 
endothelium 
Endothelial 
tumors 
+ + 
+ + 
Other 
tumors 
+ +b 
+ + 
Granulation 
+ + 
+ + 
Rheumatoid 
+ + 
+ + 
'Statnmg results obtained by anti-HMW-MAA MoAbs 225.285, 703 74 or TP 41.2 were similar. 
^,ηο staining; + + .marked staining. 
In chronically inflamed synovia and in granulation tissue of wound healing, anti-HMW-MAA 
MoAbs 225.28S, 763.74 or TP 41.2 stained capillaries with high intensity (Table II and Figure 4) 
In contrast, adjacent scar tissue and normal skin were not stained (not shown). 
The vascular staining pattern observed with anti-HMW-MAA monoclonal antibodies in normal 
adult tissues contrasted strongly with the results obtained in tumor lesions. Immunoperoxidase 
staining of frozen tissue sections with MoAb 225.28S, showed that HMW-MAA is barely detecta­
ble in capillaries in normal tissues of adult man, cat, cow and rabbit (Table III, figure 5). Smooth 
muscle cells in arterioles and arteries (Figure 5 and 6) and mesangial cells in renal glomerulus 
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Figure 1 Immunoperoxidase staining with anti-HMW-MAA MoAb 225.28S (1A), with 
anti-endothelium MoAb PAL-Ε (IB) and with MoAb anti-alpha-sml (1С) of frozen 
sections of a surgically removed seminoma lesion. Immunofluorescence staining 
with anti-Collagen Type IV Moab 1042 of the frozen section shown in С (ID). Moab 
225.28S stains capillaries (arrowhead) in tumor stroma. MoAb PAL-Ε stains endot­
helium in capillaries (arrowhead). Τ tumor cells. MoAb anti-alpha-sml stains pericy­
tes (arrowhead) that can be recognized by their location in the microvascular wall, 
visualized by the staining of Collagen Type IV. (x450). 
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however stained consistently. Outside the microvasculature, basal keratinocytes in hair follicles, 
chondrocytes in cartilage and smooth muscle cells were stained (Table Ш). 
Anti-HMW-MAA MoAbs 225.28S, 763.74 or TP 41.2 strongly stained blood vessels in 
placenta (Figure 7) and in tissues of a 20 week old fetus (not shown). 
Figure 2 Immunoperoxidase staining with anti-HMW-MAA MoAb 225.28S (2A,left panel) and 
with anti-endothelium MoAb PAL-Ε (2B,right panel) of serial frozen sections of a 
surgically removed astrocytoma lesion. MoAb 225.28S stains glomerulus-like 
capillary proliferation (asterisks) but does not stain lumina (arrowheads). MoAb 
PAL-Ε stains luminal endothelium of capillaries (asterisks and arrowheads). T = tumor 
cells(x450). 
Figure 3 Immunoperoxidase staining with anti-HMW-MAA MoAb 763.74 of a thick vibratome 
section of a surgically removed neuroblastoma lesion. MoAb 763.75 stains a 
continuous layer of pericytes in a network of capillaries (arrows). Τ = tumor cell 
nests (x450). 
Figure 4 Immunoperoxidase staining with anti-HMW-MAA MoAb 763.74 (4A,left panel) and 
with anti-endothelium MoAb PAL-Ε (4B,right panel) of serial frozen sections of a 
surgically removed granulation tissue of healing skin wound. MoAb 763.74 stains 
vascular wall (arrow) but does not stain lumina (asterisk). MoAb PAL-Ε stains 
vascular lumina (asterisk and arrows). I=cellular infiltrate (x450). 
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Table III. Staining with anti-HMW-MAA monoclonal antibodies (a) of frozen sections of normal 
adult tissues from man, cat, cow and rabbit (b) 
Vascular Structuras 
erte ne β, artenolee 
endothelium 
smooth muscle cells 
cepillarles 
Staming 
-(с) 
+ + 
• 
Non-Vascular Structures 
Tissue 
cartilage 
h a r follicle 
gut 
glomerulus 
Cell Type 
chondrocytes 
basal keratmocytes 
smooth muscle cells 
mesangiel cells 
Staining 
+ + 
+ + 
+ 
+ 
Is) Staining reeults obtemed only by anti-HMW-MAA Moeb 225.28S; lb) Staining resulte obtained in the specie 
mentioned were similar; Ic) -,ηο staining; +,moderate staining; + +,marked staining, '.sporadic weak staining. 
Expression of HMW-MAA by cultured cells 
In order to confirm the preferential staining for HMW-MAA by pericytes, pericytes were isolated 
and characterized, and stained by immunocytochemistry. 
Characterization of pericytes 
The phenotype of pericytes cultured from human brain were stained by MoAb anti-alpha-sml, (not 
shown) indicating that they were not fibroblasts. Between 60 and 70% of cells were also stained by 
the MoAb 3G5 (Figure 8) recognizing a ganglioside-like antigen expressed by cultured pericytes 
but not detectable in cultured smooth muscle cells. No staining was detected with anti-desmin 
Figure 5 Immunoperoxidase staining with anti-HMW-MAA MoAb 225.28S l5A,left panel), 
with MoAb anti-alpha-sml (5B, middle panel) and with anti-endothelium MoAb 
PAL-E (5C,right panel) of serial frozen sections of a surgically removed normal 
kidney. MoAb 225.28S stains smooth muscle cells in the wall of an arteriole(A). 
Peritubular capillaries are not visible. MoAb anti-alpha-sml stains smooth muscle 
cells of arteriole (A) and pericytes of peritubular capillaries (arrows). MoAb PAL-E 
stains endothelium of capillaries (arrows). Τ = tubuli; (x450). 
Figure 6 Immunoperoxidase staining with anti-HMW-MAA MoAb 763.74 of a frozen section 
of a surgically removed umbilical cord. MoAb 763.74 stains smooth muscle cells 
(arrow) in media of umbilical vein, but does not stain the endothelium (arrowhead). 
L = lumen; (x450). 
Figure 7 Immunoperoxidase staining with anti-HMW-MAA MoAb 225.28S (7A,left panel) and 
with MoAb anti-alphasml (7B,right panel) of frozen sections of a surgically removed 
full-term placenta. MoAb 225.28S and MoAb anti-alpha-sml stain fetal capillaries 
(arrows) (x450). 
Figure 8 Immunoperoxidase staining with anti-pericyte MoAb 3G5 of a cytospin preparation 
of human brain pericytes. MoAb 3G5 stains pericyte membrane (arrows) (x450). 
Figure 9 Immunoperoxidase staining with anti-HMW-MAA MoAb 225.28S of human brain 
pericytes cultured on plastic coverslip. No counterstaining. MoAb 225.28S stains 
pericyte membrane in areas with clusters of cellular processes (arrow). Other areas 
of the membrane are not stained (arrowhead) (x450). 
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MoAb RD301 (not shown). Furthermore, the cells did not express the morphological 
characteristics of smooth muscle cells (not shown), both by light, (i.e. cell shape, high number of 
nucleoli and knobs in cellular extensions), and by electron microscopic analysis, (i.e. abundant 
microfilament bundles and plasmalemmal densities). No staining of cells was detected with 
anti-vonWillebrand Factor MoAb CLB-35 and with the anti endothelial cell MoAb EN4 and 
PAL-Ε indicating that they are not of endothelial origin (not shown). No staining of cells was 
detected with antibodies to glial fibrillary acidic protein (GFAP) and to neurofilaments (not shown) 
mrm^fm 
% 
ás, 
Ί 
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arguing against their neural origin. Based on all these identification criteria, the cells cultured from 
human brain were classified as pericytes. 
Staining with anti-HMW-MAA monoclonal antibodies 
The anti-HMW-MAA MoAb AMF-6, 225.28S, 763.74 or TP41.2 stained cultured brain pericytes 
(Figure 9), smooth muscle cells and melanoma cells with a strong intensity (table IV). The staining 
of the cell membrane of pericytes was not homogeneous, but was restricted to sites of multiple 
cellular processes (Figure 9). No staining was detected of endothelial cells from umbilical vein and 
from microvascular endothelium and of fibroblasts in culture (not shown). 
Molecular profile of the antigen recognized by anti НМЛ -МАА monoclonal antibodies in 
pericytes 
To analyze the nature of the antigen recognized by anti-HMW-MAA monoclonal antibodies on 
human pericytes the components immunoprecipitated from biosynthetically labeled human brain 
pericytes were analyzed by SDS-PAGE. Their electrophoretic profile was compared to that of 
HMW-MAA immunoprecipitated from intrinsically labeled cultured melanoma cells. Figure 10 
shows that the antigen immunoprecipitated by ascites fluid containing anti-HMW-MAA MoAb 
AMF-6 from 14-leucine labeled pericytes has the characteristic two chain structure of HMW-MAA 
with a 420 kD and a 250 kD component [1,2,3,15,22]. 
Table IV. Staining of cultured human cells with MoAb EN4, MoAb 3G5 and anti-HMW-MAA 
MoAbs 225.28S, 763.75 or TP41.2 (a) 
MoAb 
anti-HMW-MAA 3G5 EN4 
Foreskin microvascular endothelium -(b) - + + 
Umbilical vein endothelium - - + + 
Brain pericytee + + + + 
Fibroblasts 
Smooth muscle calls + + 
Melanoma cells + + 
(a) The three different enti-HMW-MAA MoAbs gave similar results. 
(b) -,no staining; + +,marked staining. 
When a 35S-Sulphate labeled pericyte extract is the antigen source, only the large 420 kD 
component containing the labeled glycosaminoglycan side chains is visualized (Figure 10), since 
the core protein, devoid of sulphate groups, remains unlabeled. The results were indentical using 
culture supernatant containing anti-HMW-MAA MoAb AMF-6. 
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Immunoelectronmicroscopy 
In order to determine the nature of the microvascular cells stained by anti HMW-MAA MoAbs 
immunoelectronmicroscopy was used employing thick vibratome tissue sections and cell sus-
pensions. 
Pre-embedding immunoperoxidase staining of tissues 
In control vibratome sections, where incubation with specific first antibody was omitted, both 
light- and electronmicroscopy showed electron dense reaction product (DAB) in occasional 
intracellular lipid droplets and in sites with endogenous peroxidase activity, i.e. red blood cells and 
stromal macrophages. 
14 C-Leucine 35 S-Sulphate 
- 200 
- 116 
- 97 
- 66 
10 
Figure 10 SDS-PAGE analysis of components immunoprecipitated with ascites fluid containing 
anti-HMW-MAA MoAb AMF-6 from 14-leucine and 35S-sulphate labeled human 
brain pericytes. The results using MoAb AMF-6 containing culture supernatant were 
identical (not shown). 
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At the ultrastructural level in tumors and in placenta anti HMW-MAA MoAbs 225 28S or 
763 74 stained the membrane of perivascular cells and perivascular cellular processes with strong 
intensity (Figure 11 and 12) Some of these cells were only stained at their abluminal side (Figure 
11) The HMW-MAA stained cells were identified as pericytes because of the following 
characteristics close apposition of these cells to endothelial cells in the microvessels (Figure 11 
and 12), envelopment of similar cells and their processes by basement membrane in control 
sections by staining with anti collagen type IV MoAb 1042 (not shown), and, staining of similar 
cells and processes by MoAb anti-alpha sml (Figure 12) m control sections All vascular endothe­
lial cells in placenta and in tumor stroma were surrounded by a sheath of pericytes and their 
processes (Figure 11 and 12) The morphological appearance of these pericytes, ι e a plump cell 
body, lobed nucleus and increased number of cell organelles suggested an activated state (Figure 
12) In the examined tumor lesions, placenta and normal organs no staining of endothelial cells 
was detected with anti-HMW-MAA MoAbs 225 25S or 763 74 
Pre-embedding immunogold staining of cultured cells 
Numerous (80-200/cell) gold particles were found at the cell membrane of cultured human 
brain pericytes stained with anti-HMW-MAA MoAb 763 74 Staining was preferentially localized 
at the membrane of microspikes (Figure 13) usually situated in clusters on one side of the cell 
These processes were 1-3 micron in length and had an approximate diameter of 100 nm We 
quantitated the number of gold particles per micrometer of cell membrane of the processes and 
underlying cell membrane At the membrane of microspikes 1-3 particles/micrometer were 
observed compared to 0 1-0 5 particles/micrometer at the remaining cell surface No gold particles 
were found on the membrane of endothelial cells incubated with MoAb 763 74 and of pericytes 
incubated with the control antibody MoAb EN4 (not shown) 
Figure 11 Electronmicroscopy of immunoperoxidase staining with anti HMW MAA MoAb 
763 74 of a surgically removed colon carcinoma lesion MoAb 763 74 stains 
perivascular cells (P) Some perivascular cells are not stained on luminal side 
(arrowhead) E = endothelium, L = lumen, |x4000) 
Figure 12 Electronmicroscopy of immunoperoxidase staining with anti HMW MAA MoAb 
763 74 И 2A,left panel) and with MoAb anti alpha-sml (12B, panel) of serial 
víbrateme sections of a surgically removed placenta MoAb 763 74 stains 
perivascular cells (P) and perivascular cellular processes(arrows) MoAb 
anti-alpha sml stains actm in perivascular cells IP) E = endothelium, L = lumen 
(A,x4000 and В x7800) 
Figure 13 Electronmicroscopy of immunogold staining with anti HMW-MAA MoAb 763 74 of 
human brain pericytes cultured on melinex Immunogold staining is preferentially 
localized on microspikes (arrows) (x40 000) 
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Quantitation of immunohistochemical staining results 
In order to gain an impression on the pericyte coverage of the microvasculature in different 
conditions, the proportion of HMW-MAA and of alpha smooth muscle actin staining microvascular 
cross-sections was estimated. 
In normal adult thyroid, kidney and striated muscle the proportion of capillary cross-sections 
stained by anti-HMW-MAA monoclonal antibodies was much lower than that stained by MoAb 
anti-alpha-sml, indicating that most pericytes in normal tissues are not stained by anti-HMW-MAA 
MoAbs 225.28S, 763.74 or TP 41.2 (Figures 5 and 14). 
In contrast, in tumors, in granulation tissue and in full-term placenta most capillary cross-
sections were stained by anti-HMW-MAA MoAbs 225.25S, 763.74 or TP 41.2 (Figures 1 and 
14). Based on the previous immunoelectronmicroscopic finding of the preferential staining with 
anti-HMW-MAA MoAbs in pericytes in tumor tissues this pattern is indicative for a high number 
Tissues studied 
kidney Щжг&аиАіШЫеяггягвевга 
ІЛивСІ -^И^и««а^г<илд«»«£«л«ли«4**ьиві 
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Figure 14 Proportion of pericyte coverage of capillaries in normal adult tissues and conditions 
with neovascularization as based on immunohistochemical visualization using 
anti-HMW-MAA or anti-alpha-smooth muscle actin (ASMA) antibodies. The pericyte 
coverage is expressed as percentage of the total number of capillaries present 
(based on MoAb PAL-Ε staining!. 
The mean percentage of three samples of each normal tissue is given. Standard 
deviations of these values are 5% and 1 0 % for kidney stained with anti-HMW-MAA 
225.28S and MoAb anti-alpha-sml, respectively; 1 0 % and 3 0 % ; for striated muscle 
stained with anti HMW-MAA MoAb 225.28S and with anti ASMA MoAb anti-alpha-
s m l , respectively; and 5% and 2 0 % for thyroid stained with anti HMW-MAA MoAb 
225.28S and with anti-ASMA MoAb anti-alpha-sml, respectively. 
138 
of pericytes with marked expression of HMW-MAA. It is remarkable that in these tissues a lower 
number of capillaries is stained by MoAb anti-alpha-sml than by anti-HMW-MAA monoclonal 
antibodies. This difference suggests that in these conditions not all pericytes express alpha-sml 
(Figure 14). 
Discussion 
This study shows that in conditions associated with neovascularization capillaries are stained by 
anti-HMW-MAA monoclonal antibodies. Immuno-electron microscopic observations of placenta 
and tumor tissue demonstrated that HMW-MAA is expressed by adventitial cells in these 
microvessels, and not by endothelial cells. These adventitial cells were identified as pericytes 
because of their morphology, their location within the basement membrane and their close 
apposition to endothelial cells. Identical staining patterns were obtained with three monoclonal 
antibodies recognizing distinct determinants of the HMW-MAA. This finding suggested that the 
observed staining of pericytes reflects the expression of an antigen similar to that of the 
HMW-MAA. This possibility was corroborated by the SDS-PAGE profile of antigens 
immunoprecipitated by anti-HMW-MAA monoclonal antibodies from biosynthetically labeled 
human brain pericytes [1,2,3,22]. In normal tissues staining of capillaries by anti-HMW-MAA 
monoclonal antibodies was hardly detectable in contrast to the marked staining in conditions with 
neovascularization. This differential staining reflects enhanced expression of HMW-MAA by 
pericytes and also may indicate an increase in their number in conditions with neovascularization. 
Pericytes are found in capillaries and venules and are similar to the smooth muscle cells found 
in arterioles and arteries [22]. Interest in these cells has increased following in vitro propagation 
[24,25] and identification of markers [10,11,26,27,28,29]. Several functions have been attributed 
to pericytes, such as a role in regulation of angiogenesis [30,31,32], microvascular contractility 
and phagocytosis [23,33]. 
Serological and immunocytochemical assays detected the HMW-MAA in cultured human brain 
pericytes. The latter were differentiated from smooth muscle cells because of their antigenic 
phenotype and their morphology [24,25,321. However, it has been suggested that pericytes and 
smooth muscle cells are two closely related cell types and that pericytes may differentiate into 
smooth muscle cells [23]. If so, these two types of microvascular adventitial cells may be two 
functionally and phenotypically different forms of cells with the same common origin. This 
possibility is supported by our finding that both cell types express HMW-MAA. The preferential 
expression of the HMW-MAA by pericytes in lesions with neovascularization is remarkable. Based 
also on their morphology we assume that under these circumstances pericytes are in an 'activated' 
state and that the HMW-MAA can therefore be used as a marker for this kind of pericyte 
activation. It is further notable that the HMW-MAA appears on normal pericytes when these cells 
are grown in culture. This is in analogy with the reported expression on cultured melanocytes [34], 
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which in situ lack the HMW-MAA [1]. These findings suggest that culture conditions might 
resemble those found in regenerating or in otherwise stimulated tissues. In our cultured brain 
pericytes we found that HMW-MAA is expressed on microspikes, 1-2 micron processes present on 
the cell surface, a phenomenon also observed in cultured melanoma cells [3]. In other cell types, 
these microspikes are known to be involved in migration and contact-inhibition [35]. The localiza-
tion of HMW-MAA on these microspikes on pericytes provides further evidence for an association 
with an activated state of these cells. 
Our estimations regarding the number of pericytes in tissues with neovascularization are surprising 
in light of the proposed role of pericytes in the regulation of endothelial cell proliferation during 
angiogenesis [32]. By co-culture studies in vitro it was shown that pericyte-endothelial contact via 
pericytic processes inhibits endothelial proliferation [32] and it was suggested by these authors that 
in vivo a similar mechanism might occur. In the present study, however, we found 
immunohistochemical evidence for an almost continuous layer of pericytes and pericyte processes 
surrounding the endothelium in tumors, placenta and granulation tissue contrasting with the 
observed scattered distribution in normal adult tissues. In ultrastructural studies other authors have 
also noted increased numbers of pericytes in tumor stroma [36,37] or healing wounds [31,38]. 
Considering the proposed inhibitory role of pericytes these findings are unexpected, as endothelial 
proliferation in tumor vasculature has been reported to be much higher than in normal resting 
tissues [39,40]. Microphotographs have been published earlier showing endothelial cells 
undergoing mitosis in close relation with pericytes in wound healing [31,41,42]. Under certain 
circumstances the proposed inhibitory effect of pericytes might therefore be absent or overruled by 
the influence of locally released factors. Most of the studies on the vasculature in tumors have 
focused on the endothelial cell [43,44,45,46]. The data presented here suggest that pericytes also 
contribute to the particular nature of vessels in conditions with regenerating vasculature 
[47,48,49,50,51]. An immunohistochemical marker for an 'activated' state of this cell type can 
make a contribution to our knowledge on the biological role of the enigmatic microvascular 
pericyte. In addition, such pericytes may serve as a target for radiolabeled monoclonal antibodies 
for immunodiagnosis or immunotherapy of tumors in vivo [52]. Since anti-HMW- MAA MoAb 
225.28S recognizes pericytes of a number of animal species this hypothesis may be tested in 
preclinical animal studies. 
Summary 
In the course of immunohistochemical characterization of murinemonoclonal antibodies recognizing 
the human high molecular weight-melanoma associated antigen (HMW-MAA) a striking reactivity 
with blood vessels in the tumor stroma was noted. Immunocytochemical analysis by light- and 
electronmicroscopy of a panel of tissues and cell lines showed that the staining of microvessels by 
anti-HMW-MAA monoclonal antibodies was restricted to pericytes. Correspondingly, 
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anti-HMW-MAA monoclonal antibodies were found to react with cultured pericytes from human 
brain but not with endothelial cells in serological assays and to immunoprecipitate from 
biosynthetically labeled pericytes an antigen with the characteristic structural profile of 
HMW-MAA. At the subcellular level, the expression of HMW-MAA in cultured pericytes was 
mainly restricted to microspikes which are localized in clusters on the cellular membrane. Staining 
by anti-HMW- MAA monoclonal antibodies of pericytes was not only found in the tumor stroma, 
but also in other lesions associated with angiogenesis, such as granulation tissue of wound healing 
and synovitis. In these lesions microvascular staining for another marker of pericytes, i.e. alpha-
smooth muscle actin, was also observed. These results suggest that in conditions associated with 
vascular proliferation 1) pericytes acquire HMW-MAA and 2) the number of pericytes may be 
increased as compared to normal tissues. 
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Summary and conclusions 
In this thesis we present a number of studies on the biology of the tumor vasculature 
employing vascular markers. 
Recognizing morphological and functional differences between normal tissue vessels and those 
in the tumor stroma is of crucial importance in understanding the role of microvessels in tumors. 
Furthermore, this may lead to the development of therapeutic strategies aimed at the tumor 
microvasculature. The aim of our studies was to find such differences by means of 
immunohistochemical staining methods. 
In Chapter 1 an introduction is given into the field of microvascular research with special 
emphasis on the tumor microvasculature and angiogenesis, the growth of new blood vessels, and 
the role therein of endothelial cells and pericytes. In summary, the tumor microvasculature is 
different from normal resting tissue vasculature in its morphology, both in angioarchitecture and 
cellular ultrastructure, in its permeability for macromolecules and role in clotting mechanisms, and 
in the relatively high mitotic rate of its cellular constituents. 
During angiogenesis in tumors and in wound healing, several factors and cells are involved in 
the step-wise formation of new vessels. As the main approaches in the literature in this field have 
been investigations in vitro on cultured cells or in angiogenesis models in chicken embryos, little is 
known about neovascularization in vivo during tumor growth, e.g. its localization, regulation and 
the role, origin, properties and distribution of the cells and factors involved. An alternative 
experimental approach, studying the features of angiogenesis in situ in (human) tumors, has been 
seldomly taken, though, and to do so by immunohistochemical methods was the approach of our 
studies. 
To enable such investigations on microvessels in tissue preparations, and in particular in the 
tumor stroma, reliable immunohistochemical visualisation of endothelium and pericytes by vascular 
markers was needed. In Chapter 2 we made an inventory of the presently described monoclonal 
antibody-defined endothelial antigens, their tissue distribution and subcellular localization and their 
use in assessment of vascular invasion by tumor cells and identification of endothelial neoplasms. 
These endothelial antigens may be divided in partly overlapping categories, namely constitutive 
differentiation markers and antigens involved in particular endothelial functions, such as 
Angiotensin Converting Enzyme. Unfortunately, none of the reported antigens is fully specific and 
sensitive for endothelium. 
The characteristics of one of the most specific endothelial antigens, recognized by monoclonal 
antibody PAL-Ε, are described in Chapter 3. This antigen is expressed by endothelium of 
capillaries and veins and splenic sinusoids, but not of arteries, lymphatics or liver sinusoids, 
indicating phenotypic heterogeneity in endothelium at different sites. On the subcellular level, the 
PAL-Ε antigen is predominantly present at the openings of pinocytotic vesicles on the cell 
membrane. 
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Although demonstrable in frozen sections only, PAL-Ε is a very useful endothelial marker due 
to its high specificity. The only non-endothelial reaction sites of the antibody are the basal side of 
basal keratinocytes in epidermis and the blastema! cells in Wilm's tumor, a rare tumor of the 
kidney in children. 
In Chapter 4 the reaction patterns and value as vascular markers in tumor stroma and 
granulation tissue of wound healing of a series of antigens in endothelial celts, pericytes and basal 
lamina is described. In tumors, anti-endothelial monoclonal antibodies PAL-Ε and BMA 120 
appeared most useful in visualizing the microvasculature. Their reaction patterns were similar to 
those observed in normal tissues. In contrast, endothelial expression of Von Willebrand Factor was 
decreased in tumor capillaries and, strikingly, two markers for pericytes, alpha-smooth muscle 
actin(ASMA) and the High Molecular Weight Melanoma-Associated Antigen(HMW-MAA, 
described in more detail in chapter 7), demonstrated heterogeneous expression in tumor vessels. In 
granulation tissue, a similar heterogeneous staining of pericytes was noted. This was however 
related to the maturation level of the granulation tissue: in the most immature superficial level, 
with presumably the most abundant angiogenesis, pericytes stained markedly for HMW-MAA and 
weakly or negative for ASMA. In the deeper maturing areas, this pattern gradually reversed. An 
important conclusion from this study was that all microvascular components, including pericytes 
and basal lamina, are present in the area of active angiogenesis during wound healing. This does 
not support the step-wise angiogenesis model as derived from earlier studies in angiogenesis 
models. 
In a further study on tumor microvessels, now in brain tumors, Chapter 5 shortly deals with 
the differential expression of the PAL-Ε antigen in normal Blood-Brain Barrier(BBB) endothelium 
versus brain tumor endothelium. In normal neural tissues with a patent BBB, as found in cerebral 
parenchyma, the meninges, the retina of the eye, and peripheral nerves, endothelial PAL-E 
expression is absent. In the minor anatomical areas in the brain known to lack a BBB, such as the 
dura, pituitary gland and the choroid plexus, the marked vascular staining for PAL-Ε was 
comparable to tissues outside the CNS. In a series of brain tumors, the microvasculature also 
stained, indicating that the endothelium in brain tumors is of other nature than the surrounding 
parenchymal vessels. Furthermore, this finding supports the presumed absence of a BBB in CNS 
neoplasms. The differential expression of the highly specific PAL-Ε antigen may be useful in 
imaging brain tumors in humans. 
In ultrastructural studies of wound healing it has been observed that endothelial cells project 
abluminal cytoplasmic extensions in the surrounding interstitium, presumably preceding or 
accompagnying endothelial activation and migration during angiogenesis. In Chapter 6 the 
expression on these processes of CD34, an antigen also found in leukocytes, is described. 
Immunohistochemical staining of thick tissue sections of human tumors enabled specific 
visualization of these endothelial abluminal processes (EAM) and therefore provides a new method 
for studying angiogenesis in situ. By this staining, we observed in some tumors an abundancy of 
EAM's, suggesting widespread endothelial migration or activation and angiogenesis. In other 
tumors EAM's were only scarcely present, probably as a sign of more restricted sites of 
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angiogenesis. In fetal tissues, EAM's were similarly scarce. By immunoelectron microscopy, we 
observed that the EAM's were of a length up to 20 microns and 0.1 micron in diameter. They 
occasionally branched and were continuous with the cytoplasm of endothelial cells wich showed 
signs of amoeboid movements as described by other authors. In their course through the 
perivascular interstitium, they were often associated with electronlucent clefts, possibly due to the 
effect of proteolytic enzymes. In contrast to the marked staining with anti-CD34 antibodies of the 
EAM's, the rest of the endothelial abluminal membrane was negative or only weakly stained. Like 
in normal tissue endothelium, CD34 staining of the luminal endothelial membrane, however, was 
marked. In vitro, endothelium also expressed CD34, but this was limited to a subset of cells. 
These had a typical morphology reminiscent of migrating cells, and were apparantly lying on top 
of the endothelial monolayer. Based on these features, the positive cells might be the "sprouting" 
cells as have been observed by other authors in endothelial cell cultures. Taken together with the 
observations of CD34 staining in situ, expression of this antigen by endothelial cells appears in 
some way related to the migration step of angiogenesis. In this respect it is notable that in the 
tumor tissues endothelial cells with EAM's were closely associated with abundantly present 
pericytes. 
In Chapter 7 the expression on these pericytes of the previously mentioned High Molecular 
Weight Melanoma-Associated Antigen is reported in further detail. This study was prompted by 
the initial observation of microvascular staining by antibodies recognizing this chondroitin sulphate 
proteoglycan (previously regarded as a melanoma-specific marker) in a large series of tumors other 
than melanomas, but not in normal tissue vessels. By immunoelectron microscopy this antigen 
could be localized in the microvascular pericyte. The differential staining in tumor stroma 
appeared to be based on both an increased number of pericytes in tumor vessels but also on a 
markedly increased expression of the proteoglycan as compared to pericytes in normal resting adult 
tissues. The latter observation was interpreted as a sign of pericyte "activation" in tumor stroma. 
In gliomas, the staining of vascular glomeruli was a conspicuous finding and indicated a large 
share of pericytes in this presumed "endothelial" hyperplasia. In cultured human brain pericytes, a 
large proteoglycan could be demonstrated by immunoprecipitation studies employing 
anti-HMW-MAA antibodies, which was undistinguishable from the melanoma HMW-MAA. At the 
subcellular level, the proteoglycan in cultured pericytes was localized on microspikes, which is in 
analogy with its distribution on melanoma cells in vitro. 
In conclusion, our studies demonstrate that microvascular antigens can serve as tools to study 
morphological and, indirectly, functional aspects of important processes in the tumor stroma such 
as angiogenesis. Furthermore, they support the notion by other authors that the tumor 
microvasculature differs from normal host tissue vessels, but shares characteristics with granulation 
tissue vasculature. In addition, we have shown that in situ the stepwise angiogenesis and more 
specific an immature sprouting microvascular phenotype lacking pericytes could not be 
demonstrated in human tumors and granulation tissue. This was based on the observation of high 
numbers of pericytes in sites with presumed angiogenesis in both tumors and granulation tissue, 
which were closely associated with endothelial cells showing signs of activation, migration and 
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mitosis. We also regard these pericytes as activated, as they displayed ultrastructural cytoplasmic 
signs of active protein synthesis and migration, increased expression of HMW-MAA and decreased 
levels of alpha-smooth muscle actin, a constitutive contractile marker protein in normal tissue 
pericytes. The close association of such pericytes with mitotic endothelial cells does not support 
the presumed role of pericytes in terminating endothelial mitosis, and thereby angiogenesis 
altogether, as has been suggested from in vitro observations by other authors. 
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Samenvatting 
In dit proefschrift is een aantal artikelen gebonden met als gemeenschappelijk thema het 
vaatbed in tumoren en in granulatieweefsel en de studie daarvan met behulp van vaatmerkstoffen. 
Vaatmerkstoffen zijn moleculen die een duidelijke preferentie hebben voor een van de vasculaire 
celtypen en die daarom gebruikt kunnen worden om bloed vaatjes in weefselcoupes selectief aan te 
kleuren. Dit kan onder andere met behulp van monoclonale antistoffen die vanwege hun hoge 
specificiteit zeer geschikt zijn voor het herkennen van dergelijke moleculen. Wanneer de structuur 
of functie van het molecuul bekend is, kan de waargenomen cellulaire verdeling in coupes van een 
bepaald weefsel iets zeggen over processen die in dat weefsel gaande zijn. Met behulp van 
dergelijke monoclonale antilichamen hebben wij getracht om verschillen tussen tumorvaatjes en 
vaten in normale weefsels aan te tonen en te verklaren. 
Met betrekking tot die verschillen is het ten eerste van belang dat in het bindweefsel van een 
groeiende tumor angiogenese plaats vindt, het proces waarbij nieuwe bloedvaatjes gevormd worden 
uitgaande van het reeds aanwezige vaatbed. Bij dit proces zijn de verschillende celtypen in kleine 
bloedvaatjes - de endotheelcel en de pericyt - betrokken, maar ook een aantal zogenaamde 
angiogenesefactoren, welke het proces in gang kunnen zetten. Angiogenese heeft naar men 
aanneemt een stapsgewijs verloop, waarbij pas in de laatste fase pericyten verschijnen. Aan deze 
cellen wordt dan ook een rol bij de afronding van het proces toegekend, een hypothese die 
ondersteund wordt door de observatie in celkweken dat pericyten de proliferatie van 
endotheelcellen kunnen remmen. 
Ten tweede blijken tumorvaatjes een hogere doorlaatbaarheid voor stoffen in de circulatie te 
hebben en in tegenstelling tot normale vaatjes intravasculaire bloedstolling te bevorderen. 
Ook de structuur van de bloedvaatjes in tumorweefsel verschilt van die in normale weefsels. 
Zo zijn deze vaatjes wijder, kronkelig en anderszins onregelmatig gevormd en hebben zowel de 
endotheelcellen als pericyten kenmerken passend bij celactivatie, zoals tekenen van verhoogde 
eiwitsynthese en celmigratie. 
In het inleidende hoofdstuk 1 wordt de recente literatuur op het gebied van angiogenese en de 
kleine bloedvaatjes, met name in tumorweefsel, samengevat. Angiogenese-onderzoek wordt 
hoofdzakelijk verricht middels laboratoriumkweken van de betrokken celtypen. Een dergelijke 
benadering geeft in de regel reproduceerbare waarnemingen en is daarmee aantrekkelijk, maar gaat 
helaas noodzakelijkerwijs voorbij aan de ingewikkelder en mogelijk geheel verschillende 
omstandigheden die zich in het weefsel afspelen. Met de in dit proefschrift gebruikte benadering 
worden eigenschappen van endotheelcel en pericyt bij angiogenese, met name in tumorweefsel en 
granulatieweefsel, met behulp van de genoemde vaatmerkstoffen in situ bestudeerd. Hiertoe was 
het noodzakelijk over goed gekarakteriseerde vaatmerkstoffen te beschikken welke als standaard 
reeks kon dienen bij ons onderzoek. 
In hoofdstuk 2 wordt een overzicht gegeven van dergelijke merkstoffen herkend door 
monoclonale antilichamen zoals beschreven voor de endotheelcel. Deze kunnen verdeeld worden in 
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differentiatiemerkstoffen, antigenen kenmerkend voor een bepaald celtype en functionele 
merkstoffen, die geassocieerd zijn met een omschreven bekende functie van een cel. Uit dit 
overzicht blijkt echter dat geen van de bekende endotheelmerkstoffen volledig specifiek of volledig 
gevoelig voor endotheelcellen is. 
In hoofdstuk 3 wordt een van de meest specifieke endotheelmerkstoffen, herkend door het 
monoclonale antilichaam PAL-E, beschreven. Het PAL-E antigeen komt voor op endotheelcellen 
van capillairen, venen en in de sinusoiden van de milt, maar is niet aantoonbaar in endotheel van 
arterieên, lymfevaten en de leversinusoïden. Ook is het niet detecteerbaar op endotheel in de 
hersenen, waar de bloed-hersen barrière wordt aangetroffen, zoals in hoofdstuk S wordt toegelicht. 
Met behulp van het electronenmicroscoop werd gevonden dat het PAL-E antigeen voornamelijk 
geïdealiseerd is op de celmembraan bij de openingen van de zogenaamde pinocytoseblaasjes. 
Hoewel uitsluitend aantoonbaar in vriescoupes is het PAL-E antigeen waardevol vanwege de hoge 
specificiteit als endotheelmerkstof, gezien het vrijwel geheel onbreken van reaktiviteit in andere 
cellen of weefsels. 
De verdeling in het tumorvaatbed van merkstoffen voor endotheel, pericyt of basaalmembraan (de 
stevige eiwitlaag die endotheelcellen en pericyten scheidt van het omringende bindweefsel) wordt 
beschreven in hoofdstuk 4. en hun waarde als merkstof voor tumorvaatjes wordt onderzocht. 
Hieruit bleek dat de monoclonale antilichamen PAL-E en BMA120 het meest bruikbaar waren. De 
andere merkstoffen waren vanwege reaktiviteit met andere celtypen of structuren voor dit doel 
minder geschikt. 
De onderzochte endotheelmerkstoffen vertoonden een overeenkomstig kleuringspatroon als in 
normale weefsels, met uitzondering van de Von Willebrand Factor, welke in de tumorcapillairen 
vaak sterk verminderd of niet duidelijk tot expressie kwam. Nog opvallender was het 
reaktiepatroon van pericyten in de tumorvaatjes. Deze vertoonden een heterogene expressie van 
twee onderzochte merkstoffen, het melanoom geassocieerde antigeen HMW-MAA (waarover meer 
in hoofdstuk 7) en vooral van het gladde spiercel actine (ASMA), een differentiatiemerkstof voor 
pericyten in normale weefsels. In granulatieweefsel werd ook een dergelijk heterogeen 
reaktiepatroon gevonden, maar dit bleek gerelateerd aan zones met verschillende rijpingsgraad. In 
de meest onrijpe oppervlakkige zone, waar de meest intensieve angiogenese kan worden verwacht, 
waren de pericyten positief voor HMW-MAA en kleurden vrijwel niet voor het actine. In de rijpe 
zone van verbind weefsel ing was dit echter juist andersom, in een patroon dat ook in normale 
weefsels wordt gezien. Een belangrijke bevinding in deze studie was dat in de genoemde onrijpe 
zone in het granulatieweefsel de verschillende componenten van microvaatjes, dus met name 
endotheelcellen, pericyten en basaalmembraan, alle aantoonbaar waren. 
In hoofdstuk 5 wordt teruggekomen op het reaktiepatroon van het monoclonale antilichaam 
PAL-E in hersenvaatjes. Zoals reeds vermeld reageert endotheel op plaatsen met een bloed-hersen 
barriere(BHB), met name in vaatjes van het hersenparenchym, de meningen, de retina en de 
perifere zenuwen, niet met PAL-E. In de zeldzame plaatsen van het centrale zenuwstelsel waar de 
BHB ontbreekt, zoals in de dura, de hypofyse en de plexus chorioideus, reageren de vaatjes echter 
wel en dan met gelijke intensiteit als buiten de hersenen, hetgeen een negatieve relatie van PAL-E 
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expressie met de BHB functie suggereert. In bloedvaatjes in hersentumoren vonden wij tot onze 
verassing ook kleuring voor PAL-E. Dit geeft aan dat vaatjes in hersentumoren verschillen van 
vaatjes in de omringende weefsels, en tevens past deze bevinding bij een waarschijnlijk afwezige 
of deficiente BHB in hersentumoren. De selectieve aankleuring van tumorvaatjes in hersenweefsel 
biedt misschien mogelijkheden voor immunoscintigrafie met PAL-E van tumoren in het centrale 
zenuwstelsel. 
Een ander aspect waarin tumorvaatjes verschillen van normale weefsels wordt beschreven in 
hoofdstuk 6. Het betreft de expressie van het leukocytenantigeen CD34 op endotheelcellen en met 
name op abluminale endotheeluitlopertjes in tumorvaatjes(door ons afgekort als EAM). In 
electronenmicroscopische studies van granulatieweefsel en embryonale angiogenese waren 
dergelijke uitlopertjes reeds eerder beschreven. Hun aanwezigheid werd door de betreffende 
auteurs in verband gebracht met migratie en activatie van de endotheelcellen tijdens angiogenese. 
In onze studie vonden wij in dikke vibratoomcoupes, dankzij de aankleuring met monoclonale 
antilichamen gericht tegen CD34, de aanwezigheid van EAM's in tumorvaatjes. In sommige 
tumoren in groten getale, uitgaande van vrijwel alle vaatjes, in andere tumoren slechts plaatselijk 
voorkomend. De variabele aanwezigheid van EAM's zou kunnen passen bij een sterk wisselende 
mate van angiogenese in verschillende tumoren. Met behulp van immunoelektronenmikroskopie 
werd gevonden dat deze uitlopertjes wel tot 20 micron lang kunnen zijn en dat ze soms vertakken. 
Zij waren duidelijk verbonden met het cytoplasma van endotheelcellen. Gekweekte endotheelcellen 
kleurden ook aan met anti-CD34 monoclonalen, maar dit bleef beperkt tot een kleine fractie die 
kenmerken had van migrerende cellen. Concluderend lijkt CD34 expressie op 
cytoplasmauitlopertjes van endotheelcellen in tumorvaatjes gerelateerd aan angiogenese en dan 
mogelijk aan de migratiestap. Hierbij is opvallend dat de EAM bevattende cellen in de 
tumorvaatjes steeds geassocieerd waren met pericyten. 
In het laatste hoofdstuk 7 van het proefschrift wordt de expressie van het reeds genoemde High 
Molecular Weight Melanoma-Associated Antigen onderzocht op pericyten in tumorvaatjes. Dit 
chondroitine sulfaat proteoglycaan werd oorspronkelijk beschreven als een marker voor 
melanoomcellen. Een opvallende aankleuring van vaatjes in andere typen tumoren, maar niet in 
normale weefsels, vormde de aanleiding tot onze studie. Met behulp van 
immunoelektronenmikroskopie bleek ons dat deze vaatkleuring voor rekening van de pericyt 
kwam, de endotheelcellen waren negatief. De sterkere kleuring van tumorvaatjes vergeleken met 
normale weefsels berustte zeer waarschijnlijk op zowel een toename van het aantal pericyten als 
een sterk verhoogde expressie van het HMW-MAA door deze cellen. Op grond hiervan en van het 
ultrastructurele aspect van de pericyten in het tumorvaatbed beschouwen wij deze cellen als 
"geactiveerd", naar analogie van de endotheelactivatie in deze vaatjes. Ook in gekweekte pericyten 
kon het HMW-MAA met behulp van immunokleuring en immunoprecipitatie worden aangetoond. 
Op deze cellen was het proteoglycaan preferentieel gelocaliseerd op kleine celuitlopertjes, hetgeen 
door andere auteurs ook in melanoomcellen werd waargenomen. 
Waarnemingen in dit proefschrift brengen ons ertoe vraagtekens te zetten bij het momenteel 
vigerende stapsgewijze model van angiogenese. Volgens dit model zijn er in de onrijpe 
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vaatspniitjes geen pericyten aanwezig, en deze afwezigheid zou, zoals reeds genoemd, een van de 
voorwaarden voor endotheelproliferatie in deze spruiten zijn. In ons materiaal, zowel in het 
tumorweefsel als in de oppervlakkige laag van granulatieweefsel, hebben wij een dergelijk type vat 
echter niet kunnen aantonen. Wij vinden daarentegen in deze weefsels een toename van pericyten 
in de vaatjes. Deze pericyten lijken bovendien geactiveerd te zijn. 
Concluderend toont dit proefschrift aan dat er in het angiogeneseonderzoek een duidelijke 
plaats is weggelegd voor immunohistochemische studies van het tumorvaatbed in situ met behulp 
van vaatmerkstoffen. Enerzijds voor het bevestigen van resultaten verkregen met celcultures, 
anderzijds voor het doen van nieuwe waarnemingen in de weefsels waar de betreffende processen, 
zoals angiogenese, zich daadwerkelijk afspelen. Juist het integreren van dergelijke waarnemingen 
met in vitro resultaten geeft de mogelijkheid een vollediger begrip te ontwikkelen van de aard en 
ontstaanswijze van deze processen en daarmee therapeutische strategieën gericht op het 
tumorvaatbed dichterbij te brengen. 
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Appendix I. Endothelium-associated components and their alleged functions 
(references from introduction) 
Component/Alleged function Molecular In In Remarks/epecificity 
weight vitro situ 
Function in Coagulation 
Membrane aasociated 
1 thrombomodulin 
2 tissue factor 
3 13 hydroxy octedecadienoic века (13 HOOE) 
4 Factor V binding sites 
5 Factor lX/IXa binding sites 
6 Factor X/Xa binding sites 
7 Factor XII binding sites 
8 Fibrinogen binding sites 
9 heparan sulphate 
Cytokine induced 
Many other cells 
14 200 
198 
132 
132 
132 
132 
132 
132 
Synthesis or secretion 
1 von Wille brand Factor 
2 Factor V 
3 Protein S 
Endothelial Derived Relaxing Factor 
(EDRR = nitric oxide 
urokinase 
tissue plasminogen activator (tPA) 
tPA inhibitor 
Prostaglandins PGi2 PGE2 
PGH2 PGF2 alpha TXA2 
55kDa 
+ Platelets + 
+ Cancer cells + , all ec + 
132 
4 
68 
68 
156 
88,156 
68 
68 132 
Inflammation and immunoregulation 
Membrane associated antigens 
1 major histocompatibility antigens Class I 
(MHC I HLA A B) 
2 MHC Class II (HLA DP DQ DR) 
3 blood group antigens А В H2 
4 lymphocyte antigen Leu 2 (MoAb Leu2) 
5 lymphocyte antigen О KT 8 (MoAb 0KT8) 
6 monocyte antigen OKM-1 (MoAb OKM-1) 
7 monocyte antigen OKM 5 (MoAb OKM 5) 
8 monocyte antigen 63D3 (MoAb 63D3) 
9 monocyte antigen 6103 (MoAb 61D3) 
10 monocyte antigen Leu M3 (MoAb LeuM3) 
Cytokine enhanced 
Only spleen sinusoid ec + 
bke Leu 2 
Monocytes and granulocytes + 
Uke OKM 1 
Only liver sinusoid ec + 
Uke 6303 
Like 6303 
Θ8 
66 
265 
265 
107 
107 
265 
265 
265 
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Component/Alleeed function Molecular In In Remarks/specificity Ref 
weight vitro situ 
11. mucosal vascular eddressm (MVA) (MoAb 
МЕСА-Э67) 
12. high endothelial cell antigen (McAb HECA-425) 
13. penpheral lymph node VA (MoAb MECA-79) 
14. intercellular adhesion molecule-1 (ICAM-I) 
(MoAbRRI/D 
58-
бкОа 
+ Mouse high endothelial venules 250 
(HEV) 
+ Human HEV 56 
+ Mouse HEV 250 
+ Lymphocytes and fibroblasts + 39 
Synthesis/secretion 
1. transforming growth factor-beta (TGF-beta) 
Endothelial activation/regeneration 
Membrane-associated 
1. endothelial leukocyte adhesion molecule-l 
(ELAM-I) (MoAbH4/18) 
2. endothelial activation antigen E12.1 (MoAb 
Ε12.ΊΪ 
3. inducible call adhesion molecule-110 
(1NCAM-110) (MoAb El/6) 
4. endothelial activation antigen 4010 (MoAb 
4010) 
5. tumor necrosis factor (TNF) binding sites 
6. epidermal growth factor receptor (EGFR) 
(MoAbs 29.1.1 and 455) 
7. endothelial budding antigen 7/44 (MoAb 7/44) 
100/ 
120kDa 
110/ 
95kDe 
81kDa 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
posl-capillary venules, 
ec-specific 
non-confluent cells 
normal brain ec ; 
choroid plexus ec + 
38 
264 
212 
88 
98 
239 
Synthesis/secretion 
1. basic-fibroblast growth factor (b-FGF) 
2. msulin-like growth factor-l 
3. heparanase 
4. collageneees 
5. platelet activating factor 
6. platelet denved growth factor (PDGF) 
7. mterleukm 1 (IL-1) 
8. IL-6 
9. granulocyte/monocyte-colony etimuleting factor 
(GM-CSF) 
10. lymphocyte chemoattractant activity 
+ many other cells + 
Cytokine-induced 
Platelets+ 
Cytokma-induced 
Cytokine-induced 
40 
54 
9 
9 
9 
Integnns 
1. glycoprotein llb/llla (cytoadhesm) 
2. Iibronectin receptor (VLA-family) 
3. VLA-2 
Blood-tissue barners/transport functions 
1. tranefern η receptor (MoAb OKT9) Brain ec and spleen sinusoid 
ec + , lymphocytes and cancer 
cells + 
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Component/Alleged function Molecular In In Remarks/specificity Ref. 
weight vitro situ 
2. gamma-glutamyl transpeptidase 
3. albumin-binding sites 
4. mouse brain endothelium HT7 (MoAb HT7) 
5. brain capillary marker protein 
6. brain capillary marker protein 
SOkOa + + 
74kDa 
46K0a 
+ 
+ 
+ 
+ 
Only brain ec +, kidney and 
choroid plexus epithelium + 
Brain endothalium-
Only brain 6C + , kidney 
epithelium + 
Only brain ec + , liver 
epithelium + 
Only brain ec +, kidney 
epithelium + 
47 
99,175 
217,250 
151 
151 
Extracellular matnx constituents 
1. 
2. 
3. 
A. 
5 
6. 
7. 
8. 
collagene l,lll,IV,V 
endothelial collagen 
lamimn 
fibronectm 
thrombospondin 
tropoelaetin (elastm) 
dermetan sulphate 
chondroitm sulphate 
ее 
ее 
68 
68 
68 
68 
68 
68 
Miscellaneous/metabolic functions 
I . angiotensin converting enzyme (ACE) 
2 angiotensmases А,С 
Э. endothelin 
4 insulin-receptor 
5. high density lipoprotein (HDD-receptor 
6. beta-low density lipoprotein (LDU-receptor 
7. acetyt-LDL-receptor 
8. chylomicron-receptor 
9. alkaline phosphatase 
10. acid phosphatase 
I I . 5'nucleotidase 
12. alpha-naphtyt acetate esterase 
13. beta-glueuronidase 
14. adenosine tnphosphatase 
15. aldose reductase 
+ + Kidney epithelium 
+ Many other cells 
Glomerular ec-
Spleen sinusoide + , HEV + 
All ac + 
Spleen sinusoids -t-
Spleen sinusoids + , HEV + 
Glomerular ec-
132 
132 
132 
132 
132 
132 
132 
132 
265 
265 
265 
265 
265 
265 
89 
Antibody-defined endothelial components 
1. MoAb CIV and C.VI 92kDa 
2. MoAb НЕС-1 170kDa 
3 MoAb 44G4 170kDa 
4. MoAb PAL-E 
5. MoAb BMA 120 (BW200) 200kDa 
6. MoAbEN4/EN3 130kDa 
Monocytes + Ch.2 
Haemopoiatic cells + Ch.2 
Haemopoietic cells + 103 
Basal epidermis + Ch.3 
Mesothehum +, glomerular Ch.2 
epithelium + 
Platelet + .leukocyte + Ch.2 
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Component/Alleged function Molecular In In Remarka/specificity 
weight vitro situ 
Ref. 
7. MoAbB721 
8. MoAb E 431 
9. MoAb 1F10 
11. MoAb MB1 
12. MoAb anti-CD34 
+ Smooth muscle cells + , 233 
lymphocytes + 
+ Macrophages -4- 233 
+ ec specific, sinusoid ec- 102 
+ Quail ec only, heemopoietic 199 
cells+ 
+ Heemopoietic progenitor cells 4- 284 
ec= endothelial cells 
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Appendix IL Angiogenic Factors 
1) Angiogenic heparin-binding endothelial cell growth factors (HBGF) 
These factors, members of the so-called Fibroblast Growth Factor family (FGF) [162], stimulate 
endothelial proliferation, migration, and the production of collagenase and plasminogen activator 
in vitro at concentrations of 1-10 ng/ml [80,106] They also induce angiogenesis at equally low 
concentrations in vivo in chick embryo CAM and rabbit cornea [106,130] In implanted sponges 
in rats they induce vascularized granulation tissue [260,261] In addition to their angiogenic 
capacity, they have many other biological activities [106], of which the most exciting is the ability 
of basic-FGF to act as a primordial morphogen in embryogenesis (demonstrated in experimental 
embryogenesis, by basic-FGF instructing cells destined to form ectodermal structures to shift and 
form mesodermal structures instead [140,147,177] 
These factors have been well characterized and the corresponding genes were recently cloned 
[238,277] Interestingly, these genes lack a functional secretory signal sequence, and therefore the 
FGF's appear not to be secreted by their cells of origin [118] Probably they leave the cells bound 
to extracellular matrix components, such as heparan sulphate proteoglycans [83,106] Two classes 
of these growth factors, with approximately 55% sequence homology, are recognized 
a) Class-1 hepann-binding endothelial growth factors, which have isoelectric points between 5 and 
7 and molecular weights between 15,000 and 18,000 Da This group contains acidic-Fibroblast 
Growth Factor (acidic-FGF) and Endothelial Cell Growth Factor (ECGF) They have been isolated 
from neural tissues, ι e brain, hypothalamus and retina, and from kidney, smooth muscle cells 
and glioma cells [95,167,277,295] Class-1 HBGF messenger-RNA could be demonstrated in 
brain, kidney and glioma cells, but not in other tissues with active angiogenesis, such as placenta 
and fetal liver [277] 
b) The canonie heparin binding endothelial growth factors (Class-2) have isoelectric points between 
7 and 10 and molecular weights ranging from 16,000 to 18,500 Da Basic-FGF, the main 
representative of this group, and related molecules have been isolated from various tissues, ι e 
malignant tumors, brain, hypothalamus, cartilage, adrenal gland, kidney, thymus, and placenta 
In vitro, basic-FGF is produced by tumor cells [148], but also by vascular endothelial cells 
themselves Corresponding messenger-RNA could, however, only be detected in brain cortex and 
hypothalamus, but not in other tissues from which basic-FGF has been isolated [238] This 
suggests that in these tissues synthesis of basic-FGF is low or absent, but that the mitogen only 
is stored within these tissues, probably in the extracellular matrix [15,106,272] Recently, a 
receptor for basic-FGF was isolated from chicken embryos [162] 
2) Angiogenm. This polypeptide with molecular weight of 14,400 Da shows 35% homology with 
pancreatic nbonucleases [80] It was originally isolated from an adenocarcinoma cell line It 
potently stimulates angiogenesis in chick embryo CAM and rabbit cornea, but is not mitogenic for 
cultured endothelium Corresponding messenger RNA could be demonstrated in low levels m fetal 
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and adult tissues, but in high levels in adult liver, and its activity was therefore apparantly not 
related to vascular development [288]. 
3) Transforming prowth factors alpha and beta (TGFI: These factors, originally isolated from virally 
transformed rodent cells, are angiogenic in vivo [80]. In vitro, TGF-alpha stimulates endothelial 
proliferation, which paradoxically is inhibited by TGF-beta. It has not been well established 
whether the in vivo effects of these factors are direct or mediated by other angiogenic factors. In 
addition to its angiogenic capacity, TGF-beta has many other biological activities related to 
inflammation and tissue repair [274]. 
4) Tumor Necrosis Factor-alpha frNF-alphal: Macrophages and blood monocytes produce TNF-alpha 
[296]. This component is angiogenic in bio-assays, but inhibits endothelial cell proliferation in 
vitro. TNF-alpha also stimulates endothelial migration and endothelial procoagulant activity in 
vitro [80]. 
5) Vascular Permeability Factor (VPFt: this 40 kDa glycoprotein was originally described for its 
ability to increase vascular permeability [145], but it also appears to be angiogenic in vivo and to 
stimulate endothelial proliferation in vitro. It is similar to the Vascular Endothelial Growth factor 
(VEGF) [165] and related to Platelet Derived Growth Factor (PDGF), the mitogen found in 
platelets and endothelial cells [54,145]. These factors are secreted by a number of cultured tumor 
cells [35,165]. 
6) Platelet-Derived Endothelial Cell Growth Factor (PD-ECGFÌ: from platelets, a 45 kDa protein, 
distinct from PDGF, was isolated that is angiogenic in vivo and stimulates migration and 
proliferation of cultured endothelial cells, but not of fibroblasts [254]. Corresponding messenger 
RNA of this factor was demonstrated in placenta. Like the FGF's, PD-ECGF lacks a signal 
peptide and may therefore not be secreted directly by its producer cells. 
7) Other angiogenic factors 
Chemotactic factors: From wound fluid and monocytes, factors were isolated that have no 
mitogenic effect on cultured endothelial cells but stimulate their directional migration [80]. 
Prostaglandins: Prostaglandin El (PGE1) induces angiogenesis in vivo. Its action is enhanced by 
the presence of certain gangliosides [303]. 
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appendix III. Angiogenis Inhibitors 
1) Cartilage-derived factors: Cartilage, as an avascular tissue, probably contains a mechanism by 
wich vascular ingrowth is prevented. It was shown that cartilage after extraction with guanidine 
could become vascularized [154]. Since then, several partly characterized factors, mostly with 
protease inhibitory activity, have been isolated from avascular tissues and shown to have 
anti-angiogemc activity in bio-assays [154,170]. 
2) Protamine-sulphate: Heparin was shown to play an important role as a potentiator of angiogenesis 
in vivo and endothelial migration in vitro. The heparin-antagonist protamine sulphate, although 
with high toxicity, appeared to have anti-angiogenic activity in bio-assays and reduced occurence 
of lung metastases in a mouse tumor model [258]. 
3) Combination of angiostatic steroids and heparin: 
More or less by serendipity it was discovered that heparin, which by itself has a potentiating effect 
on angiogenesis, could also, when combined with cortisone, inhibit angiogenesis [84]. It is now 
recognized that certain circulating steroids like tetrahydrocortisone, previously thought biologically 
inactive, have a potent anti-angiogenic effect, both in bio-assays and in tumor-bearing animals 
[46,128,253], when combined with heparin, non-anticoagulant heparin fragments, synthetic heparin 
substitutes [73] or other polysaccharides [253]. The mode of action of these components is 
unknown, but it is believed that the saccharides act as carriers of the steroids to the endothelial 
cell surface [71]. In vivo, in the chick embryo CAM, heparin and angiostatic steroids induce 
basement membrane degradation, endothelial cell rounding and capillary retraction during 
angiogenesis inhibition [128,177]. 
4) Collagen metabolism modulators: As the anti-angiogenic action of angiostatic steroids is 
accompanied by basement membrane dissolution, components modulating collagen metabolism in 
vivo were investigated for anti-angiogenic activity in the developing chick embryo CAM. 
Regression of capillaries was observed after administration of proline analogs and and also by an 
inhibitor of prolyl hydroxylase, preventing triple helix formation and collagen deposition, an 
inhibitor of collagen cross-linking and all-transretinoic acid, a component known to alter ECM 
turnover. These components enhanced the anti-angiogenic effect of angiostatic steroids with 
heparin [129]. 
5) Platelet factor-4 (PF-4V A protein present in platelet alpha-granules, with high affinity for heparin 
and released during platelet aggegration, was shown to inhibit growth factor stimulated 
proliferation of HUVEC, but not of other cell types. In addition, PF-4 inhibited angiogenesis in 
bio-assays [173]. 
6) 140kDa angiogenesis inhibitor: From the medium of normal hamster kidney cells, but not from 
the medium of transformed cells, a glycoprotein inhibiting angiogenesis in rat corneas was 
isolated. This activity was tightly linked to and probably regulated by a cancer suppressor gene 
that is lost during neoplastic transformation of these hamster kidney cells [208]. 
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7) D-penicillamine (D-pen): In the presence of copper sulfate, D-pen inhibits endothelial cell 
proliferation in vitro and, by systemic administration in rabbits, neovascularization in the cornea 
[181]. 
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